

CURRICULUM VITAE

Stephen P. Salloway, MD, MS

PERSONAL INFO

Current Position Professor of Neurology and Psychiatry
Warren Alpert Medical School of Brown Medical School

Neurology, Memory & Aging
Butler Hospital
345 Blackstone Boulevard
Providence, RI 02906

Associate Director
Brown Center for Alzheimer's Disease Research
Robert J. and Nancy D. Carney Institute for Brain Science

Staff Neurologist
Department of Neurology
Rhode Island Hospital
593 Eddy Street
Providence, RI 02903

Business Telephone 401-455-6403
401-455-6405 (fax)

Email Stephen_Salloway@Brown.edu

EDUCATION

1971-1975 Antioch College, B.A. - Psychology
1979-1981 University of California, Berkeley, M.S. - Medical Psychology
1981-1985 Stanford Medical School, M.D.

POSTGRADUATE TRAINING

1985-1986 Hospital of St. Raphael, New Haven, CT - Rotating Medical Internship
1986-1988 Yale University Department of Psychiatry - Psychiatry Resident
1988-1991 Yale University Department of Neurology - Neurology Resident
1990-1991 Yale University - Neurology Chief Resident

POSTGRADUATE HONORS AND AWARDS

1975-1977 Thomas J. Watson Fellow
1981-1985 Roland Jackson Scholar - fellowship support for medical training and research
1984 Rock Sleyster Award - National AMA Scholarship in Psychiatry
1985 Stanford University Primary Care Program Award for Outstanding Achievement
in Clinical Teaching
1985 Stanford Medical School - Honors in Research

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

- 1987-1989 American Psychiatric Association Burroughs - Wellcome Fellow
- 1995 Fellow, Summer Geriatric Research Institute American Association of Geriatric Psychiatry, UC San Diego
- 1995-96 Surdna Foundation Fellow for Geriatric Research - Brown University
- 1995 Outstanding Teaching Award - Brown University Department of Psychiatry and Human Behavior
- 1996 Distinguished Visiting Professor Wilford Hall Medical Center, San Antonio, Texas
- 1998 Care New England Care Awards Honorable Mention, Butler Hospital Memory Disorders Program
- 1999 Brown University Honorary Master of Arts Eundem
- 2000 Fellow, American Neuropsychiatric Association
- 2001 Outstanding Teaching Award for Undergraduate Medical Student Education, Brown Medical School
- 2004 Fellow, American Academy of Neurology
- 2004 Dean's Teaching Excellence Award, Brown Medical School
- 2006 Dean's Teaching Excellence Award, Brown Medical School
- 2009 Certificate of Recognition for Exemplary Teaching in BIOL 3652 IMS II: Brain Science, Warren Alpert Medical School of Brown University
- 2010 Certificate of Recognition for Exemplary Teaching in BIOL 3652 IMS II: Brain Science, Warren Alpert Medical School of Brown University
- 2011 Certificate of Recognition for Exemplary Teaching in BIOL 3652 IMS II: Brain Science, Warren Alpert Medical School of Brown University
- 2011 US News and World Report Top Doctors in the United States
- 2013 Castle Connolly Top Doctors
- 2013 Outstanding Teaching Award in the Geriatric Fellowship Training Program
- 2013 Certificate of Recognition for Exemplary Teaching in BIOL 3652 IMS II: Brain Science, Warren Alpert Medical School of Brown University
- 2014 Certificate of Recognition for Exemplary Teaching in BIOL 3652 IMS II: Brain Science, Warren Alpert Medical School of Brown University
- 2016 Certificate of Recognition for Exemplary Teaching in BIOL 3652 IMS II: Brain Science, Warren Alpert Medical School of Brown University
- 2017 Certificate of Recognition for Exemplary Teaching in BIOL 3652 IMS II: Brain Science, Warren Alpert Medical School of Brown University
- 2018 Certificate of Recognition for Exemplary Teaching in BIOL 3652 IMS II: Brain Science, Warren Alpert Medical School of Brown University
- 2019 Certificate of Recognition for Exemplary Teaching in BIOL 3652 IMS II: Brain Sciences, Warren Alpert Medical School of Brown University
- 2019 Elected to the Rhode Island Heritage Hall of Fame, May 2019
- 2019 Named 2019 Rhode Island Man of the Year by GoLocalProv

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

2023 Leon Thal Prize for Alzheimer’s Research from the Cleveland Clinic Lou Ruvo Center for Brain Health, January 19, 2023

MILITARY SERVICE

None.

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

Certification: National Board of Medical Examiners
American Board of Neurology, 1991
American Board of Psychiatry, Eligible

Licenses: Connecticut, July 1987-August 1991
Rhode Island, July 1991-present

ACADEMIC APPOINTMENTS

1983-1985 Lecturer in Primary Care Internal Medicine, Stanford Medical School
1990-1991 Instructor in Neurology, Yale University School of Medicine
1991-1998 Assistant Professor, Department of Clinical Neurosciences, Brown Medical School
1993-1998 Assistant Professor, Department of Psychiatry and Human Behavior Brown Medical School
1998-2004 Associate Professor; Department of Clinical Neurosciences, Brown Medical School
1998-2004 Associate Professor; Department Psychiatry and Human Behavior, Brown Medical School
2004-present Professor, Department of Clinical Neurosciences, Brown Medical School
2004-present Professor, Department Psychiatry and Human Behavior, Brown Medical School
2018-2023 Martin M. Zucker Professor of Psychiatry and Human Behavior, Alpert Medical School of Brown University
2021-present Associate Director, Brown Center for Alzheimer’s Disease Research

HOSPITAL APPOINTMENTS

1987-1991 Emergency Psychiatric Privileges, Hospital of St. Raphael, New Haven, CT
1990-1991 Staff Physician, West Haven VA Medical Center
1991-present Director of Neurology, Butler Hospital, Providence, RI
1991-present Neurology Staff, Rhode Island Hospital, Providence, RI
1992-present Co-director, Laboratory for Quantitative Neuroimaging, Butler Hospital
1997-2022 Director, Butler Hospital Memory and Aging Program

OTHER APPOINTMENTS

EDITORIAL BOARD

1994-2015 Associate Editor, Journal of Neuropsychiatry and Clinical Neurosciences

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

1997-2000 Editorial Advisory Board, GeroPsychiatry Report
2004-2007 Editorial Board Applied Neurology
2014-present Journal of Prevention of Alzheimer's Disease
2014-present Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

GUEST EDITOR

Salloway S, Duffy J, Malloy P, eds. The Frontal Lobes and Neuropsychiatric Illness. Fall issue of the Journal of Neuropsychiatry and Clinical Neurosci 1994;6:341-477.

Salloway S, Malloy P, Cummings J. The neuropsychiatry of limbic and subcortical disorders. Summer 1997 issue of the Journal of Neuropsychiatry and Clinical Neurosciences 1997;9:403-600.

REVIEWER

Journals

Aging and Mental Health, 2006-present
Alzheimer's Disease and Associated Disorders, 2004-present
Alzheimer's and Dementia, 2007-present
Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2016-present
American Journal of Geriatric Psychiatry, 2000-present
American Journal of Psychiatry, 2001-present
American Journal of Psychiatry and the Law, 2000-present
Annals of Internal Medicine, 2001-present
Annals of Neurology, 2012-present
Archives of Neurology, 2005-present
Biological Psychiatry, 2017-present
BMC Geriatrics, 2007-present
BMC Neurology, 2013-present
Canadian Journal of Neurological Sciences, 2006-present
CNS Spectrums, 2000-2008
Dementia and Geriatric Cognitive Disorders, 2005-present
European Journal of Neurology 2005-present
European Journal of Nuclear Medicine and Medical Imaging, 2013-present
European Neurological Review-2018-present
Expert Opinion-2007-present
Frontiers Aging Neuroscience-2017-present
International Journal of Psychiatry in Clinical Practice, 2006-present
International Psychogeriatrics, 2006-present
Journal of Affective Disorders, 1997-present

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

Journal of the American Medical Association- 2014-present
Journal of Clinical Psychiatry, 1997-present
Journal of the American Geriatrics Society, 2007-present
Journal of Geriatric Psychiatry and Neurology, 1998-present
Journal of Internal Medicine, 2020-present
Journal of Neuroimaging 2016-present
Journal of Neurological Sciences, 2007-present
Journal of Neurology, 2006-present
Journal of Neuropsychiatry and Clinical Neurosciences, 1993-present
Journal of Stroke and Cerebrovascular Diseases, 2020-present
Lancet Neurology-2015-present
Medical Letter, 2006-present
Nature Communications-2017-present
Nature Medicine-2018-present
Nature Reviews Neurology 2009-present
Neurobiology of Aging, 1998-present
Neuroepidemiology, 2001-present
Neuroimage: Clinical, 2019-present
Neurology, 2002-present
Neuropsychiatry, Neuropsychology and Behavioral Neurology, 1993-present
Neuropsychopharmacology, 2001-present
Neuroscience Letters, 2010-present
New England Journal of Medicine, 2008-present
PLOS ONE, 2013-present
Proceedings of the national Academy of Sciences, 2017-present
Psychopharmacology 2003-present
Psychosomatics, 1999-present
Science, 2023-present
Science Translational Medicine-2017-present
Southern Medical Journal, 1998-2002
Stroke, 2001-present
Tohoku Journal of Experimental Medicine, 2006-present

National Institutes of Health

National Strategy for Clinical Studies Recruitment and Participation: Capacity Building, 2017-present

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

Clinical Development in Frontotemporal Disorders, National Institute of Neurological Disorders and Stroke/The Association for Frontotemporal Degeneration, Washington, D.C, June, 2012

National Institute on Aging Alzheimer's Disease Clinical Centers Study Section-ad hoc reviewer
2010-present

National Institute on Aging Neuroscience Branch Ad-hoc grant reviewer, 2001-present

NIMH Advisory Panel "Perspectives on Depression, Mild Cognitive Impairment, and Cognitive Decline," 2003-present

NINDS Genetics of Vascular Cognitive Impairment Study Group, 2004-present

NINDS Special Emphasis Panel ZNS1 SNRB-S, 2004

Adult Psychopathology and Disorders of Aging IRG, February, 2005-present

NINDS Vascular Cognitive Impairment Harmonization Criteria Workshop, April, 2005

Professional Societies, Universities and Research Foundations

Alzheimer's Association and Related Disorders Inc., 1994-present

Alzheimer's Association International Conference, 2016-present

Alzheimer's Association Clinician Scientist Fellowship Program, 2017-present

Alzheimer's Foundation of America Medical Advisory Board, 2003-present

American Academy of Neurology, 1994-present

American Neuropsychiatric Association, 1991-present

American Psychiatric Association, 1993-present

Dana Foundation-2014-present

German Research Foundation-2016-present

Harvard University Center for Neurodegeneration and Repair External Peer Review Committee,
1999-2004

Human Amyloid Imaging Scientific Program Committee 2018-present

Hydrocephalus 2012, 2012-present

Institute for the Study of Aging Scientific Review Board, 2003-present

International Stroke Conference 2009-present

Lewy Body Dementia Association 2017-present

Mayo Alzheimer's Disease Research Center, 2021-present

Medical Research Council (England), 2009-present

Ontario Mental Health Foundation, 2011-present

The Michael J Fox Foundation for Parkinson's Disease Research, 2008-present

The New York Academy of Sciences, 1997-present

The Wellcome Trust, 1997-present

Edward N. and Della L. Thome Memorial Foundation Awards Program in Alzheimer's Disease
Drug Discovery Research

Weston Brain Institute Transformational Research Program, Toronto, 2015-present

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

ZonMw Netherlands Organization for Health Research and Development, 2010-present

Book Publishers

American Psychiatric Press Inc., 1995-present

Cambridge University Press, 1995-present

F.A. Davis Publishers, 1991-present

John Wiley and Sons, 1994-present

Mosby Publishers, 1995-present

Oxford University Press, 1997-present

Swets and Zeitlinger, 1997-present

Internet Sites

WebMD, 2001-present

COLUMNIST

Psychiatric Times- The Aging Brain Column, 1997-2005

CONSULTANT FOR DRUG DEVELOPMENT

Hoechst, Marion, Roussel Dementia Advisory Panel, 1997-2002

Eisai, Alzheimer's Disease Program, 1998-present

Bayer, Dementia Advisory Panel, 1998-2003

Novartis Neuroscience, 1999-present

Pfizer Alzheimer's Disease Development Program 1999-present

Consultant, Dementia Research, Janssen Pharmaceutica 2000-present

Sention Inc., Dementia Drug Development, 2002-2005

Sanofi-Aventis Alzheimer's Disease, 2005-present

Elan Alzheimer's Disease, 2007-present

HOSPITAL COMMITTEES

Member, Emergency Medical Committee, Butler Hospital, 1991-1996

Member, Executive Committee, Medical Staff Association, Butler Hospital, 1994-2000

Member, Butler Hospital Research Strategic Planning Committee. 2009-2010

UNIVERSITY COMMITTEES

Member, Stanford Medical School Medical Ethics Committee, 1983-1985

Member, Yale Hillel Medical Ethics Study Section, 1986-1991

Member, Brown University Brain Imaging Center Planning Committee, 1994-1996

Associate Director, Brown University Geriatric Neuropsychiatry Research and Treatment Program, 1994-present

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

Member, Brown University Biomedical Computing Committee, 1995-1998
Member, Brown University Geriatric Psychiatry Fellowship Planning Committee, 1997-present
Member, Brown University Psychiatric Residency Curriculum Committee, 1997-present
Member, Brown University Department of Psychiatry Education Committee, 1997-present
Member, Providence VA/Brown University Geriatric Psychiatry Faculty Search Committee, 1997-2000
Member, Brown University Neurology Residency Education Committee, 1998-present
Member, Brown University Greer Professorship/Director of the Division of Geriatric Medicine Search Committee, 1998 -1999
Member, Brown University Psychiatry Residency Research Track Planning Committee, 1998-present
Member, Brown University Surdna Fellowship Review Committee, 1998-present
Reviewer, Royce Fellowship Committee, 2000-present
Member, Brown MRI Research Facility Executive Committee, 2000-2012
Co-Director, Brown Department of Psychiatry Imaging Core, 2000-present
Member, Brown Medical School Director of Pediatric Neurology Search Committee, 2001-2002
Member-Departments of Psychiatry and Psychology Research Planning Committee, 2002-present
Member-Steering Committee, Brown Cooperative for Translational Brain Research, 2002-present
Member, Department of Clinical Neurosciences Promotions Committee, 2004-2023
Member, Search Committee Director of Stroke Service Rhode Island Hospital, 2009-present
Member, Department of Psychiatry Genetics Research Committee, 2009-present
Member, Department of Psychiatry Imaging Research Committee, 2009-present
Member, Department of Psychiatry Chair Search Committee, 2011-2012
Co-chair, Alzheimer's Disease Molecular and Cellular Endowed Chair Search, 2018-present
Member, Executive Committee, Brown Center for Translational Neuroscience, 2019-present
Member, Carney Brain Sciences Executive Committee, 2020-present

STATE COMMITTEES

Member, Rhode Island Advisory Council on Alzheimer's Resarch and Treatment, 2019-present

NATIONAL COMMITTEES:

Member, Consultation-Liaison Committee, American Psychiatric Association, 1987-1989
Chairman, Scientific Program Committee, American Neuropsychiatric Association, 1993-1995
President, American Neuropsychiatric Association, 1997-1998
Member, Old-Old Depression Research Consortium, 1998-present
Member, International Neuropsychological Society Scientific Program Committee, 2003-4

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

Member, Data Safety Monitoring Board, Rasgaline for Treatment of Mild-Moderate Alzheimer's Disease, Eisai Inc., 2004-2005

Member, Institute for the Study of Aging Working Group on Guidelines for the Treatment of Alzheimer's Disease in the Managed Care Setting in New York City on October 10, 2005

Member, Medical Advisory Board. Alzheimer's Federation of America, 2004-present

Member, Guidelines for the Treatment of Dementia Panel, American Academy of Neurology, 2006-present

Member, Scientific Advisory Board. CADASIL: Together We Have Hope Foundation, 2006-present

Co-chair, Safety Evaluation Committee, Merck amyloid vaccine trial V950-001, 2007-present

Member, Steering Committee ELND005-AD201-A Phase II, Double Blind, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of Oral ELND005 in Mild to Moderate Alzheimer's Disease. 2008-present

Chair, Steering Committee, of the phase III, multicenter, randomized, double-blind, placebo-controlled trial of bapineuzumab (AAB-001, ELN115727) in patients with mild-moderate Alzheimer's disease who are apolipoprotein E ϵ 4 carriers and non-carriers.

Research Against Alzheimer's, member, 2012-present

Member, AI Coverage with Evidence Development Executive and Scientific Committees, 2013-present

Member, Alzheimer's Disease Discovery Foundation Advisory Panel on Combination Therapy in Alzheimer's Disease. 2015-present

Member, Global Alzheimer's Platform Site Leadership Committee, 2015-present

Member, Global Alzheimer's Platform Site Activation Committee, 2015-present

Member, Alzheimer's Disease Discovery Foundation Scientific Advisory Board, 2015-present

Member, NIA-funded Ante-Amyloid in Asymptomatic Alzheimer's Disease Compound Selection Committee, 2017-present

Member, Executive, Steering and Project Evaluation Committees, Alzheimer's Disease Clinical Trials Consortium, NIA and Alzheimer's Disease Therapeutic Research Institute, 2018-present

Member, Steering Committee, Longitudinal Early-onset Alzheimer's Disease Study, 2018-present

Member, Trial Leadership Committee and Steering Committee, US POINTER, 2019-present

Member, National Disease Modifying Treatment & Diagnostic Registry Work Group, Alzheimer's Association, 2021-present

INTERNATIONAL COMMITTEES:

Member, Advisory Panel, Third International Neuropsychiatry Congress Scientific Program Committee, Kyoto, Japan, 2000, 1997-2000

Member, Eisai/Pfizer International Advisory Board on Vascular Dementia, 2001-present

Member, Executive Committee International Neuropsychiatry Congress Planning Committee, 1998-present

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

Co Chair: International working group to revise the NINDS vascular dementia criteria for the International Society for Vascular Behavioral and Cognitive Disorders, 2002-present

Member, International Stroke Society to Develop an Organizing World Federation Committee for Stroke and Vascular Dementia, 2002-present

Member, Vascular Risk Factors and Dementia: Raising Risk Awareness Study Group, Madrid, Spain, October, 2005

Member, International CADASIL Study Steering Committee, Eisai, 2005-present

Member, Scientific Program Committee, 3rd Congress of the International Society for Vascular Behavioral and Cognitive Disorders, 2006-present

Member, Dimebon phase 3 Data Monitoring Committee, 2008-present

Member, Steering Committee Alzheimer's Disease Neuroimaging Initiative, 2004-present

Member, Steering Committee, Dominantly Inherited Alzheimer's Network, 2007-present

Member, International Hydrocephalus Society Neuropsychology Consensus Panel, 2009-present

Member, Clinical Trials Committee, Dominantly Inherited Alzheimer's Network, 2009-present

Member, Scientific Program Committee, 6th Clinical Trials in Alzheimer's Disease Annual Meeting, 2013-present

Member, EU/US Task Force on Alzheimer's Trials: Outcome Measures, 2014-present

Faculty member, 2015 Margoliese National Brain and Heart Disorders Prizes, 2015-present

Alzheimer's Association CSF Biomarkers Appropriate Use Criteria Work Group, 2016-present

Advisory Board, LSP Dementia Fund, 2019-present

Member, Alzheimer's Association Appropriate Use Criteria to Update Indications for Amyloid and Tau PET, 2020-present

MEMBERSHIP IN SOCIETIES

2013-present New York Academy of Sciences

2004-present American Neurological Association

2008-present International Society to Advance Alzheimer Research and Treatment

1988-present American Neuropsychiatric Association
1995-7 Associate Director, 1997-8 President, 1993-5 Chair Scientific Program Committee, Member, Committee on Research

1989-present American Academy of Neurology, Neuroimaging Section, Geriatric Neurology Section, Behavioral Neurology Section

1994-2005 Society for Neuroscience

1994-present Behavioral Neurology Society

2003-present International College of Geriatric Psychoneuropharmacology

2002-present International Society for Vascular Behavioral and Cognitive Disorders

2000-present American Association of Geriatric Psychiatry Affiliate Member

2004-present International Psychogeriatrics Association

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

- 1987-1997 American Psychiatric Association
Consultation - Liaison Committee, 1987-1989
- 1986-1995 American Medical Association

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. **Salloway S**, Price L, Charney D, Shapiro M. Multiple sclerosis presenting as major depression: A diagnosis suggested by MRI but not CT Scan. *J Clin Psychiatry*. 1988 Sep;49(9):364-66. PMID: 3417622.
2. **Salloway S**, Southwick S, Sadowsky M. Opiate withdrawal presenting as post-traumatic stress disorder. *Hospital and Community Psychiatry*. 1990 Jun;41(6):666-7. PMID: 2361672.
3. Farran C, Keane-Hagerty E, **Salloway S**, Kupferer S, Wilken C. Finding meaning: an alternative paradigm for Alzheimer's disease family caregivers. *Gerontologist*. 1991 Aug;31(4):483-9. PMID: 1894152.
4. Fogel B, Duffy J, McNamara E, **Salloway S**. Skeptics and enthusiasts in neuropsychiatry *J Neuropsychiatry and Clin Neurosci*. 1992 Fall;4(4):458-62. Review. PMID: 1422176.
5. Karper L, **Salloway S**, Seibyl J, Krystal J. Prolonged post-ictal encephalopathy in two patients following clozapine-induced seizures. *J Neuropsychiatry and Clin Neurosci*. 1992 Fall;4(4):454-7. Review. PMID: 1422175.
6. Daly J, **Salloway S**. Clozapine-induced seizures and EEG changes. *Jefferson Journal of Psychiatry*. 1993; 11:36-42.
7. Tate C, **Salloway S**, Rogg J. Clinicopathological case conference: Behavior change, hallucinations and memory loss in a twenty-five year old man. *J Neuropsychiatry and Clin Neurosci*. 1993 Fall; 5(4):435-41. PMID: 8286944.
8. **Salloway S**, Cummings J. Subcortical disease and neuropsychiatric illness. *J Neuropsychiatry and Clin Neurosci*. 1994 Spring;6(2):93-99. Review. PMID: 8044049.
9. Daly J, **Salloway S**. Dopamine receptors in the human brain. *Psychiatric Times* 1994;11:27-32.
10. Campbell J, Duffy J, **Salloway S**. Treatment strategies for patients with dysexecutive syndromes. *J Neuropsychiatry Clin Neurosci*. 1994 Fall;6(4):411-18. Review. PMID: 7841812.
11. **Salloway S**. Diagnosis and treatment of patients with frontal lobe syndromes. *J Neuropsychiatry and Clin Neurosci*. 1994 Fall;6(4):388-98. PMID: 7841810.
12. Coffey CE, Cummings JL, Duffy J, Fink M, Lauterbach EC, Lovell M, Malloy P, Nussbaum P, Royall, DR, **Salloway S**. Assessment of treatment outcomes in neuropsychiatry: a report from the Committee on Research of the American Neuropsychiatric Association. *J Neuropsychiatry and Clin Neurosci*. 1995 Summer;7(3):287-9. PMID: 7580185.
13. **Salloway S**, Malloy P, Kohn R, Gillard E, Duffy J, Rogg J, Tung G, Richardson E, Thomas C, Westlake R. MRI and neuropsychological differences in early and late-life onset geriatric depression. *Neurology*. 1996 Jun;46(6):1567-74. PMID: 8649550.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

14. **Salloway S.** Clinical-Pathological Case Conference: Depression, behavior change and subcortical dementia in a 57-year-old woman. A case of biopsy-proven CADASIL syndrome. *J Neuropsychiatry and Clin Neurosci.* 1996 Spring;8(2):215-21. PMID: 9081561.
15. **Salloway S,** Cummings J. Subcortical structures and neuropsychiatric disorders. *The Neuroscientist.* 1996;2:66-75.
16. **Salloway S,** Stewart CF, Morales X, Israeli L, Rasmussen S, Brin MF, Blitzer A. Botulinum toxin for refractory vocal tics. *Movement Disorders.* 1996 Nov;11(6): 746-8. PMID: 8914108.
17. Cahn D, Malloy P, **Salloway S,** Rogg J, Kohn R, Gillard E, Tung G, Richardson E. Subcortical hyperintensities on magnetic resonance imaging and activities of daily living in geriatric depression. *J Neuropsychiatry and Clin Neurosci.* 1996 Fall;8(4):404-11. PMID: 9116476.
18. Jenkins M, **Salloway S,** Westlake R. The diagnosis and treatment of geriatric depression. *Journal of Practical Psychiatry and Behavioral Health.* 1996;6:336-349.
19. **Salloway S,** Mermel LA, Seamans M, Aspinall G, Nam Shin J, Kurjanczyk L, Penner J. Miller Fisher Syndrome associated with Campylobacter Jejuni bearing lipopolysaccharide molecules that mimick human ganglioside GD 3. *Infection and Immunity.* 1996 Aug;64(8):2945-9. PMID: 8757818.
20. Harrington C, **Salloway S,** Malloy P. Dramatic neurobehavioral disorder in two cases following anteromedial frontal lobe injury: delayed psychosis and marked change in personality. *Neurocase.* 1997;3:137-149.
21. Jenkins M, Cimino C, Malloy P, **Salloway S,** Cohen R, Kohn R, Westlake R. Neuropsychiatric factors in the illusion of visitors among geriatric patients: a case series. *J Geriatric Psychiatry and Neurology.* 1997 Apr;10(2):79-87. PMID: 9188024.
22. **Salloway S,** White J. Paroxysmal limbic disorders in neuropsychiatry. *J Neuropsychiatry Clin Neurosci.* 1997 Summer;9(3):403-19. Review. PMID: 9276842.
23. Mega M, Cummings C, **Salloway S,** Malloy P. The limbic system: an anatomic, phylogenetic, and clinical perspective. *J Neuropsych Clin Neurosci.* 1997 Summer;9(3):315-30. Review. PMID: 9276837.
24. Jenkins M, Cohen R, Malloy P, **Salloway S,** Gillard E, Penn J, Neeper R. Neuropsychology measures discriminate among adults with residual ADD and other attentional complaints. *The Clinical Neuropsychologist.* 1998;12:74-83.
25. Jenkins M, Malloy P, **Salloway S,** Cohen R, Rogg J, Tung G, Kohn R, Westlake R, Johnson E, Richardson E. Memory processes in Depressed Geriatric Patients with and without subcortical contributions to memory: Evidence from geriatric depressed patients with subcortical hyperintensities on MRI. *Journal of Neuroimaging.* 1998 Jan;8(1):20-26. PMID: 9442586.
26. Kleiner-Fisman GK, **Salloway S,** Fisman SN. Recollection of childhood sexual abuse following endotracheal intubation. *Psychosomatics.* 1998 Nov-Dec;39(6):561-2. PMID: 9819960.
27. Cohen R, Kaplan R, Zuffante P, Moser D, Jenkins M, **Salloway S,** Wilkinson H. Alteration of intention and self-initiated action associated with bilateral anterior cingulotomy. *J Neuropsych Clin Neurosci.* 1999 Fall;11(4):444-453. Review. PMID: 10570756.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

28. Cahn-Weiner D, Malloy P, Boyle P, Marran M, **Salloway S**. Prediction of Functional Status from Neuropsychological Tests in Community-Dwelling Elderly Individuals. *The Clinical Neuropsychologist*. 2000 May; 14(2):187-95. PMID: 10916193.
29. Norton L, Malloy PF, **Salloway S**. The Impact of Behavioral Symptomatology on Activities of Daily Living in Patients with Dementia. *Am J Geriatr Psych*. 2001 Winter;9(1):41-8. PMID: 11156751.
30. **Salloway S**, Boyle P, Correia S, Malloy P, Cahn-Weiner D, Schneider L, K. Krishnan R, Nakra R. The Relationship of MRI Subcortical Hyperintensities to Treatment Response in a Placebo-Controlled Trial of Sertraline in Geriatric Depressed Outpatients. *Am J Ger Psych*. 2002 Jan-Feb;10(1):107-111. PMID: 11790641.
31. **Salloway S**, Gur T, Berzin T, Tavares R, Zipser B, Correia S, Hovanesian V, Fallon J, Tavares R, Kuo-Leblanc V, Glass D, Hulette C, Rosenberg C, Vitek M, Stopa E. Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease. *J Neurological Sciences*. 2002 Nov 15;203-204:183-187. Erratum in: *J Neurological Sciences*. 2003 Jan 15;206(1):115. PMID: 12417381.
32. **Salloway S**, Correia S, Boyle P, Malloy P, Schneider L, Lavretsky H, Sackheim H, Roose S, Krishnan KRR. MRI subcortical hyperintensities in old and very-old depressed outpatients: the important role of age in late-life depression. *J Neurological Sciences*. 2002 Nov 15;203-4:227-233. PMID: 12417389.
33. Rymer S, **Salloway S**, Norton L, Malloy P, Correia S, Monast D. Impaired awareness, behavior disturbance and caregiver burden in Alzheimer's disease. *Alzheimer's Disease and Associated Disorders*. 2002 Oct-Dec;16(4):248-53. PMID: 12468899.
34. Boyle P, Malloy P, **Salloway S**, Cahn-Weiner D, Cpjem R, Cummings J. Executive dysfunction and apathy predict functional impairment in Alzheimer's disease. *Am J Ger Psych*. 2003 Mar-Apr;11(2):214-221. PMID: 12611751.
35. Black S, Roman G, Geldmacher D, **Salloway S**, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R. Donepezil 307 Vascular Dementia Study Group. Efficacy and Tolerability of Donepezil in Vascular Dementia: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled trial. *Stroke*. 2003 Oct;34(10):2323-30. Epub 2003 Sep 11. PMID: 12970516.
36. Malloy P, Belanger H, Hall S, Aloia M, **Salloway S**. Assessing visuoconstructional performance in AD, MCI and normal elderly using the Berry Visual-Motor Integration Test. *The Clinical Neuropsychologist*. 2003 Nov;17(4):544-550. PMID: 15168918.
37. **Salloway S**, Stopa S, Douglas F, Wilterdink J, Rogg J. Amyloid angiopathy associated with cerebral hemorrhage, extensive microhemorrhages and fluctuating leukoencephalopathy. *J Neurological Sciences* 2005, in press.
38. **Salloway S**, Ferris S, Kluger A, Goldman T, Griesing T, Kumar D, Richardson S. Donepezil 401 Study Group. Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial. *Neurology*. 2004 Aug;63(4):651-7. PMID: 15326237.
39. Belanger H, Wilder-Willis K, Malloy P, Hamman R, **Salloway S**, Hamman R, Grigsby J. Assessing motor and cognitive regulation in Alzheimer's disease, mild cognitive impairment and controls using the behavioral dyscontrol scale. *Archives of Clinical Neuropsychology*. 2005 Mar;20(2):183-189. PMID: 15708728.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

40. Maclean A, Woods R, Alderson L, **Salloway S**, Correia S, Cortez S, Stopa E. Spontaneous lobar hemorrhage in CADASIL. *J Neurology Neurosurgery and Psychiatry*. 2005 Mar;76(3):456-7. PMID: 15716553.
41. Roman G, Wilkinson D, Doody R, Black S, **Salloway S**, Schindler R. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. *Dementia and Geriatric Cognitive Disorders*. 2005;20(6):338-344. Epub 2005 Sep 23. PMID: 16192723.
42. Steffens D, Otey E, Alexopoulos G, Butters M, Cuthbert B, Ganguli M, Geda Y, Hendrie H, Krishnan R, Kumar A, Lopez O, Lyketsos C, Mast B, Morris J, Norton C, Peavy G, Petersen R, Reynolds C, **Salloway S**, Welsh-Bohmer K, Yesavage J. Perspectives on depression, mild cognitive impairment, and cognitive decline. *Arch Gen Psychiatry*. 2006 Feb;63(2):130-8. PMID: 16461855.
43. Grundman M, Petersen R, Bennett D, Feldman H, **Salloway S**, Visser P, Thal L, Schenk D, Khachaturian Z, Thies W, for the Alzheimer's Association Research Roundtable. Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: What have we learned? *Alzheimer's and Dementia*. 2006 Jul;2(3):220-233. doi: 10.1016/j.jalz.2006.04.010. PMID: 19595891.
44. **Salloway S**, Correia S, Richardson S. Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnesic MCI. *Int Psychogeriatrics*. 2008 Feb;20(1):40-46. Epub 2007 Jun 28. PMID: 17597552.
45. Greenberg BD, Malone DA, Friehs GM, Rezai AR, Kubu CS, Malloy PF, **Salloway SP**, Okun MS, Goodman WK, Rasmussen SA. Three year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder: *Neuropsychopharmacology*. 2006 Nov;31(11):2384-93. Epub 2006 Jul 19. Erratum in: *Neuropsychopharmacology*. 2006 Nov;31(11):2384. PMID: 16855529.
46. Fillit H, Doody RS, Binaso K, Crooks G, Ferris S, Farlow M, Leifer B, Mills C, Minkoff N, Orland B, Reichman W, **Salloway S**. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. *Am J Geriatric Pharmacother*. 2006;4 Suppl A:S9-S24; quiz S25-S28. PMID: 17157793.
47. **Salloway S**. Buying time: Management of mild cognitive impairment and early dementia. *Int Psychogeriatr*. 2006 Sep;18 Suppl 1:S17-23.
48. Laidlaw DH, Lee SY, Correia S, Tate DF, Paul RH, Zhang S, **Salloway SP**, Malloy PF. Quantitative tract-of-interest metrics for white matter integrity based on diffusion tensor MRI data. *Views Radiology*. 2007;8:2-4.
49. Cohen R, Butala P, **Salloway S**, Gonzalez L, Johansen C, Tovares R, Hovanesian V, Hulette C, Vitek M, Stopa E. Cerebral arteriolar angiopathy, Braak Stage, vascular β -amyloid and APOE genotype. *Stroke*. 2008;39:814-821.
50. Auchus AP, Brashear HR, **Salloway S**, Korczyn AD, De Deyn PP, Gassmann-Mayer C. Galantamine treatment of vascular dementia: a randomized trial. *Neurology*. 2007 Jul;69(5):448-458. PMID: 17664404.
51. Dubois B, Feldman H, Jacova C, Dekosky S, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, **Salloway S**, Stern Y, Visser P, Scheltens P. Research criteria for the diagnosis

- of Alzheimer's disease: Revising the NINCDS-ADRDA Criteria. *Lancet Neurol.* 2007 Aug;6(8):734-746. Review. PMID: 17616482.
52. **Salloway S**, Mintzer J, Weiner M, Cummings J. Disease modifying therapies in Alzheimer's disease. *Alzheimer's and Dementia.* 2008 Mar;4(2):65-79. doi: 10.1016/j.jalz.2007.10.001. Epub 2008 Feb 20. Review. PMID: 18631951.
53. Dichgans M, Markus H, **Salloway S**, Verkkoniemi A, Wang Q, Moline M, Posner H, Chabriat H. Donepezil in Patients with Subcortical vascular cognitive impairment: a randomized double blind trial in CADASIL. *Lancet Neurol.* 2008 Apr;7(4):310-8. doi: 10.1016/S1474-4422(08)70046-2. Epub 2008 Feb 28. PMID: 18296124.
54. Stopa E, Butala P, **Salloway S**, Johanson C, Gonzales L, Tavares R, Hovanesian V, Hulette C, Vitek M, Cohen R. Cerebral Cortical Arteriolar Angiopathy, Vascular beta-amyloid, Smooth Muscle Actin, Braak Stage, and APOE Genotype. *Stroke.* 2008 Mar;39(3):814-21. doi: 10.1161/STROKEAHA.107.493429. Epub 2008 Feb 7. Erratum in: *Stroke.* 2010 Aug;41(8):e551. PMID: 18258839.
55. **Salloway S**, Correia S. Alzheimer disease: Time to improve its diagnosis and treatment. *Cleveland Clinic Journal of Medicine.* 2009 Jan;76(1):49-58. doi: 10.3949/ccjm.76a.072178. PMID: 19122111.
56. Greenberg BD, Gabriels LA, Malone DA Jr, Rezai AR, Friehs GM, Okun MS, Shapira NA, Foote KD, Cosyns PR, Kubu CS, Malloy PF, **Salloway SP**, Giftakis JE, Rise MT, Machado AG, Baker KB, Stypulkowski PH, Goodman WK, Rasmussen SA, Nuttin BJ. Deep Brain Stimulation of the Ventral Internal Capsule/Ventral Striatum for Obsessive-Compulsive Disorder: Worldwide Experience. *Molecular Psychiatry.* 2010 Jan;15(1):64-79. doi: 10.1038/mp.2008.55. Epub 2008 May 20. PMID: 18490925.
57. Correia S, Lee S, Voorn T, Tate D, Paul R, Zhang S, **Salloway S**, Malloy P, Laidlaw D. Quantitative tractography metrics for white matter integrity in diffusion tensor MRI. *Neuroimage.* 2008 Aug 15;42(2):568-81. doi: 10.1016/j.neuroimage.2008.05.022. Epub 2008 May 24. Erratum in: *Neuroimage.* 2009 May 15;46(10):344. PMID: 18617421.
58. Malone D, Dougherty D, Rezai A, Carpenter L, Friehs G, Eskander E, Rauch S, Rasmussen S, Machado A, Kubu C, Tyrka A, Price L, Stypulkowski P, Giftakis J, Malloy P, **Salloway S**, Greenberg B. Deep brain stimulation of the ventral capsule/ventral striatum for treatment resistant depression. *Biological Psychiatry.* 2009 Feb 15;65(4):267-275. doi: 10.1016/j.biopsych.2008.08.029. Epub 2008 Oct 8. PMID: 18842257.
59. Doody RS, Ferris S, **Salloway S**, Sun Y, Goldman R, Xu Y, Murthy A. Donepezil treatment of patients with MCI: a 48 week randomized, placebo-controlled trial. *Neurology.* 2009 May 5; 72(18):1555-61. doi: 10.1212/01.wnl.0000344650.95823.03. Epub 2009 Jan 28. PMID: 19176895.
60. **Salloway S**, Sperling R, Gilman S, Fox N, Blennow K, Raskind M, Sabbagh M, Honig L, Doody R, van Dyck C, Mulnard R, Gregg K, Liu E, Lieberburg L, Schenk D, Black R, Grundman M for the Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer's disease. *Neurology.* 2009 Dec 15;73(24):2061-70. doi: 10.1212/WNL.0b013e3181c67808. Epub 2009 Nov 18. PMID: 19923550.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

61. Wilkinson D, Roman G, **Salloway S**, Hecker J, Boundy K, Kumar D, Posner H, Schindler R. The long-term efficacy and tolerability of donepezil in patients with vascular dementia. *Intl J Geriatr Psychiatry*. 2010 Mar;25(3):305-313. doi: 10.1002/gps.2340. PMID: 19623601.
62. Doody R, Ferris S, **Salloway S**, Sun Y, Goldman R, Xu Y, Gao J, Murthy A. Safety and tolerability of donepezil in patients with mild cognitive impairment: A 28-week open-label extension study. *Am Journal of Alzheimer's Disease and Other Dementias*. 2010 Mar;25(2):155-9. doi: 10.1177/1533317509352334. Epub 2009 Nov 30. PMID: 19949165.
63. Roman G, **Salloway S**, Black S, Royall D, Decarli C, Weiner M, Moline M, Kumar, D, Schindler R, Posner H. Randomized, placebo-controlled clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. *Stroke*. 2010 Jun;41(6):1213-21. doi: 10.1161/STROKEAHA.109.570077. Epub 2010 Apr 15. PMID: 20395618.
64. Brennan-Krohn T, **Salloway S**, Correia S, Dong M, delaMonte S. Glial-vascular degeneration in cerebral autosomal dominant arteriopathy with leukoencephalopathy and subcortical infarction (CADASIL). *Journal of Alzheimer's Disease*. 2010;21(4): 1393-1402. PMID: 21504125.
65. Farlow MR, **Salloway S**, Tariot PN, Yardley J, Moline M, Wang Q, Hsu T. Effectiveness and Tolerability of high dose (23 mg/d) versus standard dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. *Clinical Therapeutics*. 2010 Jul;32(7):1234-51. doi: 10.1016/j.clinthera.2010.06.019. PMID: 20678673.
66. Doody R, Ferris S, **Salloway S**, Meuser T, Murthy A, Li C, Goldman R. Identifying amnesic mild cognitive impairment in primary care: a feasibility study. *Clinical Drug Investigation*. 2011;31(7):483-91. doi: 10.2165/11588810-000000000-00000. PMID: 21627337.
67. Dubois B, Feldman, H, Jacova C, Cummings J, DeKosky S, Barberger-Gateau P, Delacourte A, Frisoni G, Fox N, Galasko D, Gauthier S, Hampel H, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, **Salloway S**, Sarazin M, de Souza L, Stern Y, Visser P, Scheltens P. Revising the definition of Alzheimer's disease: a new lexicon. *Lancet Neurol*. 2010 Nov;9(11):1118-27. doi: 10.1016/S1474-4422(10)70223-4. Epub 2010 Oct 9. PMID: 20934914.
68. Bateman R, Aisen P, De Strooper B, Fox N, Lemere C, Ringman J, **Salloway S**, Sperling R, Windisch M, Xiong C. Autosomal dominant Alzheimer's disease: A review and proposal for the prevention of Alzheimer's disease. *Alzheimer's Research and Therapy*. 2011 Jan 6;3(1):1-10. doi: 10.1186/alzrt59. PMID: 21211070.
69. Becker AJ, Hedden T, Carmasin J, Maye J, Rentz D, Putcha D, Fischl B, Greve D, Marshall G, **Salloway S**, Marks D, Buckner R, Sperling R, Johnson K. Amyloid- β associated cortical thinning in clinically normal elderly. *Annals of Neurology*. 2011 Jun;69(6): 1032-42. doi: 10.1002/ana.22333. Epub 2011 Mar 17. PMID: 21437929.
70. Epstein-Lubow G, Gaudiano B, Hinckley M, **Salloway S**, Miller I. Evidence for the Validity of the American Medical Association's caregiver self-assessment questionnaire as a screening measure for depression. *American Journal of Geriatric Psychiatry*. 2010 Feb;58(2):387-8. doi: 10.1111/j.1532-5415.2009.02701.x. PMID: 20370867.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

71. **Salloway S**, Sperling R, Keren R, Porsteinsson A, van Dyck C, Tariot P, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Bairu M, Pastrak A, Cedarbaum J. A phase 2 randomized trial of ELND005 (scyllo-inositol) in Mild to Moderate Alzheimer's Disease. *Neurology*. 2011 Sep 27;77(13):1253-62. doi: 10.1212/WNL.0b013e3182309fa5. Epub 2011 Sep 14. PMID: 21917766.
72. Epstein-Lubow G, Guadiano B, Darling E, Hinckley M, Tremont G, Kohn R, Marino L, **Salloway S**, Grinnell R, Miller I. Differences in Depression severity in family caregivers of hospitalized individuals with dementia and family caregivers of outpatients with dementia. *Am J Geriatric Psychiatry*. 2012 Sep;20(9):815-9. doi: 10.1097/JGP.0b013e318235b62f. PMID: 21997604.
73. Frakey L, **Salloway S**, Buelow M, Malloy P. A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild to moderate Alzheimer's disease. *J Clin Psychiatry*. 2012 Jun;73(6):796-801. doi: 10.4088/JCP.10m06708. Epub 2012 May 15. PMID: 22687392.
74. Blennow K, Zetterberg H, Rinne J, **Salloway S**, Wei J, Black R, Grundman M, Liu E. Effect of Immunotherapy with bapineuzumab lowered CSf tau levels in patients with mild-moderate Alzheimer's disease. *Archives of Neurology*. 2012 Aug;69(8):1002-10. PMID: 22473769.
75. Sperling R, **Salloway S**, Brooks D, Tampieri, Barakos G, Fox N, Raskind M, Sabbagh M, Honig L, Porsteinsson A, Lieberburg A, Arrighi M, Morris K, Lu, Liu E, Gregg K, Brashear R, Black R, Grundman M. Amyloid related imaging abnormalities (ARIA) in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. *Lancet Neurol*. 2012 Mar;11(3):241-9. doi: 10.1016/s1474-4422(12)70015-7. Epub 2012 Feb 3. PMID: 22305802.
76. Bakken TE, Roddey JC, Djurovic S, Akshoomoff N, Amaral DG, Bloss CS, Casey BJ, Chang L, Ernst TM, Gruen JR, Jernigan TL, Kaufmann WE, Kenet T, Kennedy DN, Kuperman JM, Murray SS, Sowell ER, Rimol LM, Mattingsdal M, Melle I, Agartz I, Andreassen OA, Schork NJ, Dale AM; Alzheimer's Disease Neuroimaging Initiative; Pediatric Imaging, Neurocognition, and Genetics Study, Weiner M, Aisen P, Petersen R, Jack CR Jr, Jagust W, Trojanowki JQ, Toga AW, Beckett L, Green RC, Saykin AJ, Morris J, Liu E, Montine T, Gamst A, Thomas RG, Donohue M, Walter S, Gessert D, Sather T, Harvey D, Kornak J, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Bandy D, Koeppe RA, Foster N, Reiman EM, Chen K, Mathis C, Cairns NJ, Taylor-Reinwald L, Trojanowki JQ, Shaw L, Lee VM, Korecka M, Crawford K, Neu S, Foroud TM, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder PJ, Molchan S, Kaye J, Quinn J, Lind B, Dolen S, Schneider LS, Pawluczyk S, Spann BM, Brewer J, Vanderswag H, Heidebrink JL, Lord JL, Johnson K, Doody RS, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig LS, Bell KL, Morris JC, Ances B, Carroll M, Leon S, Mintun MA, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Mitsis E, Romirowsky A, deToledo-Morrell L, Shah RC, Duara R, Varon D, Roberts P, Albert M, Onyike C, Kielb S, Rusinek H, de Leon MJ, Glodzik L, De Santi S, Doraiswamy PM, Petrella JR, Coleman RE, Arnold SE, Karlawish JH, Wolk D, Smith CD, Jicha G, Hardy P, Lopez OL, Oakley M, Simpson DM, Porsteinsson AP, Goldstein BS, Martin K, Makino KM, Ismail MS, Brand C, Mulnard RA, Thai G, Mc-Adams-Ortiz C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, Martin-Cook K, DeVous M, Levey

- AI, Lah JJ, Cellar JS, Burns JM, Anderson HS, Swerdlow RH, Apostolova L, Lu PH, Bartzokis G, Silverman DH, Graff-Radford NR, Parfitt F, Johnson H, Farlow MR, Hake AM, Matthews BR, Herring S, van Dyck CH, Carson RE, MacAvoy MG, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Ging-Yuek, Hsiung R, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam MM, Lipowski K, Wu CK, Johnson N, Sadowsky C, Martinez W, Villena T, Turner RS, Johnson K, Reynolds B, Sperling RA, Johnson KA, Marshall G, Frey M, Yesavage J, Taylor JL, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Kowall N, Killiany R, Budson AE, Norbash A, Johnson PL, Obisesan TO, Wolday S, Bwayo SK, Lerner A, Hudson L, Ogrocki P, Fletcher E, Carmichael O, Olichney J, Kittur S, Borrie M, Lee TY, Bartha R, Johnson S, Asthana S, Carlsson CM, Potkin SG, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre DW, Katakami M, Zimmerman EA, Celmins D, Brown AD, Pearlson GD, Blank K, Anderson K, Santulli RB, Schwartz ES, Sink KM, Williamson JD, Garg P, Watkins F, Ott BR, Querfurth H, Tremont G, **Salloway S**, Malloy P, Correia S, Rosen HJ, Miller BL, Mintzer J, Longmire CF, Spicer K, Finger E, Rachinsky I, Drost D, Jernigan T, McCabe C, Grant E, Ernst T, Kuperman J, Chung Y, Murray S, Bloss C, Darst B, Pritchett L, Saito A, Amaral D, DiNino M, Eyngorina B, Sowell E, Houston S, Soderberg L, Kaufmann W, van Zijl P, Rizzo-Busack H, Javid M, Mehta N, Ruberry E, Powers A, Rosen B, Gebhard N, Manigan H, Frazier J, Kennedy D, Yakutis L, Hill M, Gruen J, Bosson-Heenan J, Carlson H. Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. *Proc Natl Acad Sci USA*. 2012 Mar 6;109(10):3985-90. doi: 10.1073/pnas.1105829109. Epub 2012 Feb 16. PMID: 22343285.
77. Boxer A, Gold M, Huey E, Gao FB, Burton E, Chow T, Kao A, Leavitt B, Lamb B, Grether M, Knopman D, Cairns N, Mackenzie I, Mitic L, Roberson E, Van Kammen D, Cantillon M, Zahr K, **Salloway S**, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian Z, Sutherland M, Farese R, Miller B, Cummings J, and FTD: The next therapeutic frontier, Part I: Molecules and animal models for FTD drug development. *Alz and Dementia*. 2013 Mar;9(2):176-88. doi: 10.1016/j.jalz.2012.03.002. Epub 2012 Oct 5. PMID: 23043900.
78. Boxer A, Gold M, Huey E, Hu W, Rosen H, Kramer J, Gao FB, Burton E, Chow T, Kao A, Leavitt B, Lamb B, Grether M, Knopman D, Cairns N, Mackenzie I, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahr K, Jackson G, **Salloway S**, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian Z, Sutherland M, Abushakra S, Seubert P, Lewcock J, Farese R, Kenet R, LaFerla F, Perrin S, Whittaker S, Honig L, Boeve B, Grossman M, Miller B, Cummings J. The advantages of FTD drug development. *Alz and Dementia*. 2013 Mar;9(2):189-198. doi: 10.1016/j.jalz.2012.03.003. Epub 2012 Oct 19. PMID: 23062850.
79. Coric V, van Dyck C, **Salloway S**, Andreasen N, Brody M, Richter R, Soininen H, Thein S, Shiovitz T, Pilcher G, Colby S, Rollin L, Dochins R, Pachai C, Portelius E, Andreasson U, Blennow K, Albright C, Feldman H, Berman R. Safety and tolerability of the gamma secretase inhibitor BMS-708163 in a Phase 2 study in mild-to-moderate Alzheimer's disease. *Archives of Neurology*. 2012 Nov;69(11):1430-40. PMID: 22892585.
80. **Salloway S**, Mintzer J, Cummings J, Geldmacher D, Sun Y, Yardley J, Mackell J. Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease. *Am J Alz Dis and other Dementias*. 2012 Sep;27(6):421-32. doi: 10.1177/1533317512454708. PMID: 22930699.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

81. Tariot P, **Salloway S**, Yardley J, Mackell J, Moline M. Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease. *BMC Res Notes*. 2012 Jun 8;5:283. doi: 10.1186/1756-0500-5-382. PMID: 22681723.
82. Bateman R, Xiong C, Benzinger T, Fagan A, Goate A, Storandt M, Fox N, Marcus D, Cairns N, Xie X, Holtzman D, Santacruz A, Buckles V, Oliver A, Moulder K, Ghetti B, Klunk W, McDade E, Martins R, Masters C, Mayeux R, Ringman J, Rossor M, Schofield P, Sperling R, **Salloway S**, Morris J, and The Dominantly Inherited Alzheimer Network (DIAN)*. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's disease. *New England Journal of Medicine*. 2012 Aug;30;367(9):795-804. doi: 10.1056/NEJMoA1202753. Epub 2012 Jul 11. Erratum in NEJM. 2012 Aug 23; 367(8):780. PMID: 22784036.
83. Morris J, Aisen P, Bateman R, Benzinger T, Buckholtz N, Cairns N, Fagan A, Ghetti B, Goate A, Hawver D, Holtzman D, Klunk W, Mani R, Marcus D, Martins R, Masters C, Mayeux R, Oliver A, Quaid K, Ringman J, Rossor M, **Salloway S**, Schofield P, Selsor N, Sperling R, Weiner M, Xiong C, Moulder K, Buckles V for the Dominantly Inherited Alzheimer Network. Developing an international network for Alzheimer's research: the Dominantly Inherited Alzheimer's Network. *Clinical Investigation*. 2012 Oct 1;2(10):975-984. doi: 10.1177/1533317512454708. PMID: 23139856.
84. Grundman M, Pontecorvo M, **Salloway S**, Doraiswamy P, Fleischer A, Sadowsky C, Nair A, Siderowf A, Lu M, Arora A, Agbulos A, Flitter M, Krautkramer M, Beaudry M, Sarsour K, Skovronsky D, Mintun M for the AV45-A17 Study Group. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. *Alzheimer's Disease and Associated Disorders*. 2013 Jan-Mar;27(1):4-15. doi: 10.1097/WAD.0b013e318279d02a. PMID: 23203162.
85. Gierman-Riblon, C, **Salloway S**. Teaching Interprofessionalism to Nursing Students: A learning Experience Based on Allport's Intergroup Contact Theory. *Nursing Education Perspect*. 2013 Jan-Feb;34(1):59-62. PMID: 23586209.
86. Barakos J, Sperling R, **Salloway S**, Jack C, Gass A, Fiebach J, Tampieri D, Melanson D, Miaux Y, Rippon G, Black R, Yu Y, Liu E, Brashear H, Arrighi H, Morris K, Grundman M. MR imaging features of ARIA (Amyloid-related imaging abnormalities) in subjects treated with bapineuzumab. *Am J Neuroradiology*. 2013 Oct;34(10):1958-65. doi: 10.3174/ajnr.A3500. Epub April 11, 2013. PMID: 23578674.
87. Wendell L, Potter S, Roth J, **Salloway S**, Thompson B. Successful Management of Severe Neuroinvasive Eastern Equine Encephalitis, *Neurocritical Care*. 2013 Aug;19(1):111-115. doi: 10.1007/s12028-013-9822-5. PMID: 23733173.
88. Chhatwal J, Schultz A, Johnson K, Benzinger T, Jack C, **Salloway S**, Ringman J, Koeppe R, Marcus D, Thompson P, Saykin A, Correia S, Schofield P, Rowe C, Fox N, Goate A, Xiong C, Buckles V, Moulder K, Morris J, Sperling R for the Dominantly Inherited Alzheimer's Network. Impaired default network functional connectivity in autosomal dominant Alzheimer's disease: Findings from the DIAN study. *Neurology*. 2013 Aug 20;81(8):736-44. doi: 10.1212/WNL.9b913e3182a1aafe. Epub 2013 Jul 24. PMID: 23884042.
89. Cash D, Ridgway G, Modat M, Ryan NS, Kinnunen KM, Cardoso MJ, Benzinger TLS, Jack Jr. CR, Raichle M², Marcus D, Ringman J, Thompson PM, Ghetti BF, **Salloway S**,

- Sperling R, Schofield P, Masters CL, Martins R, Mayeux R, Weiner M, Bateman R, Fagan A, Goate A, Buckles V, Moulder K, Morris JC, Rossor MN, Ourselin S, Fox NC, for the DIAN study group. The Pattern of Atrophy in Familial Alzheimer's Disease: Volumetric MRI results from the DIAN study group. *Neurology*. 2013 Oct 15;81(16):1425-33. doi: 10.1212/WNL.0b013e3182a841c6. Epub 2013 Sep 18. PMID: 24049139.
90. Mills S, Mallmann J, Santacruz A, Fuqua A, Carril M, Aisen P, Althage M, Belyew S, Benzinger T, Brooks W, Buckles V, Cairns N, Clifford D, Danek A, Fagan A, Farlow M, Fox N, Ghetti B, Goate A, Heinrichs D, Hornbeck R, Jack C, Jucker M, Klunk W, Marcus D, Masters C, Martins R, Mayeux R, McDade E, Morris J, Oliver A, Ringman J, Rossor M, **Salloway S**, Schofield P, Snider J, Snyder P, Sperling R, Stewart C, Thomas R, Xiong C, Bateman R. Preclinical Trials in Autosomal Dominant Alzheimer's Disease: Implementation of the DIAN-TU Trial. *Revue Neurologique*. 2013 Oct;169(10):737-43. doi: 10.1016/j.neurol.2013.07.017. Epub 2013 Sep 6. PMID: 24016464.
91. **Salloway S**, Sperling R, Fox N, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig L, Porsteinsson A, Ferris S, Reichert M, Ketter N, Nedjadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor J, Liu E, Grundman M, Yuen E, Black R, Brashear R. Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. *New England Journal of Medicine*. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. PMID: 24450891.
92. Benzinger T, Blazey T, Jack C, Koeppe R, Su Y, Xiong C, Raichle M, Snyder A, Ances B, Bateman R, Cairns N, Fagan A, Goate A, Marcus D, Aisen P, Christensen J, Ercole L, Hornbeck R, Farrar A, Aldea P, M Jasielc M, Owen C, Xie X, Mayeux R, Brickman A, McDade E, Klunk W, Mathis C, Ringman J, Thompson P, Ghetti B, Saykin A, Sperling R, Johnson K, **Salloway S**, Correia S, Schofield P, Masters C, Rowe C, Villemagne V, Martins R, Ourselin S, Rossor M, Fox N, Cash D, Weiner M, Holtzman D, Buckles V, Moulder K, Morris J. Dominantly Inherited Alzheimer Network. Regional Variability of Imaging Biomarkers in Autosomal Dominant Alzheimer's Disease. *Proceedings National Academy of Sciences*. 2013 Nov 19;110(47):E4502-4509. doi: 10.1073/pnas.1317918110. Epub 2013 Nov 5. PMID: 24194552.
93. Snyder PJ, Lim YY, Schindler R, Ott BR, **Salloway S.**, Daiello L, Getter C, Gordon CM & Maruff P. (2014). Micro-Dosing of Scopolamine as a "Cognitive Stress Test": Rationale and Test of a Very Low Dose in an At-Risk Cohort of Older Adults. *Alzheimer's & Dementia*. 2014 Mar;10(2):262-7. doi: 10.1016/j.jalz.2014.01.009. PMID: 24698030.
94. Fagan A, Xiong C, Jasielc S, Bateman R, Goate A, Benzinger T, Ghetti B, Martins R, Masters C, Mayeux R, Ringman J, Rossor M, **Salloway S**, Schofield P, Sperling R, Marcus D, Cairns N, Buckles V, Ladenson J, Morris J, Holtzman D. Longitudinal Change in CSF biomarkers in autosomal-dominant Alzheimer's disease. *Science Translational Medicine*. 2014 Mar 5;6(226):226ra30. doi: 10.1126/scitranslmed.3007901. PMID: 24598588.
95. Ryman D, Natalia Acosta-Baena N, Aisen P, Bird T, Danek A, Fox N, Goate A, Frommelt P, Ghetti B, Langbaum J, Lopera F, Martins R, Masters C, Mayeux R, McDade E, Moreno S., Reiman E, Ringman J, **Salloway S**, Schofield P, Sperling R, Tariot P, Xiong C, Morris J, Bateman R. Symptom onset in autosomal dominant Alzheimer disease: a systematic

- review and meta-analysis. *Neurology*. 2014 Jul 15;83(3):253-60. doi: 10.1212/WNL.0000000000000596. Epub 2014 Jun 13. PMID: 24928124.
96. Dubois B, Feldman H, Jacova C, Hampel H, Molinuevo J, Blennow K, DeKosky S, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni G, Fox N, Galasko D, Habert M, Jicha G, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, **Salloway S**, Sarazin M, Epelbaum S, de Souza L, Vellas B, Visser P, Schneider L, Stern Y, Scheltens P, Cummings J. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 Criteria. *Lancet Neurol*. 2014 Jun;13(6):614-29. doi: 10.1016/S1474-4422(14)70090-0. Erratum in: *Lancet Neurol*. 2014 Aug;13(8):757. PMID 24849862.
97. Stephenson D, Perry D, Bens C, Bain L, Berry D, Krams M, Sperling R, Dilts D, Luthman J, Hanna D, McKew J, Temple R, Fox A, Fields O, **Salloway S**, Katz R. Charting a path toward combination therapy for Alzheimer's disease. *Expert Rev Neurotherapeutics*. 2015 Jan;15(1):107-13. doi: 10.1586/14737175.2015.995168. Epub 2014 Dec 26. PMID: 25540951.
98. Thomas JB, Brier MR, Bateman RJ, Snyder AZ, Benzinger TL, Xiong C, Raichle M, Holtzman DM, Sperling RA, Mayeux R, Ghetti B, Ringman JM, **Salloway S**, McDade E, Rossor MN, Ourselin S, Schofield PR, Masters CL, Martins RN, Weiner MW, Thompson PM, Fox NC, Koeppe RA, Jack CR Jr, Mathis CA, Oliver A, Blazey TM, Moulder K, Buckles V, Hornbeck R, Chhatwal J, Schultz AP, Goate AM, Fagan AM, Cairns NJ, Marcus DS, Morris JC, Ances BM. Functional connectivity in autosomal dominant and late-onset Alzheimer's disease. *JAMA Neurol*. 2014 Sep;71(9):1111-22. doi: 10.1001/jamaneurol.2014.1654. PMID: 25069482.
99. Curtis C, Gamez J, Sadowsky C, Villena T, Sabbagh M, Beach T, Duara R, Fleischer A, Frey K, Walker Z, Hunjan A, Holmes C, Escovar Y, Vera C, Agronin M, Ross J, Bozoki A, Akinola M, Shu J, Vandenberghe R, Ikonovic M, Sherwin P, Grachev I, Farrar G, Smith A, Buckley C, McLain R, **Salloway S**. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. *JAMA Neurol*. 2015 Mar;72(3):287-94. doi: 10.1001/jamaneurol.2014.4144. PMID: 25622185.
100. Ringman J, Liang L, Vangala S, Teng E, Kremen S, Wharton D, Goate A, Marcus D, Farlow M, Ghetti B, McDade E, Masters C, Mayeux R, Rossor M, **Salloway S**, Schofield P, Cummings J, Buckles V, Bateman R, Morris J. Early behavioral changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. *Brain* 2015 Apr;138:1036-45. doi: 10.1093/brain/awv004. Epub 2015 Feb 15. Erratum in *Brain*. 2015 Dec;138:e401. PMID: 25688083.
101. Monserrate A, Ryman D, Ma S, Xiong C, Noble J, Ringman J, Morris J, Danek A, Muller-Sarnowski F, Clifford D, McDade E, Brooks W, Darby D, Masters C, Weston P, Farlow M, Graff-Radford N, **Salloway S**, Fagan A, Oliver A, Bateman R. Factors associated with the onset and persistence of post-lumbar puncture headache. *JAMA Neurol*. 2015 Mar;72(3):325-32. doi: 10.1001/jamaneurol.2014.3974. PMID: 25622095.
102. Perry D, Sperling R, Katz R, Berry D, Dilts D, Hanna D, **Salloway S**, Trojanowski J, Bountra C, Krams M, Luthman J, Potkin S, Gribkoff V, Temple R, Wang Y, Carrillo M, Stephenson D, Snyder H, Liu E, Ware T, McKew J, Fields F, Bain L, Bens C. Building a roadmap for developing combination therapies for Alzheimer's disease. *Expert Rev*

- Neurotherapeutics*. 2015 Mar;15(3):327-33. doi: 10.1586/14737175.2015.996551. PMID: 25708309.
103. Liu E, Schmidt M, Margolin R, Sperling R, Koeppe R, Mason N, Klunk W, Mathis C, **Salloway S**, Fox N, Hill D, Les A, Collins P, Gregg K, Di J, Lu Y, Tudor I, Wyman B, Booth K, Broome S, Yuen E, Grundman M, Brashear R. Amyloid-beta 11C-PiB PET imaging results from two randomized bapineuzumab phase 3 AD trials. *Neurology*. 2015 Aug 25;85(8):692-700. doi: 10.1212/WNL.0000000000001877. Epub 2015 Jul 24. PMID: 26208959.
 104. Vellas B, Bateman R, Blennow K, Frisoni G, Johnson K, Katz R, Langbaum J, Marson D, Sperling R, Wessels A, **Salloway S**, Doody R, Aisen P. Endpoints for pre-dementia AD trials: A report from the EU/US/CTAD Task Force. *J Prev Alzheimers Dis*. 2015 Jun;2(2):128-135. PMID: 26247004.
 105. Coric V, **Salloway S**, van Dyck C, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Pilcher G, Ferris S, Colby S, Kerselaers W, Dockens R, Soares H, Kaplita S, Luo F, Pachai C, Bracoud L, Mintun M, Grill J, Marek K, Seibyl J, Cedarbaum J, Albright C, Feldman H, Berman R. Targeting prodromal Alzheimer's disease with Avagacestat: A Randomized Clinical Trial. *JAMA Neurol*. 2015 Nov;72(11):1324-33. doi: 10.1001/jamaneurol.2015.0607. PMID: 26414022.
 106. Holroyd K, Fosdick L, Smith G, Leoutsakos J, Munro C, Oh E, Drake K, Rosenberg P, Anderson W, **Salloway S**, Pendergrass C, Burke A, Wolk D, Tang-Wai D, Ponce F, Asaad W, Sabbagh M, Okun M, Baltuch G, Foote K, Targum S, Lozano A, Lyketsos C. Deep brain stimulation targeting the fornix for mild Alzheimer Dementia: design of the ADvance randomized controlled trial. *Open Access Journal of Clinical Trials* 2015, in press.
 107. Correia S, Ahern D, Rabinowitz A, **Salloway S**, Malloy P, Deoni S. Lowering the floor on Trail Making Test – Part B: psychometric evidence for a new scoring metric. *Arch Clin Neuropsychol*. 2015 Nov;30(7):643-56. doi: 10.1093/arclin/acv040. Epub 2015 Jul 11. PMID: 26164816.
 108. Wang F, Gordon B, Ryman D, Ma S, Xiong C, Hassenstab J, Goate A, Fagan A, Cairns N, Marcus D, McDade E, Ringman J, Graff- Radford N, Ghetti B, Farlow M, Sperling R, **Salloway S**, Schofield P, Masters C, Martins R, Rossor M, Jucker M, Danek A, Förster S, Lane C, Morris J, Benzinger T, Bateman R. Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. *Neurology* 2015 Sep 1;85(9):790-8. doi: 10.1212/WNL.000000001903. Epub 2015 Aug 5. PMID: 26245925.
 109. Lim Y, Maruff P, Schindler R, Ott B, **Salloway S**, Yoo D, Noto R, Santos C, Snyder P. Disruption of cholinergic neurotransmission exacerbates A-beta related cognitive impairment in preclinical Alzheimer's disease. *Neurobiology of Aging*. 2015 Oct;36(10):2709-15. doi: 10/1016/j.neurobiolaging.2015.07.009. Epub 2015 Jul 10. PMID: 26233262.
 110. Rossetti M, Piryatinsky I, Ahmed F, Klinge P, Relkin N, **Salloway S**, Ravdin L, Malloy P, Levin B, Broggi M, Gavett R, Maniscalco J, Katzen H. Two Novel Psychomotor Tasks in Idiopathic Normal Hydrocephalus. *J Int Neuropsychol Soc* 2016 Mar;22(3):341-9. doi: 10.1017/S1355617715001125. Epub 2016 January 28. PMID: 26817685.

111. Scheltens P, Blennow K, Breteler M, De Stropper B, Frisoni G, **Salloway S**, Van der Flier W. Seminar: Alzheimer's Disease. *Lancet* 2016 Jul 30;388(10043):505-17. doi: 10.1016/S0140-6736(15)01124-1. Epub 2016 February 24. PMID: 26921134.
112. Aisen P, Touchon J, Andrieu S, Boada M, Doody R, Roehy R, Langbaum J, Schneider L, Hendrix S, Wilcock D, Molinuevo J, Ritchie C, Ouesset P, Cummings J, Sperling R, Dekosky S, Lovestone S, Hampel H, Petersen R, Legrand V, Egan M, Randolph C, **Salloway S**, Weiner M, Vellas B. Registries and Cohorts to Accelerate Early Phase Alzheimer's Trials: A Report from the E.U./U.S. Clinical Trials in Alzheimer's Disease Task Force. *J Prevention of Alzheimer's Disease* 2016;3(2):68-74. doi: 10.14283/jpad.2016.97. PMID: 29210442.
113. Su Y, Blazey T, Owen C, Christensen J, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck R, Ances B, Snyder A, Cash L, Koeppe R, Klunk W, Galasko D, Brickman A, McDade E, Ringman J, Thompson P, Saykin A, Ghetti B, Sperling R, Johnson K, **Salloway S**, Schofield P, Masters C, Villemagne V, Fox N, Forster S, Chen K, Reiman E, Xiong C, Marcus D, Weiner M, Morris J, Bateman R, Benzinger T. Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer Disease: Results from the DIAN Study Group. *PLOS ONE* 2016 Mar 24;11(3):e0152082. doi: 10.1371/journal.pone.0152082. eCollection 2016. Erratum in: *PLoS One*. 2106;11(9):30163669. PMID: 27010959.
114. Lee S, Viqar M, Zimmerman A, Narkhede G, Tosto T, Benzinger D, Marcus A, Fagan A, Goate A, Fox N, Cairns N, Holtzman D, Buckles V, Ghetti B, McDade E, Martins R, Saykin A, Masters C, Ringman J, Ryan N, Forster S, Laske C, Schofield P, Sperling R, **Salloway S**, Correia S, Jack C, Weiner M, Bateman R, Morris J, Mayeux R, Brickman A. White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the Dominantly Inherited Alzheimer Network. *Annals of Neurology* 2016 Jun;79(6):929-39. doi: 10.1002/ana.24647. Epub 2016 Apr 27. PMID: 27016429.
115. Su Y, Blazey T, Owen C, Christensen J, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck R, Ances B, Raichle M, Snyder A, Cash L, Koeppe R, Klunk W, Galasko D, Brickman A, McDade E, Ringman J, Thompson P, Saykin A, Ghetti B, Sperling R, Johnson K, **Salloway S**, Schofield P, Masters C, Villemagne V, Fox N, Forster S, Chen K, Reiman E, Xiong C, Marcus D, Weiner M, Morris J, Bateman R, Benzinger T. Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer Disease: Results from the DIAN Study Group. *PLOS ONE*. 2016 Sep 20;11(9):e0163669. doi: 10.1371/journal.pone.0163669. eCollection 2016. PMID: 27649320.
116. Dubois B, Hampel H, Feldman H, Scheltens, P, Aisen, P, Andrieu S, Bakardjian, H, Benali, H, Bertram, L, Blennow K, Broich K, Cavado E, Crutch S, Dartigues J, Duyckaerts C, Epelbaum S, Frisoni G, Gauthier S, Genthon R, Gouw, A, Habert M, Holtzman D, Kivipelto M, Lista S, Molinuevo J, O'Bryant S, Rabinovici G., Rowe C, **Salloway S**, Schneider L, Sperling R, Teichmann M, Carrillo M, Cummings J, Jack C. Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on "The Preclinical State of AD; July 23, 2015; Washington DC. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. *Alzheimers Dement*. 2016 Mar;12(3): 292-323. doi: 10/1016/j.jalz.2016.02.002. Review. PMID: 27012484.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

117. Lozano A, Fosdick L, Chakravarty M, Leoutsakos J, Munro C, Esther Oh E, Drake K, Lyman C, Rosenberg P, Anderson W, Tang-Wai D, Pendergrass C, **Salloway S**, Asaad W, Ponce F, Burke A, Sabbagh M, Wolk D, Baltuch G, Okun M, Foote K, McAndrews M, Giacobbe P, Targum S, Lyketsos C, Smith G. A phase 2 study of Fornix deep brain stimulation in mild Alzheimer's disease. *J Alz Dis*. 2016 Sep 6;54(2):777-87. doi: 10.3233/JAD-160017. PMID: 27567810.
118. Lim Y, Hassenstab J, Cruchaga C, Goate A, Fagan A, Benzinger T, Maruff P, Snyder P, masters C, Allegri R, Chhatwal J, Farlow M, Graff-Radford N, Laske C, Levin J, McDade E, Ringman J, Rossor M, **Salloway S**, Schofield P, Holtzman D, Morris J, Bateman R. *BDNF* Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. *Brain*. 2016;139:2766-2777. PMID: 27521573.
119. Sevigny J, Chiao P, Bussiere T, Weinreb P, Williams L, Maier M, Dunstan R, **Salloway S**, Chen T, Ling Y, O'Gorman J, Qian F, Arusta M, Li M, Chollate S, Brennen M, Quintero Monzon O, Scannevin R, Arnold H, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hoch C, Nitsch R, Sandrock A. The antibody aducanumab reduces amyloid plaques in Alzheimer's disease. *Nature*. 2016 Sep 1; 537(7618):50-56. doi: 10.1038/nature19323. PMID: 27582220.
120. Tang M, Ryman DC, McDade E, Jasielec MS, Buckles VD, Cairns NJ, Fagan AM, Goate A, Marcus DS, Xiong C, Allegri RF, Chhatwal JP, Danek A, Farlow MR, Fox NC, Ghetti B, Graff-Radford NR, Laske C, Martins RN, Masters CL, Mayeux RP, Ringman JM, Rossor MN, **Salloway SP**, Schofield PR, Morris JC, Bateman RJ. Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study. *Lancet Neurol*. 2016 Dec;15:1317-1325. doi: 10.1016/S1474-4422(16)30229-0. Epub 2016 Oct 21. PMID: 27777020.
121. Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, Fanning K, Farlow MR, Hassenstab J, McDade EM, Mills S, Paumier K, Quintana M, **Salloway SP**, Santacruz A, Schneider LS, Wang G, Xiong C. The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. *Alz Dementia*. Epub 2016 Aug 29. 2017 Jan;13(1):8-19. doi: 10.1016/j.jalz.2016.07.005. PMID: 27583651.
122. Cummings J, Aisen P, Barton R, Bork J, Doody r, Dwyer J, Eagan J, Feldman H, Lappin D, Truyen L, **Salloway S**, Sperling R, Vradenburg G. Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network. *J Prev Alzheimer's Dis*. 2016 Jun;3:114-120. doi: 10.14283/jpad.2016.93. Epub 2016 Mar 4. PMID: 28459045.
123. Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, **Salloway S**, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. Addendum: The antibody aducanumab reduces A β plaques in Alzheimer's disease. *Nature*. 2017 Jun 21;546(7659):564. doi: 10.1038/nature22809. PMID: 28640269.
124. Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, **Salloway S**, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, Mintun MA; 18F-AV-

- 1451-A05 investigators. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. *Brain*. 2017 Mar 1;140(3):748-763. doi: 10.1093/brain/aww334. PMID: 28077397.
125. Müller S, Preische O, Sohrabi HR, Gräber S, Jucker M, Dietzsch J, Ringman JM, Martins RN, McDade E, Schofield PR, Ghetti B, Rossor M, Graff-Radford NR, Levin J, Galasko D, Quaid KA, **Salloway S**, Xiong C, Benzinger T, Buckles V, Masters CL, Sperling R, Bateman RJ, Morris JC, Laske C. Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. *Sci Report*. 2017 Apr 27;7(1):1225. doi: 10.1038/s41598-017-01327-w. PMID: 28450713.
126. **Salloway S**, Gamez j, Singh U, Sadowsky C, Villena T, Sabbagh M, Beach T, Duara R, Fleischer A, Frey K, Walker Z, Hunjan A, Escovar Y, Agronin M, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonovic M, Sherwin P, Farrar G, Smith A, Buckley C, Thal D, Zanette M, Curtis C. Performance of Flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current NIA-AA recommendations for the neuropathological diagnosis of Alzheimer's disease. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*. 2017 Jul 1;9:25-34. PMID: 28795133.
127. Pontecorvo MJ, Siderowf A, Dubois B, Doraiswamy PM, Frisoni GB, Grundman M, Nobili F, Sadowsky CH, **Salloway S**, Arora AK, Chevrette A, Deberdt W, Dell'Agnello G, Flitter M, Galante N, Lowrey MJ, Lu M, McGeehan A, Devous MD Sr, Mintun MA. Effectiveness of Florbetapir PET Imaging in Changing Patient Management. *Dement Geriatr Cogn Disord*. 2017 Aug 5;44(3-4):129-143. doi: 10.1159/000478007. [Epub ahead of print]. PMID: 28787712.
128. Brown BM, Sohrabi HR, Taddei K, Gardener SL, Rainey-Smith SR, Peiffer JJ, Xiong C, Fagan AM, Benzinger T, Buckles V, Erickson KI, Clarnette R, Shah T, Masters CL, Weiner M, Cairns N, Rossor M, Graff-Radford NR, **Salloway S**, Vöglein J, Laske C, Noble J, Schofield PR, Bateman RJ, Morris JC, Martins RN. Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease. *Alzheimers Dement*. 2017 Nov;13(11):1197-1206. doi: 10.1016/j.jalz.2017.03.008. Epub 2017 May 11. PMID: 28501451.
129. Alber J, Lee A, Menard W, Monast D and **Salloway SP** (2017): Recruitment of At-Risk Participants for Clinical Trials: A Major Paradigm Shift for Alzheimer's Disease Prevention. *J Prev Alzheimer's Dis*. 2017;4(4):213-214. doi: 10.14283/jpad.2017.32. PMID: 29181484.
130. Kinnunen KM, Cash DM, Poole T, Frost C, Benzinger TLS, Ahsan RL, Leung KK, Cardoso MJ, Modat M, Malone IB, Morris JC, Bateman RJ, Marcus DS, Goate A, **Salloway S**, Correia S, Sperling RA, Chhatwal JP, Mayeux R, Brickman AM, Martins RN, Farlow MR, Ghetti B, Saykin AJ, Jack CR Jr, Schofield PR, McDade E, Weiner MW, Ringman JM, Thompson PM, Masters CL, Rowe CC, Rossor MN, Ourselin S, Fox NC. Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial MRI study. Dominantly Inherited Alzheimer Network (DIAN). *Alzheimers Dement*. 2018 Jan;14(1):43-53. doi: 10.1016/j.jalz.2017.06.2268. [Epub Jul 22.] PMID: 28738187.
131. Aisen PS, Siemers E, Michelson D, Salloway S, Sampaio C, Carrillo MC, Sperling R, Doody R, Scheltens P, Bateman R, Weiner M, Vellas B. What Have We Learned from

- Expedition III and EPOCH Trials? Perspective of the CTAD Task Force. *J Prev Alzheimers Dis.* 2018;5(3):171-174. doi: 10.14283/jpad.2018.23. PMID: 29972209.
132. **Salloway SP**, Sperling R, Fox NC, Sabbagh MN, Honig LS, Porsteinsson AP, Rofael H, Ketter N, Wang D, Liu E, Carr S, Black RS, Brashear HR. Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study. *J Alzheimers Dis.* 2018 Jun 8;64(3):689-707. doi: 10.3233/JAD-171157. [Epub ahead of print] PMID: 29914022.
133. Leoutsakos JS, Yan H, Anderson WS, Asaad WF, Baltuch G, Burke A, Chakravarty MM, Drake KE, Foote KD, Fosdick L, Giacobbe P, Mari Z, McAndrews MP, Munro CA, Oh ES, Okun MS, Pendergrass JC, Ponce FA, Rosenberg PB, Sabbagh MN, **Salloway S**, Tang-Wai DF, Targum SD, Wolk D, Lozano AM, Smith GS, Lyketsos CG. Deep Brain Stimulation Targeting the Fornix for Mild Alzheimer Dementia (the ADvance Trial): A Two Year Follow-up Including Results of Delayed Activation. *J Alzheimers Dis.* 2018;64(2):597-606. doi: 10.3233/JAD-180121. PMID: 29914028.
134. Kinnunen KM, Cash DM, Poole T, Frost C, Benzinger TLS, Ahsan RL, Leung KK, Cardoso MJ, Modat M, Malone IB, Morris JC, Bateman RJ, Marcus DS, Goate A, **Salloway SP**, Correia S, Sperling RA, Chhatwal JP, Mayeux RP, Brickman AM, Martins RN, Farlow MR, Ghetti B, Saykin AJ, Jack CR Jr., Schofield PR, McDade E, Weiner MW, Ringman JM, Thompson PM, Masters CL, Rowe CC, Rossor MN, Ourselin S, Fox NC. Presymptomatic Atrophy in Autosomal Dominant Alzheimer's Disease: A Serial Magnetic Resonance Imaging Study. Dominantly Inherited Alzheimer Network (DIAN). *Alzheimers Dement.* 2018 Jan;14(1):43-53. doi: 10.1016/j.jalz.2017.06.2268. Epub 2017 Jul 22. PMID: 28738187.
135. Rasmussen SA, Norén G, Greenberg BD, Marsland R, McLaughlin NC, Malloy PJ, **Salloway SP**, Strong DR, Eisen JL, Jenike MA, Rauch SL, Baer L, Lindquist C. Gamma Ventral Capsulotomy in Intractable Obsessive-Compulsive Disorder. *Biol Psychiatry.* 2018 Sep 1;84(5):355-364. doi: 10.1016/j.biopsych.2017.11.034. Epub 2017 Dec 15. PMID: 29361268.
136. Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, Cairns NJ, Hassenstab J, Marcus DS, Fagan AM, Jack CR Jr, Hornbeck RC, Paumier KL, Ances BM, Berman SB, Brickman AM, Cash DM, Chhatwal JP, Correia S, Förster S, Fox NC, Graff-Radford NR, la Fougère C, Levin J, Masters CL, Rossor MN, **Salloway S**, Saykin AJ, Schofield PR, Thompson PM, Weiner MM, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS. Spatial Patterns of Neuroimaging Biomarker Change in Individuals from Families with Autosomal Dominant Alzheimer's Disease: A Longitudinal Study. *Lancet Neurol.* 2018 Mar;17(3):241-250. doi: 10.1016/S11474-4422(18)30028-0. Epub 2018 Feb 1. PMID: 29397305.
137. Liu E, Wang D, Sperling R, **Salloway S**, Fox NC, Blennow K, Scheltens P, Schmidt ME, Streffer J, Novak G, Einstein S, Booth K, Ketter N, Brashear HR; ELN115727-301/302 Investigator Group. Biomarker Pattern of ARIA-E Participants in Phase 3 Randomized Clinical Trials with Bapineuzumab. *Neurology.* 2018 Mar 6;90(10):e877-e886. doi: 10.1212/WNL.0000000000005060. [Epub 2018 Feb 2]. PMID: 29429971.

138. Franzmeier N, Düzel E, Jessen F, Buerger K, Levin J, Duering M, Dichgans M, Haass C, Suárez-Calvet M, Fagan AM, Paumier K, Benzinger T, Masters CL, Morris JC, Pernecky R, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Teipel S, Kilimann I, Ramirez A, Rossor M, Jucker M, Chhatwal J, Spottke A, Boecker H, Brosseron F, Falkai P, Fliessbach K, Heneka MT, Laske C, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Kofler B, Westerteicher C, Speck O, Wiltfang J, Bartels C, Araque Caballero MÁ, Metzger C, Bittner D, Weiner M, Lee JH, **Salloway S**, Danek A, Goate A, Schofield PR, Bateman RJ, Ewers M. Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. *Brain*. 2018 Apr 1;141(4):1186-1200. doi: 10.1093/brain/awy008. PMID: 29462334.
139. Chhatwal JP, Schultz AP, Johnson KA, Hedden T, Jaimes S, Benzinger TLS, Jack C Jr, Ances BM, Ringman JM, Marcus DS, Ghetti B, Farlow MR, Danek A, Levin J, Yakushev I, Laske C, Koeppe RA, Galasko DR, Xiong C, Masters CL, Schofield PR, Kinnunen KM, **Salloway S**, Martins RN, McDade E, Cairns NJ, Buckles VD, Morris JC, Bateman R, Sperling RA; Dominantly Inherited Alzheimer Network. Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. *Brain*. 2018 May 1;141(5):1486-1500. Doi: 10.1093/brain/awy053. PMID: 29522171.
140. Lee S, Zimmerman ME, Narkhede A, Nasrabad SE, Tosto G, Meier IB, Benzinger TLS, Marcus DS, Fagan AM, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, Martins RN, Saykin AJ, Masters CL, Ringman JM, Förster S, Schofield PR, Sperling RA, Johnson KA, Chhatwal JP, **Salloway S**, Correia S, Jack CR Jr, Weiner M, Bateman RJ, Morris JC, Mayeux R, Brickman AM; Dominantly Inherited Alzheimer Network. White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. *PLoS One*. 2018 May 9;13(5):e0195838. doi: 10.1371/journal.pone.0195838. eCollection 2018. PMID: 29742105.
141. Ikonomic MD, Fantoni ER, Farrar G, **Salloway S**. Infrequent false positive (18F)flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques. *Alzheimers Res Ther*. 2018 Jun 23;10(1):60. doi: 10.1186/s13195-0387-6. PMID: 29935545.
142. **Salloway S**, Marshall GA, Lu M, Brashear HR. Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-To-Moderate Alzheimer's Disease: A Phase 2, Open Label Extension Study. *Curr Alzheimer Res*. 2018 Aug 20. doi: 10.2174/1567205015666180821114813. [Epub ahead of print]. PMID: 30129411.
143. **Salloway S**. Improving Evaluation of Patients with Cognitive Impairment with Amyloid Positron Emission Tomography. *JAMA Neurol*. 2018 Sept 1;75(9):1045-1046. doi: 10.1001/jamaneurol.2018.1010. PMID: 29889928.
144. Rasmussen SA, Noren G, Greenberg BD, Marsland R, McLaughlin NC, Malloy PJ, **Salloway SP**, Strong DR, Eisen JL, Jenike MA, Rauch SL, Baer L, Lindquist C. Gamma Ventral Capsulotomy in Intractable Obsessive-Compulsive Disorder. *Biol Psychiatry*. 2018 Sep 1;84(5):355-364. doi: 10.1016/j.biopsych.2017.11.034. Epub 2017 Dec 15. PMID: 29361268.

145. Lim YY, Hassenstab J, Goate A, Fagan AM, Benzinger TLS, Cruchaga C, McDade E, Chhatwal J, Levin J, Farlow MR, Graff-Radford NR, Laske C, Masters CL, **Salloway S**, Schofield P, Morris JC, Maruff P, Bateman RJ; Dominantly Inherited Alzheimer Network. Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease. *Ann Neurol*. 2018 Sep;84(3):424-435. 10.1002/ana.25299. [Epub 2018 Aug 25.] PMID: 30014553.
146. McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, Berman SB, Klunk W, Noble J, Ringman J, Ghetti B, Farlow M, Sperling RA, Chhatwal J, **Salloway S**, Graff-Radford NR, Schofield PR, Masters C, Rossor MN, Fox NC, Levin J, Jucker M, Bateman RJ; Dominantly Inherited Alzheimer Network. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer's disease. *Neurology*. 2018 Sep 14. pii: 10.1212/WNL.0000000000006277. doi: 10.1212/WNL.0000000000006277. [Epub ahead of print.] PMID: 30217935.
147. **Salloway S**, Honigberg LA, Cho W, Ward M, Friesenhahn M, Brunstein F, Quartino A, Clayton D, Mortensen D, Bittner T, Ho C, Rabe C, Schauer SP, Wildsmith KR, Fuji RN, Suliman S, Reiman EM, Chen K, Paul R. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE). *Alzheimers Res Ther*. 2018 Sep 19;10(1):96. doi: 10.1186/s13195-018-0424-5. PMID: 30231896.
148. Araque Caballero MÁ, Suárez-Calvet M, Duering M, Franzmeier N, Benzinger T, Fagan AM, Bateman RJ, Jack CR, Levin J, Dichgans M, Jucker M, Karch C, Masters CL, Morris JC, Weiner M, Rossor M, Fox NC, Lee JH, **Salloway S**, Danek A, Goate A, Yakushev I, Hassenstab J, Schofield PR, Haass C, Ewers M. White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease. *Brain*. 2018 Oct 1;141(10):3065-3080. doi: 10.1093/brain/awy229. PMID: 30239611.
149. Müller S, Preische O, Sohrabi HR, Gräber S, Jucker M, Ringman JM, Martins RN, McDade E, Schofield PR, Ghetti B, Rossor M, Fox NN, Graff-Radford NR, Levin J, Danek A, Vöglein J, **Salloway S**, Xiong C, Benzinger T, Buckles V, Masters CL, Sperling R, Bateman RJ, Morris JC, Laske C; Dominantly Inherited Alzheimer Network (DIAN). Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. *Alzheimers Dement*. 2018 Nov;14(11):1427-1437. doi: 10.1016/j.jalz.2018.06.3059. [Epub 2018 Sept 25.] PMID: 30266303.
150. Shaw LM, Arias J, Blennow K, Galasko D, Molinuevo JL, **Salloway S**, Schindler S, Carrillo MC, Hendrix JA, Ross A, Illes J, Ramus C, Fifer S. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. *Alzheimers Dement*. 2018 Nov;14(11):1505-1521. doi: 10.1016/j.jalz.2018.07.220. Epub 2018 Oct 10. Review. PMID: 30316776.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

151. Brashear HR, Ketter N, Bogert J, Di J, **Salloway SP**, Sperling R. Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies. *J Alzheimers Dis.* 2018;66(4):1409-1424 Dec. doi: 10.3233/JAD-180675. PMID: 30412493.
152. Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, Gräber S, Kuder-Buletta E, LaFougere C, Laske C, Vöglein J, Levin J, Masters CL, Martins R, Schofield PR, Rossor MN, Graff-Radford NR, **Salloway S**, Ghetti B, Ringman JM, Noble JM, Chhatwal J, Goate AM, Benzinger TLS, Morris JC, Bateman RJ, Wang G, Fagan AM, McDade EM, Gordon BA, Jucker M; Dominantly Inherited Alzheimer Network. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. *Nat Med.* 2019 Feb;25(2):277-283. doi: 10.1038/s41591-018-0304-3. [Epub 2019 Jan 21]. PMID: 30664784.
153. Su Y, Flores S, Wang G, Hornbeck RC, Speidel B, Joseph-Mathurin N, Vlassenko AG, Gordon BA, Koeppe RA, Klunk WE, Jack CR Jr, Farlow MR, **Salloway S**, Snider BJ, Berman SB, Roberson ED, Brosch J, Jimenez-Velazques I, van Dyck CH, Galasko D, Yuan SH, Jayadev S, Honig LS, Gauthier S, Hsiung GR, Masellis M, Brooks WS, Fulham M, Clarnette R, Masters CL, Wallon D, Hannequin D, Dubois B, Pariente J, Sanchez-Valle R, Mummery C, Ringman JM, Bottlaender M, Klein G, Milosavljevic-Ristic S, McDade E, Xiong C, Morris JC, Bateman RJ, Benzinger TLS. Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. *Alzheimers Dement (Amst).* 2019 Feb 22;11:180-190. doi: 10.1016/j.dadm.2018.12.008. eCollection 2019 Dec. PMID: 30847382.
154. Franzmeier N, Ren J, Damm A, Monté-Rubio G, Boada M, Ruiz A, Ramirez A, Jessen F, Düzel E, Rodríguez Gómez O, Benzinger T, Goate A, Karch CM, Fagan AM, McDade E, Buerger K, Levin J, Duering M, Dichgans M, Suárez-Calvet M, Haass C, Gordon BA, Lim YY, Masters CL, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Milz E, Moreno-Grau S, Teipel S, Grothe MJ, Kilimann I, Rossor M, Fox N, Laske C, Chhatwal J, Falkai P, Perneczky R, Lee JH, Spottke A, Boecker H, Brosseron F, Fliessbach K, Heneka MT, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Westerteicher C, Speck O, Wiltfang J, Bartels C, Araque Caballero MÁ, Metzger C, Bittner D, **Salloway S**, Danek A, Hassenstab J, Yakushev I, Schofield PR, Morris JC, Bateman RJ, Ewers M. The BDNF Val66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. *Mol Psychiatry.* 2019 Mar 21. doi: 10.1038/s41380-019-0404-6. [Epub ahead of print]. PMID: 30899092.
155. Vöglein J, Noachtar S, McDade E, Quaid KA, **Salloway S**, Ghetti B, Noble J, Berman S, Chhatwal J, Mori H, Fox N, Allegri R, Masters CL, Buckles V, Ringman JM, Rossor M, Schofield PR, Sperling R, Jucker M, Laske C, Paumier K, Morris JC, Bateman RJ, Levin J, Danek A. Seizures as an early symptom of autosomal dominant Alzheimer's disease. Dominantly Inherited Alzheimer Network. *Neurobiol Aging.* 2019 Apr;76:18-23. doi: 10.1016/j.neurobiolaging. 2018.11.022. [Epub Dec5]. PMID: 30616208.

156. Shoamanesh A, **Salloway S**, Kase CS. Are lobar microbleeds of diagnostic value in the community? Editorial in *Neurology*. 2019 Jan 15;92(3):121-122. doi: 10.1212/WNL.0000000000006767. Epub 2018 Dec 19. PMID: 30568006.
157. Vöglein J, Paumier K, Jucker M, Preische O, McDade E, Hassenstab J, Benzinger TL, Noble JM, Berman SB, Graff-Radford NR, Ghetti B, Farlow MR, Chhatwal J, **Salloway S**, Xiong C, Karch CM, Cairns N, Mori H, Schofield PR, Masters CL, Goate A, Buckles V, Fox N, Rossor M, Chrem P, Allegri R, Ringman JM, Höglinger G, Steiner H, Dieterich M, Haass C, Laske C, Morris JC, Bateman RJ, Danek A, Levin J. Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. *Brain*. 2019 May 1;142(5):1429-1440. doi: 10.1093/brain/awz050. PMID: 30897203.
158. Bateman RJ, Blennow K, Doody R, Hendrix S, Lovestone S, **Salloway S**, Schindler R, Weiner M, Zetterberg H, Aisen P, Vellas B. Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report. *J Prev Alzheimers Dis*. 2019;6(3):169-173. doi: 10.14283/jpad.2019.21. PMID: 31062827.
159. Gauthier S, Alam J, Fillit H, Iwatsubo T, Liu-Seifert H, Sabbagh M, **Salloway S**, Sampaio C, Sims JR, Sperling B, Sperling R, Welsh-Bohmer KA, Touchon J, Vellas B, Aisen P. Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force. *J Prev Alzheimers Dis*. 2019;6(3):164-168. doi: 10.14283/jpad.2019.12. PMID: 31062826.
160. Wolk D, **Salloway S**, Dickerson B. Putting the New Alzheimer Disease Amyloid, Tau, Neurodegeneration (AT[N]) Diagnostic System to the Test. *JAMA*. 2019 Jun 18;321(23):2289-2291. doi: 10.1001/jama.2019.7534. No abstract available. PMID: 31211328.
161. Pontecorvo MJ, Devous MD, Kennedy I, Navitsky M, Lu M, Galante N, **Salloway S**, Doraiswamy PM, Southeikal S, Arora AK, McGeehan A, Lim NC, Xiong H, Trucchio SP, Joshi AD, Shcherbinin S, Teske B, Fleisher AS, Mintun MA. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia. *Brain*. 2019 Jun 1;142(6):1723-1735. doi: 10.1093/brain/awz090. PMID: 31009046.
162. Deeb W, Salvato B, Almeida L, Foote KD, Amaral R, Germann J, Rosenberg PB, Tang-Wai DF, Wolk DA, Burke AD, **Salloway S**, Sabbagh MN, Chakravarty MM, Smith GS, Lyketsos CG, Lozano AM, Okun MS. Fornix-Region Deep Brain Stimulation-Induced Memory Flashbacks in Alzheimer's Disease. *N Engl J Med*. 2019 Aug 22;381(8):783-785. doi: 10.1056/NEJMc1905240. PubMed PMID: 31433930.
163. Dube U, Del-Aguila JL, Li Z, Budde JP, Jiang S, Hsu S, Ibanez L, Fernandez MV, Farias F, Norton J, Gentsch J, Wang F; Dominantly Inherited Alzheimer Network (DIAN), **Salloway S**, Masters CL, Lee JH, Graff-Radford NR, Chhatwal JP, Bateman RJ, Morris JC, Karch CM, Harari O, Cruchaga C. An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. *Nat*

- Neurosci.* 2019 Oct 7. doi:10.1038/s41593-019-0501-5. [Epub ahead of print] PMID: 31591557.
164. Llibre-Guerra JJ, Li Y, Schindler SE, Gordon BA, Fagan AM, Morris JC, Benzinger TLS, Hassenstab J, Wang G, Allegri R, Berman SB, Chhatwal J, Farlow MR, Holtzman DM, Jucker M, Levin J, Noble JM, **Salloway S**, Schofield P, Karch C, Fox NC, Xiong C, Bateman RJ, McDade E. Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy with Disease Progression in Patients With Alzheimer Disease. *JAMA Netw Open.* 2019 Dec 2;2(12):e1917126. doi:10.1001/jamanetworkopen.2019.17126. PMID: 31825500.
165. Alber J, Goldfarb D, Thompson LI, Arthur E, Hernandez K, Cheng D, DeBuc DC, Cordeiro F, Proveti-Cunha L, den Haan J, Van Stavern GP, **Salloway SP**, Sinoff S, Snyder PJ. Developing retinal biomarkers for the earliest stages of Alzheimer's disease: What we know, what we do't, and how to move forward. *Alzheimers Dement.* 2020 Jan;16(1):229-243. doi:10.1002/alz.12006. PMID: 31914225.
166. Aschenbrenner AJ, James BD, McDade E, Wang G, Lim YY, Benzinger TLS, Cruchaga C, Goate A, Xiong C, Perrin R, Buckles V, Allegri R, Berman SB, Chhatwal JP, Fagan A, Farlow M, O'Connor A, Ghetti B, Graff-Radford N, Goldman J, Gräber S, Karch CM, Lee JH, Levin J, Martins RN, Masters C, Mori H, Noble J, **Salloway S**, Schofield P, Morris JC, Bateman RJ, Hassenstab J; Dominantly Inherited Alzheimer Network. Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). *Alzheimers Dement.* 2020 Jan;16(1):219-228. doi:10.1002/alz.12010. PMID: 31914221.
167. Castillo-Barnes D, Su L, Ramirez J, Salas-Gonzales D, Martinez-Murcia F, Illan I, Segovia F, Ortiz A, Cruchaga C, Farlow M, Xiong C, Graff-Radford N, Schofield P, Masters C, **Salloway S**, Jucker M, Mori H, Levin J, Gorriz J. Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning. *Dominantly Inherited Alzheimer Network (DIAN). Inf Fusion.* 2020 Jun;58:153-167. doi.org/10.1016/j.inffus.2020.01.001. Epub 2020 Jan 7. PMID: 32284705.
168. Franzmeier N, Koutsouleris N, Benzinger T, Goate A, Karch CM, Fagan AM, McDade E, Duering M, Dichgans M, Levin J, Gordon BA, Lim YY, Masters CL, Rossor M, Fox NC, O'Connor A, Chhatwal J, **Salloway S**, Danek A, Hassenstab J, Schofield PR, Morris JC, Bateman RJ. Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine-learning. Alzheimer's disease neuroimaging initiative (ADNI); Dominantly Inherited Alzheimer Network (DIAN), Ewers M. *Alzheimers Dement.* 2020 Mar;16(3):501-511. doi:10.1002/alz.12032. Epub 2020 Feb 11. PMID: 32043733.
169. Barthélemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Perrin RJ, Goate AM, Morris JC, Karch CM, Xiong C, Allegri R, Mendez PC, Berman SB, Ikeuchi T, Mori H, Shimada H, Shoji M, Suzuki K, Noble J, Farlow M, Chhatwal J, Graff-Radford NR, **Salloway S**, Schofield PR, Masters CL, Martins RN, O'Connor A, Fox NC, Levin J, Jucker M, Gabelle A, Lehmann S, Sato C, Bateman RJ, McDade E; Dominantly Inherited Alzheimer Network. A soluble phosphorylated tau

- signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. *Nat Med*. 2020 Mar;26(3):398-407. doi: 10.1038/s41591-020-0781-z. Epub 2020 Mar 11. PMID: 32161412.
170. Alber J, Maruff P, Santos CY, Ott BR, **Salloway SP**, Yoo DC, Noto RB, Thompson LI, Goldfarb D, Arthur E, Song A, Snyder PJ. Disruption of cholinergic neurotransmission, within a cognitive challenge paradigm, is indicative of A β -related cognitive impairment in preclinical Alzheimer's disease after a 27-month delay interval. *Alzheimers Res Ther*. 2020 Mar 24;12(1):31. doi:10.1186/s13195-020-00599-1. PMID: 32209123.
171. Fleisher AS, Pontecorvo MJ, Devous MD Sr, Lu M, Arora AK, Trucchio SP, Aldea P, Flitter M, Locascio T, Devine M, Siderowf A, Beach TG, Montine TJ, Serrano GE, Curtis C, Perrin A, **Salloway S**, Daniel M, Wellman C, Joshi AD, Irwin DJ, Lowe VJ, Seeley WW, Ikonovic MD, Masdeu JC, Kennedy I, Harris T, Navitsky M, Souhekal S, Mintun MA; A16 Study Investigators. Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. *JAMA Neurol*. 2020 Jul 1;77(7):829-839. doi:10.1001/jamaneurol.2020.0528. Online ahead of print 2020. PMID: 32338734.
172. Dubbelman MA, Verrijp M, Facal D, Sánchez-Benavides G, Brown LJE, van der Flier WM, Jokinen H, Lee A, Leroi I, Lojo-Seoane C, Milošević V, Molinuevo JL, Pereira Rozas AX, Ritchie C, **Salloway S**, Stringer G, Zygouris S, Dubois B, Epelbaum S, Scheltens P, Sikkes SAM. The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countries. *Alzheimers Dement (Amst)*. 2020 May 13;12(1):e12021. doi:10.1002/dad2.12021. eCollection 2020. PMID: 32420446.
173. Niermeyer M, Gaudet C, Malloy P, Piryatinsky I, **Salloway S**, Klinge P, Lee A. Frontal Behavior Syndromes in Idiopathic Normal Pressure Hydrocephalus as a Function of Alzheimer's Disease Biomarker Status. *J Int Neuropsychol Soc*. 2020 May 20:1-11. doi: 10.1017/S1355617720000387. Online ahead of print 2020. PMID: 32430087.
174. Asken BM, Thomas KR, Lee A, Davis JD, Malloy PF, **Salloway SP**, Correia S. Discrepancy-Based Evidence for Loss of Thinking Abilities (DELTA): Development and Validation of a Novel Approach to Identifying Cognitive Changes. *J Int Neuropsychol Soc*. 2020 May;26(5):464-479. doi:10.1017/S1355617719001346. Epub 2019 Dec 11. PMID: 31822312.
175. Finsterwalder S, Vlegels N, Gesierich B, Araque Caballero MÁ, Weaver NA, Franzmeier N, Georgakis MK, Konieczny MJ, Koek HL; Dominantly Inherited Alzheimer Network (DIAN), Karch CM, Graff-Radford NR, **Salloway S**, Oh H, Allegri RF, Chhatwal JP; DELCODE study group, Jessen F, Düzel E, Dobisch L, Metzger C, Peters O, Incesoy EI, Priller J, Spruth EJ, Schneider A, Fließbach K, Buerger K, Janowitz D, Teipel SJ, Kilimann I, Laske C, Buchmann M, Heneka MT, Brosseron F, Spottke A, Roy N, Ertl-Wagner B, Scheffler K; Alzheimer's Disease Neuroimaging Initiative (ADNI); Utrecht VCI study group, Seo SW, Kim Y, Na DL, Kim HJ, Jang H, Ewers M, Levin J, Schmidt R, Pasternak

- O, Dichgans M, Biessels GJ, Duering M. Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. *Alzheimers Dement.* 2020 Aug 18. doi:10.1002/alz.12150. Online ahead of print. PMID: 32808747.
176. Schultz SA, Strain JF, Adedokun A, Wang Q, Preische O, Kuhle J, Flores S, Keefe S, Dincer A, Ances BM, Berman SB, Brickman AM, Cash DM, Chhatwal J, Cruchaga C, Ewers M, Fox NN, Ghetti B, Goate A, Graff-Radford NR, Hassenstab JJ, Hornbeck R, Jack C Jr, Johnson K, Joseph-Mathurin N, Karch CM, Koeppe RA, Lee AKW, Levin J, Masters C, McDade E, Perrin RJ, Rowe CC, **Salloway S**, Saykin AJ, Sperling R, Su Y, Villemagne VL, Vöglein J, Weiner M, Xiong C, Fagan AM, Morris JC, Bateman RJ, Benzinger TLS, Jucker M, Gordon BA; Dominantly Inherited Alzheimer Network. Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. *Neurobiol Dis.* 2020 Aug;142:104960. doi:10.1016/j.nbd.2020.104960. Epub 2020 Jun 6. PMID: 32522711.
177. **Salloway SP**, Sevingy J, Budur K, Pederson JT, DeMattos RB, Von Rosenstiel P, Paez A, Evans R, Weber CJ, Hendrix JA, Worley S, Bain LJ, Carrillo MC. Advancing combination therapy for Alzheimer's disease. *Alzheimers Dement* (N Y). 2020 Oct 7;6(1):e12073. doi:10.1002/trc2.12073. eCollection 2020. PMID: 33043108.
178. Bruchhage MMK, Correia S, Malloy P, **Salloway S**, Deoni S. Machine Learning Classification Identifies Cerebellar Contributions to Early and Moderate Cognitive Decline in Alzheimer's Disease. *Front Aging Neurosci.* 2020 Nov 3;12:524024. doi:10.3389/fnagi.2020.524024. eCollection 2020. *Front Aging Neurosci.* 2020. PMID: 33240072.
179. Montal V, Vilaplana E, Pegueroles J, Bejanin A, Alcolea D, Carmona-Iragui M, Clarimón J, Levin J, Cruchaga C, Graff-Radford NR, Noble JM, Lee JH, Allegri R, Karch CM, Laske C, Schofield PR, **Salloway S**, Ances B, Benzinger T, McDade E, Bateman R, Blesa R, Sánchez-Valle R, Lleó A, Fortea J; Dominantly Inherited Alzheimer Network (DIAN). Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease. *Alzheimers Dement.* 2020 Nov 16. doi:10.1002/alz.12224. Online ahead of print. PMID: 33196147.
180. Dincer A, Gordon BA, Hari-Raj A, Keefe SJ, Flores S, McKay NS, Paulick AM, Shady Lewis KE, Feldman RL, Hornbeck RC, Allegri R, Ances BM, Berman SB, Brickman AM, Brooks WS, Cash DM, Chhatwal JP, Farlow MR, la Fougère C, Fox NC, Fulham MJ, Jack CR Jr, Joseph-Mathurin N, Karch CM, Lee A, Levin J, Masters CL, McDade EM, Oh H, Perrin RJ, Raji C, **Salloway SP**, Schofield PR, Su Y, Villemagne VL, Wang Q, Weiner MW, Xiong C, Yakushev I, Morris JC. Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. *Neuroimage Clin.* 2020;28:102491. doi:10.1016/j.nicl.2020.102491. Epub 2020 Nov 5. *Neuroimage Clin.* 2020. PMID: 33395982.
181. Germann J, Elias GJB, Boutet A, Narang K, Neudorfer C, Horn A, Loh A, Deeb W, Salvato B, Almeida L, Foote KD, Rosenberg PB, Tang-Wai DF, Wolk DA, Burke AD,

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

- Salloway S**, Sabbagh MN, Chakravarty MM, Smith GS, Lyketsos CG, Okun MS, Lozano AM. Brain structures and networks responsible for stimulation-induced memory flashbacks during forniceal deep brain stimulation for Alzheimer's disease. *Alzheimers Dement*. 2021 Jan 21. doi:10.1002/alz.12238. Online ahead of print. PMID: 33480187.
182. Alber J, Popescu D, Thompson LI, Tonini GM, Arthur E, Oh H, Correia S, **Salloway SP**, Lee AK. Safety and Tolerability of APOE Genotyping and Disclosure in Cognitively Normal Volunteers from the Butler Alzheimer's Prevention Registry. *J Geriatr Psychiatry Neurol*. 2021 Feb 8;891988721993575. doi:10.1177/0891988721993575. Online ahead of print. PMID: 33550928.
183. Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, **Salloway SP**, Skovronsky DM. Donanemab in Early Alzheimer's Disease. *N Engl J Med*. 2021 May 6;384(18):1691-1704. doi: 10.1056/NEJMoa2100708. Epub 2021 Mar 13. PMID: 33720637.
184. O'Shea DM, Thomas KR, Asken B, Lee AKW, Davis JD, Malloy PF, **Salloway SP**, Correia S; Alzheimer's Disease Neuroimaging Initiative. Adding cognition to AT(N) models improves prediction of cognitive and functional decline. *Alzheimers Dement (Amst)*. 2021 Mar 31;13(1):e12174. doi:10.1002/dad2.12174. eCollection 2021. PMID: 33816757.
185. Lu M, Pontecorvo MJ, Devous MD Sr, Arora AK, Galante N, McGeehan A, Devadanam C, **Salloway SP**, Doraiswamy PM, Curtis C, Trucchio SP, Flitter M, Locascio T, Devine M, Zimmer JA, Fleisher AS, Mintun MA; AVID Collaborators. Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results from 2 Phase III Clinical Trials. *JAMA Neurol*. 2021 Apr 1;78(4):445-453. doi:10.1001/jamaneurol.2020.5505. PMID: 33587110.
186. Neudorfer C, Elias GJB, Jakobs M, Boutet A, Germann J, Narang K, Loh A, Paff M, Horn A, Kucharczyk W, Deeb W, Salvato B, Almeida L, Foote KD, Rosenberg PB, Tang-Wai DF, Anderson WS, Mari Z, Ponce FA, Wolk DA, Burke AD, **Salloway S**, Sabbagh MN, Chakravarty MM, Smith GS, Lyketsos CG, Okun MS, Lozano AM. Mapping autonomic, mood, and cognitive effects of hypothalamic region deep brain stimulation. *Brain*. 2021 Apr 26;awab170. doi: 10.1093/brain/awab170. Online ahead of print. PMID: 33905474.
187. Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, Habert MO, Nordberg A, Blennow K, Galasko D, Stern Y, Rowe CC, **Salloway S**, Schneider LS, Cummings JL, Feldman HH. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. *Lancet Neurol*. 2021 Jun;20(6):484-496. doi:10.1016/S1474-4422(21)00066-1. Epub 2021 Apr 29. *Lancet Neurol*. 2021. PMID: 33933186.
188. Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, **Salloway S**. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. *Alzheimers Res Ther*.

- 2021 May 10;13(1):98. doi: 10.1186/s13195-021-00838-z. *Alzheimers Res Ther.* 2021. PMID: 33971962.
189. McLaughlin NCR, Dougherty DD, Eskandar E, Ward H, Foote KD, Malone DA, Machado A, Wong W, Sedrak M, Goodman W, Kopell BH, Issa F, Shields DC, Abulseoud OA, Lee K, Frye MA, Widge AS, Deckersbach T, Okun MS, Bowers D, Bauer RM, Mason D, Kubu CS, Bernstein I, Lapidus K, Rosenthal DL, Jenkins RL, Read C, Malloy PF, **Salloway S**, Strong DR, Jones RN, Rasmussen SA, Greenberg BD. Double blind randomized controlled trial of deep brain stimulation for obsessive-compulsive disorder: Clinical trial design. *Contemp Clin Trials Commun.* 2021 Jun 5;22:100785. doi:10.1016/j.conctc.2021.100785. eCollection 2021 Jun. PMID: 34189335.
190. Kunicki ZJ, Gaudiano BA, Miller IW, Tremont G, **Salloway S**, Darling E, Broughton MK, Kraines MA, Hoopes R, Epstein-Lubow G. Differences in Burden Severity in Adult-Child Family Caregivers and Spousal Caregivers of Persons with Dementia. *J Gerontol Soc Work.* 2021 Jul-Aug;64(5):518-532. doi:10.1080/01634372.2021.1912242. Epub 2021 Apr 6. PMID: 33820479.
191. **Salloway S**, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, Hitchcock JM, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, Cruchaga C, Goate AA, Perrin RJ, Xiong C, Li Y, Morris JC, Snider BJ, Mummery C, Surti GM, Hannequin D, Wallon D, Berman SB, Lah JJ, Jimenez-Velazquez IZ, Roberson ED, van Dyck CH, Honig LS, Sánchez-Valle R, Brooks WS, Gauthier S, Galasko DR, Masters CL, Brosch JR, Hsiung GR, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Jack CR Jr, Koeppe R, Snyder PJ, Aisen PS, Thomas RG, Berry SM, Wendelberger BA, Andersen SW, Holdridge KC, Mintun MA, Yaari R, Sims JR, Baudler M, Delmar P, Doody RS, Fontoura P, Giacobino C, Kerchner GA, Bateman RJ; Dominantly Inherited Alzheimer Network–Trials Unit. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease. *Nat Med.* 2021 Jul;27(7):1187-1196. doi:10.1038/s41591-021-01369-8. Epub 2021 Jun 21. *Nat Med.* 2021. PMID: 34155411.
192. Keret O, Staffaroni AM, Ringman JM, Cobigo Y, Goh SM, Wolf A, Allen IE, **Salloway S**, Chhatwal J, Brickman AM, Reyes-Dumeyer D, Bateman RJ, Benzinger TLS, Morris JC, Ances BM, Joseph-Mathurin N, Perrin RJ, Gordon BA, Levin J, Vöglein J, Jucker M, la Fougère C, Martins RN, Sohrabi HR, Taddei K, Villemagne VL, Schofield PR, Brooks WS, Fulham M, Masters CL, Ghetti B, Saykin AJ, Jack CR, Graff-Radford NR, Weiner M, Cash DM, Allegri RF, Chrem P, Yi S, Miller BL, Rabinovici GD, Rosen HJ; Dominantly Inherited Alzheimer Network. Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer’s disease. *Alzheimers Dement (Amst).* 2021 Jul 5;13(1):e12197. doi:10.1002/dad2.12197. eCollection 2021. *Alzheimers Dement (Amst).* 2021. PMID: 34258377.
193. Fagan AM, Henson RL, Li Y, Boerwinkle AH, Xiong C, Bateman RJ, Goate A, Ances BM, Doran E, Christian BT, Lai F, Rosas HD, Schupf N, Krinsky-McHale S, Silverman W, Lee JH, Klunk WE, Handen BL, Allegri RF, Chhatwal JP, Day GS, Graff-Radford NR, Jucker M, Levin J, Martins RN, Masters CL, Mori H, Mummery CJ, Niimi Y, Ringman JM, **Salloway S**, Schofield PR, Shoji M, Lott IT. Comparison of CSF biomarkers in Down

- syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. Alzheimer's Biomarker Consortium–Down Syndrome; Dominantly Inherited Alzheimer Network. *Lancet Neurol.* 2021 Aug;20(8):615-626. doi:10.1016/S1474-4422(21)00139-3. *Lancet Neurol.* 2021. PMID: 34302786.
194. Ngolab J, Donohue M, Belsha A, Salazar J, Cohen P, Jaiswal S, Tan V, Gessert D, Korouri S, Aggarwal NT, Alber J, Johnson K, Jicha G, van Dyck C, Lah J, **Salloway S**, Sperling RA, Aisen PS, Rafii MS, Rissman RA. Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial. *Alzheimers Dement (Amst).* 2021 Aug 17;13(1):e12199. doi:10.1002/dad2.12199. eCollection 2021. *Alzheimers Dement (Amst).* 2021. PMID: 34430703.
195. Ewers M, Luan Y, Frontzkowski L, Neitzel J, Rubinski A, Dichgans M, Hassenstab J, Gordon BA, Chhatwal JP, Levin J, Schofield P, Benzinger TLS, Morris JC, Goate A, Karch CM, Fagan AM, McDade E, Allegri R, Berman S, Chui H, Cruchaga C, Farlow M, Graff-Radford N, Jucker M, Lee JH, Martins RN, Mori H, Perrin R, Xiong C, Rossor M, Fox NC, O'Connor A, **Salloway S**, Danek A, Buerger K, Bateman RJ, Habeck C, Stern Y, Franzmeier N; Alzheimer's Disease Neuroimaging Initiative and the Dominantly Inherited Alzheimer Network. Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease. *Brain.* 2021 Aug 17;144(7):2176-2185. doi:10.1093/brain/awab112. *Brain.* 2021. PMID: 33725114.
196. Gonneaud J, Baria AT, Pichet Binette A, Gordon BA, Chhatwal JP, Cruchaga C, Jucker M, Levin J, **Salloway S**, Farlow M, Gauthier S, Benzinger TLS, Morris JC, Bateman RJ, Breitner JCS, Poirier J, Vachon-Preseau E, Villeneuve S; Alzheimer's Disease Neuroimaging Initiative (ADNI); Dominantly Inherited Alzheimer Network (DIAN) Study Group; Pre-symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) Research Group. Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. *Nat Commun.* 2021 Sep 9;12(1):5346. doi:10.1038/s41467-021-25492-9. *Nat Commun.* 2021. PMID: 34504080.
197. **Salloway S**, Cummings J. Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease. *Neurology.* 2021 Sep 14;97(11):543-544. doi:10.1212/WNL.00000000000012451. Epub 2021 Jul 7. PMID: 34233942.
198. Neudorfer C, Elias GJB, Jakobs M, Boutet A, Germann J, Narang K, Loh A, Paff M, Horn A, Kucharczyk W, Deeb W, Salvato B, Almeida L, Foote KD, Rosenberg PB, Tang-Wai DF, Anderson WS, Mari Z, Ponce FA, Wolk DA, Burke AD, **Salloway S**, Sabbagh MN, Chakravarty MM, Smith GS, Lyketsos CG, Okun MS, Lozano AM. Mapping autonomic, mood and cognitive effects of hypothalamic region deep brain stimulation. *Brain.* 2021 Oct 22;144(9):2837-2851. doi: 10.1093/brain/awab170. PMID: 33905474.
199. Buckles VD, Xiong C, Bateman RJ, Hassenstab J, Allegri R, Berman SB, Chhatwal JP, Danek A, Fagan AM, Ghetti B, Goate A, Graff-Radford N, Jucker M, Levin J, Marcus DS, Masters CL, McCue L, McDade E, Mori H, Moulder KL, Noble JM, Paumier K, Preische O, Ringman JM, Fox NC, **Salloway S**, Schofield PR, Martins R, Vöglein J, Morris JC; Dominantly Inherited Alzheimer's Network. Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease. *Alzheimers Dement.* 2021 Dec 2. doi:10.1002/alz.12505. Online ahead of print. PMID: 34854530.

200. **Salloway S**, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, Suhy J, Forrestal F, Tian Y, Umans K, Wang G, Singhal P, Budd Haeberlein S, Smirnakis K. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients with Early Alzheimer Disease. *JAMA Neurol.* 2022 Jan. doi:10.1001/jamaneurol.2021.4161. Online ahead of print. PMID: 34807243.
201. Lim YY, Maruff P, Barthélemy NR, Goate A, Hassenstab J, Sato C, Fagan AM, Benzinger TLS, Xiong C, Cruchaga C, Levin J, Farlow MR, Graff-Radford NR, Laske C, Masters CL, **Salloway S**, Schofield PR, Morris JC, Bateman RJ, McDade E; Dominantly Inherited Alzheimer Network. Association of BDNF Val66Met with Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. *JAMA Neurol.* 2022 Mar 1;79(3):261-270. doi: 10.1001/jamaneurol.2021.5181. PMID: 35099506.
202. Lockett PH, Chen C, Gordon BA, Wisch J, Berman SB, Chhatwal JP, Cruchaga C, Fagan AM, Farlow MR, Fox NC, Jucker M, Levin J, Masters CL, Mori H, Noble JM, **Salloway S**, Schofield PR, Brickman AM, Brooks WS, Cash DM, Fulham MJ, Ghetti B, Jack CR Jr, Vöglein J, Klunk WE, Koeppe R, Su Y, Weiner M, Wang Q, Marcus D, Koudelis D, Joseph-Mathurin N, Cash L, Hornbeck R, Xiong C, Perrin RJ, Karch CM, Hassenstab J, McDade E, Morris JC, Benzinger TLS, Bateman RJ, Ances BM; Dominantly Inherited Alzheimer Network (DIAN). Biomarker clustering in autosomal dominant Alzheimer's disease. *Alzheimers Dement.* 2022 Apr 1. doi:10.1002/alz.12661. Online ahead of print. PMID: 35362200.
203. Thompson LI, Harrington KD, Roque N, Strenger J, Correia S, Jones RN, **Salloway S**, Sliwinski MJ. A highly feasible, reliable, and fully remote protocol for mobile app-based cognitive assessment in cognitively healthy older adults. *Alzheimers Dement (Amst).* 2022 Apr 5;14(1):e12283. doi:10.1002/dad2.12283. eCollection 2022. PMID: 35415201.
204. Alber J, Popescu D, Thompson LI, Tonini GM, Arthur E, Oh H, Correia S, **Salloway SP**, Lee AK. Safety and Tolerability of APOE Genotyping and Disclosure in Cognitively Normal Volunteers from the Butler Alzheimer's Prevention Registry. *J Geriatr Psychiatry Neurol.* 2022 May;35(3):293-301. doi:10.1177/0891988721993575. Epub 2021 Feb 8. PMID: 33550928.
205. Cummings J, Rabinovici GD, Atri A, Aisen P, Apostolova L, Hendrix S, Sabbagh M, Selkoe D, Weiner M, **Salloway S**. Aducanumab: Appropriate Use Recommendations Update. *J Prev Alzheimers Dis.* 2022;9(2):221-230. doi:10.14283/jpad.2022.34. PMID: 35542993.
206. Morris JC, Weiner M, Xiong C, Beckett L, Coble D, Saito N, Aisen PS, Allegri R, Benzinger TLS, Berman SB, Cairns NJ, Carrillo MC, Chui HC, Chhatwal JP, Cruchaga C, Fagan AM, Farlow M, Fox NC, Ghetti B, Goate AM, Gordon BA, Graff-Radford N, Day GS, Hassenstab J, Ikeuchi T, Jack CR, Jagust WJ, Jucker M, Levin J, Massoumzadeh P, Masters CL, Martins R, McDade E, Mori H, Noble JM, Petersen RC, Ringman JM, **Salloway S**, Saykin AJ, Schofield PR, Shaw LM, Toga AW, Trojanowski JQ, Vöglein J, Weninger S, Bateman RJ, Buckles VD; Dominantly Inherited Alzheimer Network and the Alzheimer's Disease Neuroimaging Initiative. Autosomal dominant and sporadic late onset Alzheimer disease share a common in vivo pathophysiology. *Brain.* 2022 May 17;awac181. doi:10.1093/brain/awac181. Online ahead of print. PMID: 35580594.

207. Vöglein J, Franzmeier N, Morris JC, Dieterich M, McDade E, Simons M, Preische O, Hofmann A, Hassenstab J, Benzinger TL, Fagan A, Noble JM, Berman SB, Graff-Radford NR, Ghetti B, Farlow MR, Chhatwal JP, **Salloway S**, Xiong C, Karch CM, Cairns N, Perrin RJ, Day G, Martins R, Sanchez-Valle R, Mori H, Shimada H, Ikeuchi T, Suzuki K, Schofield PR, Masters CL, Goate A, Buckles V, Fox NC, Chrem P, Allegri R, Ringman JM, Yakushev I, Laske C, Jucker M, Höglinger G, Bateman RJ, Danek A, Levin J; Dominantly Inherited Alzheimer Network. Pattern and implications of neurological examination findings in autosomal dominant Alzheimer disease. *Alzheimers Dement*. 2022 May 24. doi:10.1002/alz.12684. Online ahead of print. PMID: 35609137.
208. Millar PR, Lockett PH, Gordon BA, Benzinger TLS, Schindler SE, Fagan AM, Cruchaga C, Bateman RJ, Allegri R, Jucker M, Lee JH, Mori H, **Salloway SP**, Yakushev I, Morris JC, Ances BM; Dominantly Inherited Alzheimer Network. Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease. *Neuroimage*. 2022 Aug 1;256:119228. doi:10.1016/j.neuroimage.2022.119228. Epub 2022 Apr 20. PMID: 35452806.
209. Aschenbrenner AJ, Hassenstab J, Wang G, Li Y, Xiong C, McDade E, Clifford DB, **Salloway S**, Farlow M, Yaari R, Cheng EYJ, Holdridge KC, Mummery CJ, Masters CL, Hsiung GY, Surti G, Day GS, Weintraub S, Honig LS, Galvin JE, Ringman JM, Brooks WS, Fox NC, Snyder PJ, Suzuki K, Shimada H, Gräber S, Bateman RJ. Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention Trials. *Front Aging Neurosci*. 2022 Jun 16;14:883131. doi:10.3389/fnagi.2022.883131. eCollection 2022. PMID: 35783127.
210. Strain JF, Brier MR, Tanenbaum A, Gordon BA, McCarthy JE, Dincer A, Marcus DS, Chhatwal JP, Graff-Radford NR, Day GS, la Fougère C, Perrin RJ, **Salloway S**, Schofield PR, Yakushev I, Ikeuchi T, Vöglein J, Morris JC, Benzinger TLS, Bateman RJ, Ances BM, Snyder AZ, For The Dominantly Inherited Alzheimer Network. Covariance-based vs. Correlation-based Functional Connectivity Dissociates Healthy Aging from Alzheimer Disease. *Neuroimage*. 2022 Jul 29;119511. doi:10.1016/j.neuroimage.2022.119511. Online ahead of print. PMID: 35914670.
211. Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, **Salloway S**, Sperling R, Zetterberg H, Teunissen CE. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. *Alzheimers Dement*. 2022 Jul 31. doi: 10.1002/alz.12756. Online ahead of print. PMID: 35908251.
212. Joseph-Mathurin N, Llibre-Guerra JJ, Li Y, McCullough AA, Hofmann C, Wojtowicz J, Park E, Wang G, Preboske GM, Wang Q, Gordon BA, Chen CD, Flores S, Aggarwal NT, Berman SB, Bird TD, Black SE, Borowski B, Brooks WS, Chhatwal JP, Clarnette R, Cruchaga C, Fagan AM, Farlow M, Fox NC, Gauthier S, Hassenstab J, Hobbs DA, Holdridge KC, Honig LS, Hornbeck RC, Hsiung GR, Jack CR Jr, Jimenez-Velazquez IZ, Jucker M, Klein G, Levin J, Mancini M, Masellis M, McKay NS, Mummery CJ, Ringman JM, Shimada H, Snider BJ, Suzuki K, Wallon D, Xiong C, Yaari R, McDade E, Perrin RJ, Bateman RJ, **Salloway SP**, Benzinger TLS, Clifford DB; Dominantly Inherited Alzheimer Network Trials Unit. Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease. *Ann Neurol*. 2022 Nov;92(5):729-744. doi:10.1002/ana.26511. Epub 2022 Oct 13. PMID: 36151869.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

213. Rhodus EK, Aisen P, Grill JD, Rentz DM, Petersen RC, Sperling RA, **Salloway SP**, Pierce D, Raman R. Alzheimer's Disease Clinical Trial Research Adaptation Following COVID-19 Pandemic Onset: National Sample of Alzheimer's Clinical Trial Consortium Sites. *J Prev Alzheimers Dis.* 2022;9(4):665-671. doi:10.14283/jpad.2022.79. PMID: 36281670.
214. Bateman RJ, Cummings J, Schobel S, **Salloway S**, Vellas B, Boada M, Black SE, Blennow K, Fontoura P, Klein G, Assunção SS, Smith J, Doody RS. Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease. *Alzheimers Res Ther.* 2022 Nov 29;14(1):178. doi:10.1186/s13195-022-01110-8. PMID: 36447240.
215. Gold D, Wisialowski C, Piryatinsky I, Malloy P, Correia S, **Salloway S**, Klinge P, Gaudet CE, Niermeyer M, Lee A. Longitudinal post-shunt outcomes in idiopathic normal pressure hydrocephalus with and without comorbid Alzheimer's disease. *J Int Neuropsychol Soc.* 2022 Dec 14:1-12. doi: 10.1017/S1355617722000868. Online ahead of print. PMID: 36515069.
216. Ríos AS, Oxenford S, Neudorfer C, Butenko K, Li N, Rajamani N, Boutet A, Elias GJB, Germann J, Loh A, Deeb W, Wang F, Setsompop K, Salvato B, Almeida LB, Foote KD, Amaral R, Rosenberg PB, Tang-Wai DF, Wolk DA, Burke AD, **Salloway S**, Sabbagh MN, Chakravarty MM, Smith GS, Lyketsos CG, Okun MS, Anderson WS, Mari Z, Ponce FA, Lozano AM, Horn A. Optimal deep brain stimulation sites and networks for stimulation of the fornix in Alzheimer's disease. *Nat Commun.* 2022 Dec 14;13(1):7707. doi: 10.1038/s41467-022-34510-3. PMID: 36517479.
217. Lee AKW, Collier MK, Thompson LI, Popescu D, Arthur E, Correia S, **Salloway SP**, Alber J. The Effects of Subjective Cognitive Decline on APOE Genotype Disclosure in the Butler Hospital Alzheimer's Prevention Registry. *J Prev Alzheimers Dis.* 2023;10(2):152-161. doi: 10.14283/jpad.2023.12. PMID: 36946441.
218. O'Connor A, Rice H, Barnes J, Ryan NS, Liu KY, Allegri RF, Berman S, Ringman JM, Cruchaga C, Farlow MR, Hassenstab J, Lee JH, Perrin RJ, Xiong C, Gordon B, Levey AI, Goate A, Graff-Radford N, Levin J, Jucker M, Benzinger T, McDade E, Mori H, Noble JM, Schofield PR, Martins RN, **Salloway S**, Chhatwal J, Morris JC, Bateman R, Howard R, Reeves S, Fox NC; Dominantly Inherited AlzheiNetwork. First presentation with neuropsychiatric symptoms in autosomal dominant Alzheimer's disease: the Dominantly Inherited Alzheimer's Network Study. *J Neurol Neurosurg Psychiatry.* 2023 May;94(5):403-405. doi: 10.1136/jnnp-2022-329843. Epub 2022 Dec 15. PMID: 36522155.
219. Schultz SA, Shirzadi Z, Schultz AP, Liu L, Fitzpatrick CD, McDade E, Barthelemy NR, Renton A, Esposito B, Joseph-Mathurin N, Cruchaga C, Chen CD, Goate A, Allegri RF, Benzinger TLS, Berman S, Chui HC, Fagan AM, Farlow MR, Fox NC, Gordon BA, Day GS, Graff-Radford NR, Hassenstab JJ, Hanseeuw BJ, Hofmann A, Jack CR Jr, Jucker M, Karch CM, Koeppe RA, Lee JH, Levey AI, Levin J, Martins RN, Mori H, Morris JC, Noble J, Perrin RJ, Rosa-Neto P, **Salloway SP**, Sanchez-Valle R, Schofield PR, Xiong C, Johnson KA, Bateman RJ, Sperling RA, Chhatwal JP. Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical and neurodegenerative measures in autosomal-dominant Alzheimer's Disease. Dominantly Inherited Alzheimer Network

- Investigators. *Aging Cell*. 2023 Jun 8:e13871. doi: 10.1111/accel.13871. Online ahead of print. PMID: 37291760.
220. Griffin P, Apostolova L, Dickerson BC, Rabinovici G, **Salloway S**, Brandt K, Masdeu J, Hammers D, Raghuram S, Hall S, Carrillo MC. Developments in understanding early onset Alzheimer's disease. *Alzheimer's Dement*. 2023 Jun 30. doi: 10.1002/alz.13353. Online ahead of print. PMID: 37390354.
221. McKay NS, Gordon BA, Hornbeck RC, Dincer A, Flores S, Keefe SJ, Joseph-Mathurin N, Jack CR, Koeppe R, Millar PR, Ances BM, Chen CD, Daniels A, Hobbs DA, Jackson K, Koudelis D, Massoumzadeh P, McCullough A, Nickels ML, Rahmani F, Swisher L, Wang Q, Allegri RF, Berman SB, Brickman AM, Brooks WS, Cash DM, Chhatwal JP, Day GS, Farlow MR, la Fougère C, Fox NC, Fulham M, Ghetti B, Graff-Radford N, Ikeuchi T, Klunk W, Lee JH, Levin J, Martins R, Masters CL, McConathy J, Mori H, Noble JM, Reischl G, Rowe C, **Salloway S**, Sanchez-Valle R, Schofield PR, Shimada H, Shoji M, Su Y, Suzuki K, Vöglein J, Yakushev I, Cruchaga C, Hassenstab J, Karch C, McDade E, Perrin RJ, Xiong C, Morris JC, Bateman RJ, Benzinger TLS. Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN). Dominantly Inherited Alzheimer Network. *Nat Neurosci*. 2023 Jul 10. doi: 10.1038/s41593-023-01359-8. Online ahead of print. PMID: 37429916.
222. Cummings J, Apostolova L, Rabinovici G, Atri A, Aisen P, Greenberg S, Hendrix S, Selkoe D, Weiner M, Petersen RC, **Salloway S**. Lecanemab: Appropriate Use Recommendations. For the Alzheimer's Disease and Related Disorders Therapeutics Work Group. *J Prev Alz Dis* 2023;3(10):362-377. Online March 27, 2023. doi: 10.14283/jpad.2023.30.
223. Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels A, Shcherbinin S, Wang H, Nery E, Collins E, Solomon P, **Salloway S**, Apostolova L, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky D, for the TRAILBLAZER-ALZ 2 Investigators. Donanemab in Early Symptomatic Alzheimer Disease The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. *JAMA*. Published online July 17, 2023. doi:10.1001/jama.2023.13239.
224. Eloyan A, Thangarajah M, An N, Borowski BJ, Reddy AL, Aisen P, Dage JL, Foroud T, Ghetti B, Griffin P, Hammers D, Iaccarino L, Jack CR Jr, Kirby K, Kramer J, Koeppe R, Kukull WA, La Joie R, Mundada NS, Murray ME, Nudelman K, Rumbaugh M, Soleimani-Meigooni DN, Toga A, Touroutoglou A, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu J, Mendez MF, Musiek E, Onyike CU, Rogalski E, **Salloway S**, Sha S, Turner RS, Wingo TS, Wolk DA, Womack K, Beckett L, Gao S, Carrillo MC, Rabinovici G, Apostolova LG, Dickerson B, Vemuri P; LEADS Consortium. White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS). *Alzheimers Dement*. 2023 Nov;19 Suppl 9(Suppl 9):S89-S97. doi:10.1002/alz.13402. Epub 2023 Jul 25. PMID: 37491599.
225. Dage JL, Eloyan A, Thangarajah M, Hammers DB, Fagan AM, Gray JD, Schindler SE, Snoddy C, Nudelman KNH, Faber KM, Foroud T, Aisen P, Griffin P, Grinberg LT,

- Iaccarino L, Kirby K, Kramer J, Koeppe R, Kukull WA, La Joie R, Mundada NS, Murray ME, Rumbaugh M, Soleimani-Meigooni DN, Toga AW, Touroutoglou A, Vemuri P, Atri A, Beckett LA, Day GS, Graff-Radford NR, Duara R, Honig LS, Jones DT, Masdeu JC, Mendez MF, Musiek E, Onyike CU, Riddle M, Rogalski E, **Salloway S**, Sha SJ, Turner RS, Wingo TS, Wolk DA, Womack KB, Carrillo MC, Dickerson BC, Rabinovici GD, Apostolova LG; LEADS Consortium. Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer's Disease Study. *Alzheimers Dement.* 2023 Nov;19 Suppl 9(Suppl 9):S115-S125. doi:10.1002/alz.13399. Epub 2023 Jul 25. PMID: 37491668.
226. Nemes S, Logan PE, Manchella MK, Mundada NS, La Joie R, Polsinelli AJ, Hammers DB, Koeppe RA, Foroud TM, Nudelman KN, Eloyan A, Iaccarino L, Dorsant-Ardón V, Taurone A, Thangarajah M, Dage JL, Aisen P, Grinberg LT, Jack CR Jr, Kramer J, Kukull WA, Murray ME, Rumbaugh M, Soleimani-Meigooni DN, Toga A, Touroutoglou A, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu J, Mendez MF, Musiek E, Onyike CU, Riddle M, Rogalski E, **Salloway S**, Sha SJ, Turner RS, Wingo TS, Womack KB, Wolk DA, Rabinovici GD, Carrillo MC, Dickerson BC, Apostolova LG; LEADS Consortium. Sex and APOE ϵ 4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's disease. *Alzheimers Dement.* 2023 Nov;19 Suppl 9(Suppl 9):S49-S63. doi: 10.1002/alz.13403. Epub 2023 Jul 26. PMID: 37496307.
227. Cho H, Mundada NS, Apostolova LG, Carrillo MC, Shankar R, Amuri AN, Zeltzer E, Windon CC, Soleimani-Meigooni DN, Tanner JA, Heath CL, Lesman-Segev OH, Aisen P, Eloyan A, Lee HS, Hammers DB, Kirby K, Dage JL, Fagan A, Foroud T, Grinberg LT, Jack CR, Kramer J, Kukull WA, Murray ME, Nudelman K, Toga A, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu J, Mendez M, Musiek E, Onyike CU, Riddle M, Rogalski EJ, **Salloway S**, Sha S, Turner RS, Wingo TS, Wolk DA, Koeppe R, Iaccarino L, Dickerson BC, La Joie R, Rabinovici GD; LEADS Consortium. Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS). *Alzheimers Dement.* 2023 Nov;19 Suppl 9(Suppl 9):S98-S114. doi:10.1002/alz.13453. Epub 2023 Sep 10. PMID: 37690109.
228. Nudelman KNH, Jackson T, Rumbaugh M, Eloyan A, Abreu M, Dage JL, Snoddy C, Faber KM, Foroud T, Hammers DB; DIAN/DIAN-TU Clinical/Genetics Committee; Taurone A, Thangarajah M, Aisen P, Beckett L, Kramer J, Koeppe R, Kukull WA, Murray ME, Toga AW, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu JC, Mendez M, Musiek E, Onyike CU, Riddle M, Rogalski E, **Salloway S**, Sha SJ, Turner RS, Wingo TS, Wolk DA, Carrillo MC, Dickerson BC, Rabinovici GD, Apostolova LG; LEADS Consortium. Pathogenic variants in the Longitudinal Early-onset Alzheimer's Disease Study cohort. *Alzheimers Dement.* 2023 Nov;19 Suppl 9(Suppl 9):S64-S73. doi:10.1002/alz.13482. Epub 2023 Oct 6. PMID: 37801072.
229. Touroutoglou A, Katsumi Y, Brickhouse M, Zaitsev A, Eckbo R, Aisen P, Beckett L, Dage JL, Eloyan A, Foroud T, Ghetti B, Griffin P, Hammers D, Jack CR Jr, Kramer JH, Iaccarino L, Joie R, Mundada NS, Koeppe R, Kukull WA, Murray ME, Nudelman K, Polsinelli AJ, Rumbaugh M, Soleimani-Meigooni DN, Toga A, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu JC, Mendez MF, Musiek E, Onyike CU, Riddle M, Rogalski E, **Salloway S**, Sha S, Turner RS, Wingo TS, Wolk DA,

- Womack K, Carrillo MC, Rabinovici GD, Apostolova LG, Dickerson BC; LEADS Consortium. The Sporadic Early-onset Alzheimer's Disease Signature of Atrophy: Preliminary Findings from The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Cohort. *Alzheimers Dement*. 2023 Nov;19 Suppl 9(Suppl 9):S74-S88. doi:10.1002/alz.13466. Epub 2023 Oct 18. PMID: 37850549.
230. Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, **Salloway S**, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. *N Engl J Med*. 2023 Nov 16;389(20):1862-1876. doi:10.1056/NEJMoa2304430. PMID: 37966285.
231. Thompson LI, Kunicki ZJ, Emrani S, Strenger J, De Vito AN, Britton KJ, Dion C, Harrington KD, Roque N, **Salloway S**, Sliwinski MJ, Correia S, Jones RN. Remote and in-clinic digital cognitive screening tools outperform the MoCA to distinguish cerebral amyloid status among cognitively healthy older adults. *Alzheimers Dement (Amst)*. 2023 Nov 27;15(4):e12500. doi:10.1002/dad2.12500. eCollection 2023 Oct-Dec. PMID: 38026761.
232. Shirzadi Z, Schultz SA, Yau WW, Joseph-Mathurin N, Fitzpatrick CD, Levin R, Kantarci K, Preboske GM, Jack CR Jr, Farlow MR, Hassenstab J, Jucker M, Morris JC, Xiong C, Karch CM, Levey AI, Gordon BA, Schofield PR, **Salloway SP**, Perrin RJ, McDade E, Levin J, Cruchaga C, Allegri RF, Fox NC, Goate A, Day GS, Koeppe R, Chui HC, Berman S, Mori H, Sanchez-Valle R, Lee JH, Rosa-Neto P, Ruthirakuhan M, Wu CY, Swardfager W, Benzinger TLS, Sohrabi HR, Martins RN, Bateman RJ, Johnson KA, Sperling RA, Greenberg SM, Schultz AP, Chhatwal JP; Dominantly Inherited Alzheimer Network and the Alzheimer's Disease Neuroimaging Initiative. Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease. *JAMA Neurol*. 2023 Dec 1;80(12):1353-1363. doi:10.1001/jamaneurol.2023.3618. PMID: 37843849.
233. Oxenford S, Ríos AS, Hollunder B, Neudorfer C, Boutet A, Elias GJB, Germann J, Loh A, Deeb W, Salvato B, Almeida L, Foote KD, Amaral R, Rosenberg PB, Tang-Wai DF, Wolk DA, Burke AD, Sabbagh MN, **Salloway S**, Chakravarty MM, Smith GS, Lyketsos CG, Okun MS, Anderson WS, Mari Z, Ponce FA, Lozano A, Neumann WJ, Al-Fatly B, Horn A. WarpDrive: Improving spatial normalization using manual refinements. *Med Image Anal*. 2024 Jan;91:103041. doi:10.1016/j.media.2023.103041. Epub 2023 Nov 19. PMID: 38007978.
234. Baker LD, Snyder HM, Espeland MA, Whitmer RA, Kivipelto M, Woolard N, Katula J, Papp KV, Ventrelle J, Graef S, Hill MA, Rushing S, Spell J, Lovato L, Felton D, Williams BJ, Ghadimi Nouran M, Raman R, Ngandu T, Solomon A, Wilmoth S, Cleveland ML, Williamson JD, Lambert KL, Tomaszewski Farias S, Day CE, Tangney CC, Gitelman DR, Matongo O, Reynolds T, Pavlik VN, Yu MM, Alexander AS, Elbein R, McDonald AM, **Salloway S**, Wing RR, Antkowiak S, Morris MC, Carrillo MC; U.S. POINTER Study Group. Study design and methods: U.S. study to protect brain health through lifestyle intervention to reduce risk (U.S. POINTER). *Alzheimers Dement*. 2024 Feb;20(2):769-782. doi:10.1002/alz.13365. Epub 2023 Sep 30. PMID: 37776210.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

235. Chen T, O’Gorman J, Castrillo-Viguera C, Rajagovindan R, Curiale GG, Tian Y, Patel D, von Rosenstiel P, von Hehn C, **Salloway S**, Hock C, Nitsch RM, Haeberlein SB, Sandrock A, Singhal P. Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab. *Alzheimers Dement*. 2024 Apr 3. doi:10.1002/alz.13755. Online ahead of print. PMID: 38567735.

OTHER PEER-REVIEWED PUBLICATIONS:

1. **Salloway S**, Malloy P, Duffy J. The frontal lobes and neuropsychiatric illness. *J Neuropsychiatry Clin Neurosci*. 1994;6:341-2.
2. **Salloway S**, Daly J. The neurochemistry of Alzheimer’s disease. In: Richter R, ed. *Alzheimer’s disease: A guide to clinical management*. New York, Mosby Press, 1996; 256-284. (Book Chapter).
3. Greenblatt S, **Salloway S**. Clinical examination of cognitive functions. In: Wilkins RH, Rengachary SS, eds. *Neurosurgery 2nd ed*. New York, McGraw-Hill 1996;49-58. (Book Chapter).
4. Saver J, **Salloway S**, Bear D, Devinsky O. Neuropsychiatry of aggression. In: Fogel B, Schiffer R, Rao S, eds. *Neuropsychiatry*. Baltimore, Williams and Wilkins 1996;523-548. (Book Chapter).
5. Cohen R, **Salloway S**. Disorders of attention in: Yudofsky S, Hales R, eds. *Textbook of Neuropsychiatry*. 3rd edition. Washington D.C., American Psychiatric Press. 1997;413-446. (Book Chapter).
6. Mega M, Cummings J, **Salloway S**, Malloy P. The limbic system: an anatomic, phylogenetic and clinical perspective, In: *The Neuropsychiatry of Limbic and Subcortical Disorders*, **Salloway S**, Malloy P, Cummings J. Washington, D.C., American Psychiatric Press. 1997, 3-18. (Book Chapter).
7. **Salloway S**, White J. Paroxysmal limbic disorders in neuropsychiatry, In: *The Neuropsychiatry of Limbic and Subcortical Disorders*, Salloway S, Malloy P, Cummings J. Washington, D.C., American Psychiatric Press. 1997, 95-112. (Book Chapter).
8. Malloy PM, Cummings JL, Coffey CE, Duffy J, Fink M, Lauterbach EC, Lovell M, Nussbaum P, Royall, DR, **Salloway S**. Cognitive screening instruments in neuropsychiatry: a report of the Committee on Research of the American Neuropsychiatric Association. *J Neuropsych Clin Neurosci*. 1997 Spring;9(2):189-97. Review. PMID: 9144098.
9. Harrington C, **Salloway S**. The Diagnosis and Treatment of Post-stroke Depression. *Med Health RI*. 1997 Jun;80(6):181-7. Review. PMID: 9200897.
10. Cummings JL, Coffey CE, Lauterbach EC, Lovell M, Malloy P, Royall, DR, Rummans TA, **Salloway S**. The clinician-scientist in neuropsychiatry: a position statement from the Committee on Research of the American Neuropsychiatric Association. *J Neuropsych Clin Neurosci*. 1998 Winter;10(1):1-9. PMID: 9547460.
11. Lauterbach E, Cummings J, Duffy J, Coffey CE, Kaufer D, Lovell M, Malloy P, Reeve A, Royall DR, Rummans TA, **Salloway S**. Neuropsychiatric correlates and treatment of

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

- lenticulostratial diseases: a review of the literature and overview of research opportunities in Huntington's, Wilson's, and Fahr's diseases. A report of the ANPA Committee on Research. *J Neuropsych Clin Neurosci*. 1998; Summer;10(3):249-66. Review. PMID: 9706533.
12. **Salloway S**, Hong J. The CADASIL Syndrome: a genetic form of vascular dementia. *J Geriatric Psychiatry and Neurology*. 1998 Summer;11(2):71-7. Review. PMID: 9877528.
 13. Rummans T, Lauterbach E, Coffey E, Royall D, Cummings J, **Salloway S**, Duffy J, Kaufer D. Pharmacologic efficacy in neuropsychiatry: a review of placebo-controlled trials. *J Neuropsych Clin Neurosci*. 1999 Spring;11(2):176-189. Review. PMID: 10333990.
 14. **Salloway S**, Harrington R, Orr D, LaFrance C. The diagnosis and treatment of dementia in *Psychiatric Care of the Medical Patient* 2nd edition, Stoudemire A, Fogel B, Greenberg D eds. New York, Oxford Press 1999, 597-620. (Book Chapter).
 15. **Salloway S**, Downie J. Infection Control Programs for Behavioral Health Care Settings. *QRC Advis*. 1999 Jan;15(3):6-12. PMID: 10345517.
 16. LaFrance C, Lauterbach E, Coffey CE, **Salloway S**, Kaufer D, Reeve A, Royall D, Aylward E, Rummans T, Lowell M. The use of herbal alternative medicines in neuropsychiatry. A report of the ANPA Committee on Research. *J Neuropsych Clin Neurosci*. 2000 Spring;12(2):177-192. Review. PMID: 11001596.
 17. **Salloway S**. Diagnosis and treatment of frontal lobe syndromes in *The Frontal Lobes and Neuropsychiatric Illness*, Salloway S, Malloy P, Duffy J eds. Washington, D.C., American Psychiatric Press, 2001, 139-152. (Book Chapter).
 18. Campbell J, Duffy J, **Salloway S**. Treatment strategies for patients with dysexecutive syndromes, in *The Frontal Lobes and Neuropsychiatric Illness*, Salloway S, Malloy P, Duffy J eds. Washington, D.C., American Psychiatric Press. 2001, 153-166. (Book Chapter).
 19. **Salloway S**, Blitz A. Introduction to functional brain circuitry, *Brain Signaling and Circuitry in Psychiatry*, Kaplan G, Hammer R eds., Amer Psychiatric Publishing. 2002, Washington, D.C. 1-29. (Book Chapter).
 20. Cohen R, **Salloway S**, Zawacki P. Disorders of attention In: Yudofsky S, Hales R, eds. *Textbook of Neuropsychiatry*. 4th edition. Washington D.C., American Psychiatric Publishing. 2002, 489-524. (Book Chapter).
 21. Stopa E, Fallon J, **Salloway S**, et al. Distribution of smooth muscle actin and agrin in the microvascular of the tg app671, 671. Korczyn ed. 2nd International Conference on Vascular Dementia, Monduzzi 2002, 159-163, Bologna.
 22. **Salloway S**, Desbiens S. CADASIL and Other Genetic Causes of Stroke and Vascular Dementia in *Vascular Dementia: Cerebrovascular Mechanisms and Clinical Management*, Paul R, Cohen R, Ott B, Salloway S eds. Humana Press. Totowa, NJ, 2004,87-98.
 23. **Salloway S**, Harrington C, Jacobson S. Psychiatric evaluation of the neurologic patient, in Friedman JH, Jeste D. eds. *Psychiatry for Neurologists*. Humana Press. Totowa, NJ 2005, 19-32. (Book Chapter).
 24. **Salloway S**. Improving the diagnosis and treatment of Alzheimer's disease. *Medicine and Health Rhode Island*. 2006 May;89(5):166-8. Review. PMID: 16764297.
 25. **Salloway S**. Cholinergic treatment across the spectrum: therapeutic trends in mild to severe dementia. *Int Psychogeriatr*. 2006 Sep;18 Suppl 1:S1-2.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

26. Cohen R, **Salloway S**, Sweet L. Neuropsychiatric aspects of disorders of attention In: Yudofsky S, Hales R, eds. *The American Psychiatric Publishing Textbook of Neuropsychiatry and Behavioral Neurosciences*, 5th edition. Washington D.C., American Psychiatric Publishing 2007, 485-529. (Book Chapter).
27. **Salloway S**. Taking the Next Steps in the Treatment of AD: Disease-Modifying Agents. *CNS Spectrums*. 2008 Mar;13, (3 suppl 3):11-4. PMID: 18564460.
28. **Salloway S**. The Prevalence of Alzheimer's Disease: A Growing Crisis, *CNS Spectrums*. 2008 Mar;13, (3 suppl 3):1. PMID: 18323759.
29. **Salloway S**, Brennan-Krohn T, Correia, S, Mellion M, delaMonte S. CADASIL: A genetic model of arteriolar degeneration, white matter injury, and dementia in later life in *The Behavioral Neurology of Dementia*, Miller B & Boeve B eds., Cambridge University Press, London, 2009:329-344.
30. **Salloway S**. Current and future treatments for Alzheimer's disease. *CNS Spectrums*. 2009 Aug;14:8 (suppl 7):4-7, discussion for 16-8. Review. PMID: 19890240.
31. Epstein-Lubow G, Gaudiano B, Hinckley M, **Salloway S**, Miller V. Evidence for the validity of the American Medical Association's Caregiver Self-Assessment Questionnaire as a screening measure for depression. *Journal of the American Geriatrics Society*. 2010 Feb;58(2):387-8. doi: 10.1111/j.1532-5415.2009.02701.x. PMID: 20370867.
32. Cabral D, Mellion M, **Salloway S**, Correia, S, Brennan-Krohn T, delaMonte S. CADASIL: A genetic model of arteriolar degeneration, white matter injury, and dementia in later life in *The Behavioral Neurology of Dementia 2nd Edition*, Miller B & Boeve B eds., Cambridge University Press, London, 2014, in press.
33. Beriault D, Diamandis E, Portelius E, Perret-Liaudet A, **Salloway S**. Biomarkers, assays and therapies for Alzheimer's disease. *Clinical Chemistry*. 2015 Jul;61(7):903-8. doi: 10.1373/clinchem.2015.241901. Epub 2015 May 26. PMID: 26015517.
34. Herman L, Atri A, **Salloway S**. Alzheimer's Disease in Primary Care: The Significance of Early Detection, Diagnosis, and Intervention. *Am J Medicine*. 2017;130:756. PMID: 28449849.

BOOKS

1. **Salloway S**, Malloy P, Cummings J. *The Neuropsychiatry of Limbic and Subcortical Disorders*. American Psychiatric Press Inc., Washington, D.C. 1997.
2. **Salloway S**, Malloy P, Duffy J. *The Frontal Lobes and Neuropsychiatric Illness*. American Psychiatric Press Inc., Washington, D.C., 2001.
3. Paul R, Cohen R, Ott B, **Salloway S** eds., *Vascular Dementia: Cerebrovascular Mechanisms and Clinical Management*, Humana Press, Totowa, NJ, 2004.

OTHER NON-PEER REVIEWED PUBLICATIONS:

1. **Salloway S**. Book review of *Neurology for the Psychiatry Specialty Board Review*, Weisberg L. *Psychiatric Times*. Nov. 1992;44 (Book Review).

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

2. **Salloway S**, Duffy J. Neuropsychiatric aspects of depression. *Rhode Island Medicine*. 1993 Aug;76(8):425-30. Review. Erratum in: *RI Med* 1994 Jun;77(6):161. PMID: 8219386.
3. **Salloway S**. Neuropsychiatric aspects of movement disorders. *Rhode Island Medicine*. 1993 Nov;76(11):549-52. Review. PMID: 8312632.
4. **Salloway S**, Fowkes V. *Behavioral Science in Primary Care*, a teaching manual, Stanford Press, 1985.
5. **Salloway S**, Clinical neuroanatomy and neurochemistry for psychiatrists. In: Kaufman D., Editor, *Clinical Neurology for Psychiatrists*, Albert Einstein, 1991.
6. **Salloway S**, Faber R. Highlights of the Fifth Annual Meeting of the American Neuropsychiatric Association. *J Neuropsychiatry and Clinical Neurosci*. 1993;5:442-3.
7. **Salloway S**. Review of Epilepsy and the Quality of Life. Trimble M, Dodson W. Raven Press 1995 in *Am J Psychiatry*. 1996;153:4 (Book Review).
8. **Salloway S**. Review of Brain Activation. Roland P, Wiley Liss 1993 in *J Neuropsychiatry and Clin Neurosci*. 1996 (Book Review).
9. **Salloway S**. CADASIL: A new disease causing subcortical dementia and depression. *Psychiatric Times*. 1997;14:8-9.
10. Harrington C, **Salloway S**. The diagnosis and treatment of post-stroke depression. *Rhode Island Medicine*. 1997;80:181-187.(invited).
11. **Salloway S**. The nucleus accumbens: a key structure mediating substance abuse and reward. *Psychiatric Times*. 1998; 15:62-4.
12. **Salloway S**. Clinical applications of brain SPECT scanning in neurology and psychiatry. *Psychiatric Times*. 1999; 16:72-74.
13. Heindel W, **Salloway S**. Memory Systems in the Human Brain. *Psychiatric Times*. 1999;16:19-21.
14. **Salloway S**. The CADASIL syndrome: a genetic cause of small vessel stroke and dementia. *Neurology Network Commentary*. 1999;3:40-45.
15. Cahn-Weiner D, **Salloway S**. Diagnosis and treatment of mild cognitive impairment. *Psychiatric Times*. 1999, 9:24-26.
16. Rymer S, **Salloway S**. Hidden victims of Alzheimer's disease. *Psychiatric Times*. 2000;17:44-51.
17. **Salloway S**. Advances in clinical neuroscience from the AAN 53rd Annual Meeting. *Psychiatric Times*. 2001;9:1,10 and 11.
18. **Salloway S**, Correia S, Peck J, Harrington C. Dementia with Lewy Bodies: A Diagnostic and Treatment Challenge. *Med Health RI*. 2002 Jul;85(7):207-9. Review. PMID: 12182091.
19. **Salloway S**. New monoclonal antibody aids diagnosis of CADASIL. *Journal Watch Neurology*. 2002;4:20.
20. **Salloway S**. Features of frontotemporal dementia-3. *Journal Watch Neurology*. 2003;5:9.
21. **Salloway S**. Advances in the treatment of dementia. *The Clinical Advisor*. 2003, in press.
22. **Salloway S**. Does social isolation influence outcomes after stroke? *Journal Watch Neurology*. 2006;8:28.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

23. **Salloway S.** Cholinergic treatment across the spectrum of Alzheimer's disease (Guest Editorial). *Int Psychogeriatrics*. 2006, in press.
24. **Salloway S.** Behavioral disturbance in CADASIL. *Journal Watch Neurology*. 2009;11:30.
25. **Salloway S.** New lessons from the Alzheimer's Disease Neuroimaging Initiative. Editorial. *Arch Neurol*. 2011 Jan;68(1):19-21. doi: 10.1001/archneurol.2010.344. PMID: 21220673.
26. **Salloway S.** Expanded hexanucleotide repeat (GGGGCC) in chromosome 9p is an important cause of FTD and ALS. *Journal Watch Neurology*. 2011, in press.
27. Carmichael O, **Salloway S.** Imaging Markers of Incipient Dementia: The white matter, matters. Editorial in *Neurology*. 2012 Aug 21;79(8):726-7. doi: 10.1212/WNL.9b913e3182662020. Epub 2012 Jul 25. PMID: 22843261.
28. **Salloway S.** Clinical and pathological examples of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia. *Medicine and Health Rhode Island*. 2012 Jul;95(7):207-9. PMID: 22928231.
29. **Salloway S**, Sperling R, Brashear R. Response Letter to the Editor, Phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. *New England Journal of Medicine*. 2014 Apr 10;370(15):1460. PMID: 24724181.
30. **Salloway S**, Sperling R. Understanding conflicting neuropathological findings in patients clinically diagnosed with Alzheimer's disease dementia. Editorial in *JAMA Neurol*. 2015 Oct;72(1):1106-08. Doi: 10.1001/jamaneurol.2015.1804. PMID: 26302229.
31. Herman L, Atri A, **Salloway S.** Alzheimer's Disease in Primary Care: The Significance of Early Detection, Diagnosis, and Intervention. *Am J Med*. 2017 Jun;130(6):756. doi: 10.1016/j.amjmed.2017.04.001. Epub 2017 Apr 25. PMID: 28449849.
32. Alber J, Lee A, Menard W, Monast D, **Salloway S.** Recruitment of at-risk AD participants for clinical trials: A major paradigm shift for AD prevention. *J Prevention Alz Dis*. 2017, in press.
33. Lee A, Correia S, **Salloway SP.** *J Prevention Alz Dis*. 2020;7(4):204-205. Doi: 10.14283/jpad.2020.43. PMID: 32920619.
34. Howe MD, Rabinovici GD, **Salloway SP.** Real-World Application of Anti- β -Amyloid Monoclonal Antibodies: Untangling Eligibility. Editorial in *Neurology*. 2023 Nov 7;101(19):811-812. doi:10.1212/WNL.0000000000207873. Epub 2023 Aug 16. PMID: 37586880.
35. Chin NA, Dinsmore D, Gonzales T, Groves B, Johnson D, Napolitano J, Ropper A, **Salloway S**, Weiss L. Alzheimer's Disease - Anti-Amyloid Medications, Early Detection, and Screening. Perspective in *N Engl J Med*. 2024 Mar 7;390(10):e22. doi:10.1056/NEJMp2310176. PMID: 38446673. No abstract available.
36. Chin NA, Dinsmore D, Gonzales T, Groves B, Houston S, Johnson D, Johnson D, Napolitano J, Ropper A, **Salloway S**, Sutherland R, Weiss L, Wheelock K. Alzheimer's Disease - Managing Stages of Dementia. Perspective in *N Engl J Med*. 2024 Mar 21;390(12):e29. doi:10.1056/NEJMp2310177. PMID: 38507749. No abstract available.

CORPORATE AUTHORSHIP OR MULTICENTER TRIALS

None.

PUBLICATIONS SUBMITTED OR IN PREPARATION

1. **Salloway S**, Towne C, Wallace S, Batish D. Spectrum of notch3 cysteine-changes in CADASIL: The Athena North American Experience, under review.
2. Correia S, **Salloway S**, Ahern D, delaMonte S. Two cases of CADASIL with concomitant Alzheimer's pathology, in preparation.
3. Sperling R, Bronen R, **Salloway S**, Greenberg S, Johnson K, Hyman B, Sorensen G, Gass A, Meadowcroft M, Berma n R, Albright C, Coric V, Feldman H. Three cases of apparent amyloid related imaging abnormalities (ARIA) in a Phase 2 clinical trial of the gamma-secretase Inhibitor avagacestat in patients with mild-to-moderate Alzheimer's disease, in preparation.
4. Feldman H, Coric V, Sperling R, Greenberg S, Bronen R, Sorensen G, **Salloway S**, Pachai C, Kaplita S, Meadowcroft M, Albright C, Berman R. Cerbral microhemorrhages in a phase 2 trial of avagacestat in Alzheimer's disease, submitted.

ABSTRACTS

1. Campbell J, Duffy J, **Salloway S**. Apathy and Memory Loss following bilateral anteromedial thalamic infarctions. *J Neuropsychiatry and Clin Neurosci* 1993; 5:446.
2. **Salloway S**, Malloy P, Rogg J, Duffy J, Kohn R, Richardson E, Gillard E, Thomas C. Subcortical MRI changes in late-life onset depression. *J Neuropsychiatry and Clin Neurosci* 1993; 5:446-447.
3. Campbell J, **Salloway S**, Duffy J, Malloy P. Utilization behavior and disinhibition in an 82 year old woman. *J Neuropsychiatry and Clin Neurosci* 1994;7:298.
4. Malloy P, **Salloway S**. Reduplicative paramnesia following lacunar infarction of the right genu of the internal capsule. *J Neuropsychiatry and Clinical Neurosci* 1994;7:317.
5. **Salloway S**, Dammers P, Eveloff S. REM Sleep Behavior Disorder associated with a cingulate lesion. *J Neuropsychiatry and Clinical Neurosci* 1994; 7:298.
6. **Salloway S**, Rasmussen S, Brin M, Blitzer A. Laryngeal botulinum toxin injection for refractory vocal tics. *J Neuropsychiatry and Clinical Neurosci* 1994;7:298-299.
7. **Salloway S**, Malloy P, Rogg J, Duffy J, Kohn R, Thomas C, Richardson E. Clinical significance of subcortical encephalomalacia in early and late onset depression. *Neurology* 1994;44 suppl 2:A375.
8. **Salloway S**, Rasmussen S, Malloy P. Resolution of longstanding obsessive compulsive disorder following left anteromedial thalamic infarction. *Neurology* 1995;45(suppl 4):A167.
9. **Salloway S**, Malloy P, Rogg J, Thomas C, Lan J. Neuroimaging Tutorial: A Practical Guide for the Clinician. (Accepted for Presentation at the 1995 American Academy of Neurology Annual Meeting but unpublished.)
10. Malloy P, Morales X, **Salloway S**, Richardson E. Sexual delusions: A case series. *J Neuropsychiatry and Clin Neurosci* 1995;7:405.
11. Jenkins M, Malloy P, Salloway S, Biber M. Aphasia and delusions as primary symptoms in a case of multiple sclerosis. *J Neuropsychiatry and Clin Neurosci* 1995;7:404.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

12. Chang K, Neeper R, Jenkins M, Penn J, Bollivar L, Israeli L, Malloy P, **Salloway S**. Clinical profile of patients referred for evaluation of adult attention deficit hyperactivity disorder. *J Neuropsychiatry and Clin Neurosci* 1995;7:400-401. (American Neuropsychiatric Association Young Investigator Award Honorable Mention).
13. Cahn DA, Malloy P, **Salloway S**, Rogg J, Gillard E, Kohn R, Tung G, Richardson ED. Subcortical hyperintensities on magnetic resonance imaging and activities of daily living in geriatric depression. *Archives of Clinical Neuropsychology* 1995;11:374. (Presented at the 15th Annual Meeting of the National Academy of Neuropsychology)
14. Jenkins M, **Salloway S**, Malloy P, Rogg J, Kohn R, Tung G, Richardson E, Gillard E. Frontal subcortical contributions to memory in depressed geriatric patients with periventricular hyperintensities on MRI. *Neurology* 1996;46:A432.
15. **Salloway S**, Stopa E. Subcortical dementia and depression in biopsy-proven CADASIL: pathological and radiological findings. *Neurology* 1996;46:A326.
16. Jenkins M, Malloy P, Cohen R, **Salloway S**, Neeper R, Penn J, Chang K. Attentional and learning dysfunction among adults with history of childhood ADHD. *J International Neuropsychological Society* 1996;2:209. Presented at International Neuropsychological Society 19th Annual Mid-Year Meeting, Veldhoven, The Netherlands, June 1996.
17. Cohen R, Aloia M, Holler K, Jenkins M, Malloy P, Gordon N, Stone W, **Salloway S**. Quantitative MRI ratings of subcortical leukoaraiosis in the assessment of dementia: reliability and clinical correlation. *J Neuropsychiatry and Clin Neurosci* 1997;9:134.
18. Westlake R, Jenkins M, Malloy P, **Salloway S**, Kohn R, Luketela K. Clinical significance of white matter hyperintensities on MRI in geriatric depression. Proceedings of the American Psychiatric Association 1997 Annual Meeting, p. 250. Poster Presentation in New Research Proceedings of the 1997 American Psychiatric Association Annual Meeting, San Diego, CA, May 1997.
19. Jenkins M, Malloy P, **Salloway S**, Kohn R, Westlake R, Javorsky D. Apathy and activities of daily living in geriatric depressed patients with and without CT scan-identified white matter disease. Proceedings of the American Psychiatric Association 1997 Annual Meeting, p. 249. Poster Presentation in New Research Proceedings of the 1997 American Psychiatric Association Annual Meeting, San Diego, CA, May 1997.
20. Abuelo D, **Salloway S**. Presymptomatic diagnosis of CADASIL. Proceedings of the American College of Medical Genetics 4th Annual Meeting and the 28th Annual Meeting of the March of Dimes Clinical Genetics Conference. Feb 1997, Ft. Lauderdale, Florida, p. A32.
21. Intal J, **Salloway S**, Stopa E, Donohue J. MRI-autopsy correlation of signal hyperintensities in leukoencephalopathy. Society of Neuroscience Abstracts 1997, 833. Presented at the 27th Annual Meeting of the Society for Neuroscience, New Orleans.
22. Jenkins M, Hong J, **Salloway S**, Malloy P, Rickler K, Cohen R. Improvement in attention with stimulant treatment in adults with ADHD. *J Neuropsychiatry Clin Neurosci* 1997, 9:649. Presented at the 9th Annual Meeting of the American Neuropsychiatric Association, Honolulu, February 1998.
23. Tremont G, Stern R, Abuelo D, Geffroy G, Walsh A, **Salloway S**. Early-onset dementia in a mentally retarded adult associated with novel presenilin-I mutations. *J Neuropsychiatry Clin*

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

- Neurosci* 1997, 9:697. Presented at the 9th Annual Meeting of the American Neuropsychiatric Association, Honolulu, February 1998.
24. **Salloway S**, Jenkins M, Intal J, Javorsky D, Malloy P. FLAIR is more sensitive than proton density weighting for visualizing and measuring SH in geriatric hypertension. *J Neuropsych Clin Neurosci* 1999; 11:155. Presented at the 10th Annual Meeting of the American Neuropsychiatric Association in New Orleans, LA.
 25. **Salloway S**, Mega M. The neuropsychiatry of limbic and subcortical disorders. Proceedings of the Third International Neuropsychiatry Congress. Kyoto, Japan, April 2000.
 26. Jenkins M, **Salloway S**, Malloy P, Hong J, McKiernan K. Effects of stimulant treatment for adult ADHD on executive functioning. *J Neuropsych Clin Neurosci* 2001;13:133. Presented at the 12th Annual Meeting of the American Neuropsychiatric Association, Ft. Myers, FL.
 27. LaFrance C, **Salloway S**, Greenberg B. Obsessive Compulsive Symptoms, Mood and Laterality in Patients with Spasmodic Torticollis. *Movement Disorders* 2001;16(Sup 1):S48. Presented at the First International Congress of Behavioral Dysfunction in Movement Disorders October 2001, Montreal, Canada.
 28. Stopa E, Fallon J, **Salloway S**, Butala P, Zipser B, Morales X, Hovanesian V, Hulette C, Rosenberg C, Tavares R, Johanson C, Vitek M. Differential distribution of smooth muscle actin and agrin in the microvasculature of the tg app670, 671 mouse and alzheimer brain. Society of Neuroscience Abstracts 2001, in press. Presented at the 31st Annual Meeting of the Society for Neuroscience, San Diego, CA, November 2001.
 29. **Salloway S**, Stopa E, Douglas F, Wilterdink J, Rogg J. Amyloid angiopathy associated with cerebral hemorrhage, extensive microhemorrhages and severe white matter edema. Presented at the 2nd International Conference on Vascular Dementia, January 2002, Salzburg, Austria.
 30. **Salloway S**, Boyle P, Malloy P, Correia S, Krishnan R, Schneider L, Cahn-Weiner D, Nakra R. MRI subcortical hyperintensities in outpatient geriatric major depression: information from two recent randomized, prospective placebo controlled trials. Presented at the 2nd International Conference on Vascular Dementia, January 2002, Salzburg, Austria.
 31. Gur T, Stopa E, Fallon J, **Salloway S**. Effect of APOE4 genotype on capillary basement membrane area in Alzheimer's disease. Presented at the 2nd International Conference on Vascular Dementia, January 2002, Salzburg, Austria.
 32. Boyle P, Malloy P, **Salloway S**. Frontal lobe function and the predictors of functional abilities in patients with dementia. *JINS* 2001;7(4):486. Presented at the Annual Meeting of the International Neuropsychological Association, February 2001, Chicago, IL.
 33. MacLean, A, **Salloway S**, Woods R, Stopa E, Douglas F, Wilterdink J, Rogg J. Novel findings in two cases of biopsy-proven small artery disease: Spontaneous cerebral hemorrhage in CADASIL and severe white matter edema in amyloid angiopathy. *Neurobiology of Aging* 2002;23(1S):S172. Presented at the World Alzheimer Congress July 2002, Stockholm, Sweden
 34. **Salloway S**, Pratt RD, Perdomo CA and The Donepezil 308 VaD Study Group. Donepezil treated patients with vascular dementia demonstrate cognitive and global benefits. *Neurobiology of Aging* 2002;23(1S):S57. Presented at the World Alzheimer Congress July 2002, Stockholm, Sweden.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

35. Malloy P, Rymer S, **Salloway S**, Lauren Norton. Contributions to caregiver burden in Alzheimer's disease: awareness of deficit and behavioral disturbance. *Neurobiology of Aging* 2002;23(1S):S159. Presented at the World Alzheimer Congress July 2002, Stockholm, Sweden.
36. Correia S, **Salloway S**, Boyle P, Malloy P, Cahn-Weiner D, Scheider L, Krishnan RR, Nakra R. Relationship of subcortical hyperintensities to treatment response in young and old elderly with outpatient geriatric depression: Results of two placebo-controlled trials. *Neurobiology of Aging* 2002;23(1S):S159. Presented at the World Alzheimer Congress July 2002, Stockholm, Sweden.
37. Boyle P, Malloy P, **Salloway S**, Correia S. Functional significance of subcortical white matter changes in Alzheimer's disease. *Neurobiology of Aging* 2002;23(1S):S495. Presented at the World Alzheimer Congress July 2002, Stockholm, Sweden.
38. **Salloway S**, Gustavo Roman G. Critical review of the NINDS-AIRENS Vascular Dementia Criteria. Presented at the Alzheimer's Imaging Consortium, July 2002, Stockholm, Sweden.
39. **Salloway S**, Pratt R, Perdomo CA. Donepezil improves cognition in patients with probable and in those with possible vascular dementia. *Eur J Neurol* 2002;9(suppl 2):192(p3114). Presented at the European Federation of Neurological Societies, October 2002, Vienna, Austria.
40. **Salloway S**, Pratt R, Perdomo CA. Donepezil is well tolerated in patients with vascular dementia: a comparison of tolerability in vascular dementia and Alzheimer's disease. Presented at the European Federation of Neurological Societies, October 2002, Vienna, Austria.
41. **Salloway S**, Richardson S, Ferris S, Kluger A. Benefits of donepezil treatment in patients with mild cognitive impairment. American Academy of Neurology 55th Annual Meeting, April 2003, Honolulu. *Neurology* 2003;60:A411-2
42. Correia S, **Salloway S**, Roman G. Critical review of the NINDS-AIREN criteria for vascular dementia. American Academy of Neurology 55th Annual Meeting, April 2003, Honolulu. *Neurology* 2003;60:A377-8.
43. **Salloway S**, Malloy P, Correia S. A comparison of the cognitive benefits of donepezil in patients with cortical versus subcortical vascular dementia: a subanalysis of two 24-week, randomized double-blind, placebo-controlled trials. American Academy of Neurology 55th Annual Meeting, April 2003, Honolulu. *Neurology* 2003;60:A141-2.
44. **Salloway S**, Richardson S. Donepezil treatment provides benefits in patients with mild cognitive impairment. International Psychogeriatric Association 11th International Congress, Chicago, August, 2003, *International Psychogeriatrics* 2003;15, suppl 2:107.
45. Correia S, **Salloway S**, Belanger H, Nassery S, Malloy P, Drodge S. Ambulatory blood pressure monitoring in Alzheimer's disease patients with high and low degree of subcortical hyperintensities. First Congress of the International Society for Vascular Cognitive and Behavioral Disorders, Gothenberg Sweden, August, 2003. *J Neurol Sci* 2004;226:150-1.
46. **Salloway S**, Pratt RD, Perdomo CA. A comparison of the cognitive benefits of donepezil in patients with cortical and subcortical vascular dementia. First Congress of the International Society for Vascular Cognitive and Behavioral Disorders, Gothenberg Sweden, August, 2003. *J Neurol Sci* 2004;226:160-161.
47. Miaux Y, Guermazi A, **Salloway S**, Sieffert M, Altman H, Pratt R. Neuroradiological Features Associated with Vascular Dementia. European Society of Neuroradiology. Istanbul Turkey, September 2003.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

48. Guermazi A, Miaux Y, Sieffert M, **Salloway S**, Altman, Pratt R. Neuroradiological findings in vascular dementia. Radiological Society of North America 89th Annual Meeting, Chicago November 2003.
49. Tremont G, Davis J, Slavin C, Bishop D, **Salloway S**. Family Functioning as a Predictor of Burden in Caregivers of Patients with Mild to Moderate Dementia. International Neuropsychological Association 32nd Annual Meeting Baltimore, MD, February, 2004. *JINS* 2004, in press.
50. **Salloway S**, Mahableschwarkar A, Brashear R. Differential efficacy of galantamine in patients with dementia and cerebrovascular disease: a subanalysis by CVD lesion subtypes. Presented at the 42nd Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 2003.
51. Wilder-Willis KE, Malloy PF, **Salloway S**, Correia S, Belanger HG, Kumariah D, Flynn-O'Brien K. Performance on the delayed response and delayed matching to sample task in patients with mild cognitive impairment and healthy elderly controls. International Neuropsychological Association 32nd Annual Meeting Baltimore, MD, February 2004. *JINS* 2004, in press.
52. **Salloway S**, Ieni J, Griesing T, Goldman R, Kluger A, Kumar D, Richardson S. Cognitive response in patients with amnesic mild cognitive impairment: benefits of donepezil. American Association of Geriatric Psychiatry 17th Annual Meeting, February, 2004 Baltimore, MD.
53. Laidlaw, DH, Zhang S, Bastin ME, Correia S, **Salloway S**, Malloy P. Ramifications of isotropic sampling and acquisition orientation on DTI analyses. International Society of Magnetic Resonance in Medicine, Tokyo, Japan, May 2004.
54. Auchus A, Brashear HR, **Salloway S**, Scheltens P, Korczyn A, Gassman-Mayer C, Gold M. Results of a trial of galantamine subjects with vascular dementia confirmed by a central reading. *Neurology* 2004; American Academy of Neurology Annual Meeting, San Francisco, CA, April 2004.
55. Davis J, Tremont G, Slavin C, **Salloway S**. Caregiver perception of executive dysfunction and behavioral problems as predictors of burden in dementia caregivers. *Journal of Neuropsychiatry and Clinical Neurosciences*. in press; Paper presented at the 2004 Meeting of the American Neuropsychiatric Association, Bal Harbour, FL
56. Correia S, Zhang S, Laidlaw D Malloy P, **Salloway S**. (2004) Diffusion-tensor imaging: linear, planar, and spherical diffusion in CADASIL. Poster. 9th International Conference on Alzheimer's Disease and Related Disorders, July 17-22, Philadelphia. Abstract P2-232 *Neurobiology of Aging* 2004;25(S2):S298.
57. Correia S, **Salloway S**, Malloy P, Song C, Li R. (2004) Systolic Blood Pressure Variability and Subcortical Hyperintensities in Patients with Mild-To-Moderate Alzheimer's Disease. Poster. 9th International Conference on Alzheimer's Disease and Related Disorders, July 17-22, Philadelphia. *Neurobiology of Aging* 2004;25(S2):S278
58. Malloy PF, Belanger H, Hall S, Grigsby J, Hamman RF, Wilder-Willis K, Aloia M, **Salloway S**. Validation of Measures of Spatial and Executive Abilities in Alzheimer's Disease and Mild Cognitive Impairment. Poster. 9th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, PA, July 17-22, 2004. *Neurobiology of Aging* 2004; 25(S2): S112.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

59. Butala P, **Salloway S**, Johanson CE, Gonzalez L, Tavares R, Hovanesian V, Donahue JE, Hulette CM, Vitek MP, Stopa EG. Microvascular Damage in Alzheimer's disease. Poster. 9th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, PA, July 17-22, 2004. *Neurobiology of Aging* 2004; 25(S2): S408.
60. **Salloway S**, Pratt R, Posner H, Kumar D. Vascular dementia patients who receive donepezil treatment for 12-18 months maintain cognitive benefits. Presented at the 8th Congress of the European Federation of Neurological Societies. Paris, France, September, 2004. *European Journal of Neurology* 2004;11 suppl 2,184.
61. Correia S, Brennan-Krohn T, Zhang S, Laidlaw D, Malloy P, **Salloway S**. Diffusion-Tensor Imaging and Executive Function in Subcortical Ischemic Vascular Disease and Mild Cognitive Impairment. Presented at the International Neuropsychological Association 33rd Annual Meeting St. Louis, MO, February 2005. *JINS* 2005, in press.
62. **Salloway S**, Ferris S, Kluger A, Goldman T, Griesing T, Kumar D, Richardson S. Key lessons learned from the design and outcome of a 24 week donepezil mild cognitive impairment trial. Cold Spring Harbor Laboratory Mechanisms of Drug Discovery in Neurodegenerative Disorders Conference, Cold Spring Harbor, NY, December, 2004.
63. Brennan-Krohn T, Dong M, Rivera E, **Salloway S**, delaMonte S,. CADASIL: Molecular Analysis of Aberrant Gene Expression in the Brain. Presented at the NIMH Summer Training in Aging Research Topics Mental Health Annual Conference, San Diego, CA, August, 2005.
64. Correia S, Lee S, Malloy P, Mehta N, Zhang S, **Salloway S**, Laidlaw DH. Diffusion-Tensor MRI Tractography Methods for Assessing White Matter Health And Its Relationship To Cognitive Functioning. International Neuropsychological Society 34th Annual Meeting, Boston, February 2006.
65. Lee SY, Correia S, Tate DF, Paul RF, Zhang S, **Salloway SP**, Malloy PF, and Laidlaw DH. Quantitative Tract-of-Interest Metrics for White Matter Integrity Based on Diffusion Tensor MRI Data. Oral Presentation. 14th International Society for Magnetic Resonance in Medicine Scientific Meeting & Exhibition, Seattle, Washington, May 2006.
66. Vascular Dementia and Vascular Cognitive Impairment: Treatment Approaches. *Brain and Cognition* 2006.
67. Correia S, Lee S, Zhang S, **Salloway SP**, Malloy PF, Laidlaw DH. Diffusion-tensor imaging tractography: correlation with processing speed in aging. *Alzheimer's and Dementia* 2006;Vol 2,#3:S317-8, S686. Presented at the 10th International Conference on Alzheimer's Disease and Related Disorders (ICAD)(Best Poster Award). Madrid, Spain, July, 2006.
68. Brennan-Krohn T, Dong M, Rivala E, **Salloway S**, delaMonte S. CADASIL: Molecular Analysis of Aberrant Gene Expression in the Brain. *Alzheimer's and Dementia* 2006;Vol 2,#3:S564-5. Presented at the 10th International Conference on Alzheimer's Disease and Related Disorders (ICAD). Madrid, Spain, July, 2006.
69. Davis C, **Salloway S**, Doody R, McRae T, Kumar D, Posner H, Surick I. Safety findings from the donepezil vascular dementia program. *Alzheimer's and Dementia* 2006;Vol 2,#3, in press. Presented at the 10th International Conference on Alzheimer's Disease and Related Disorders (ICAD). Madrid, Spain, July, 2006.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

70. Patel K., Correia S, Foley J, Schlichting E, Zhang S, Laidlaw D, **Salloway S**. Cognitive impairment, hippocampal volume, and white matter integrity in CADASIL. 35th Meeting of the International Neuropsychological Society, Portland OR, February 7-10, 2007.
71. Schlichting E, Correia S, Malloy P, **Salloway S**. N-back performance and standardized measures of processing speed, executive function, and working memory in mild cognitive impairment vs. normal controls. 35th Meeting of the International Neuropsychological Society, Portland OR, February 7-10, 2007.
72. Brennan-Krohn T, Dong M, Rivala E, **Salloway S**, delaMonte S. Aberrant Gene Expression in the Brain in CADASIL. Neurology 2007, in press. Presented at the 59th Annual Meeting of the American Academy of Neurology, Boston, MA, May, 2007.
73. Correia S, Foley J, Zhang S, Laidlaw D, Malloy P, **Salloway S**. Processing speed in CADASIL: Relationship to cingulum vs. callosal fibers. Presented at the Third Congress of the International Society for Vascular Cognitive and Behavioral Disorders, San Antonio, Texas, July, 2007.
74. Patel K, Correia S, Epstein S, Schlichting S, Zhang S, Laidlaw D, Malloy P, **Salloway S**. Grey and white matter changes on MRI and diffusion-tensor imaging and cognitive function in mild cognitive impairment. (2008). Paper presentation. 36th Meeting of the International Neuropsychological Society, Waikoloa, Hawaii, February 6-9, 2008.
75. Song S, Correia S, Schlichting S, Malloy P, **Salloway S**. Executive impairment and MoCA performance in mild cognitive impairment and Alzheimer's disease (2008). Poster abstract. 36th Meeting of the International Neuropsychological Society, Waikoloa, Hawaii, February 6-9, 2008.
76. Schlichting E, Correia S, Malloy P, **Salloway S**. Classification of patients with amnesic mild cognitive impairment vs. normal controls based on N-back, Self-Ordered Pointing Task, and standardized cognitive measures. Poster abstract. 36th Meeting of the International Neuropsychological Society, Waikoloa, Hawaii, February 6-9, 2008.
77. Dichgans M, Markus H, **Salloway S**, Moline M, Hsu T, Posner H, Hurt S, Wang Q, Chabriat H. Efficacy and tolerability of donepezil in CADASIL: A model of subcortical vascular cognitive impairment. American Heart Association International Stroke Congress, February, 2008.
78. Doody R, Ferris S, **Salloway S**, Murthy A, Goldman R, Xu Y, Sun Y. A 1 year randomized trial of donepezil in patients with mild cognitive impairment. 10th International Hong Kong/Springfield Pan-Asian Symposium on Advances in Alzheimer Therapy. Hong Kong, China February, 2008.
79. **Salloway S**, Dichgans M, Markus H, Moline M, Posner H, Wang Q, Chabriat H. Efficacy and tolerability of donepezil in CADASIL. 60th Annual Meeting of the American Academy of Neurology Late Breaking Science. Chicago, IL, April, 2008.
80. Chabriat H, Markus H, **Salloway S**, Verkkoniemi A, Moline M, Wang Q, Posner H, Dichgans M. Donepezil improves executive function in non-demented CADASIL patients. 17th European Stroke Conference, Nice, France, May, 2008.
81. **Salloway S**, Dichgans M, Markus H, Moline M, Posner H, Wang Q, Chabriat H. 18 week placebo-controlled trial of donepezil for treatment of cognitive impairment in CADASIL. International Congress of Alzheimer's Disease 2008, Chicago, IL, July, 2008.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

82. Epstein S, Correia S, MacKay-Brandt A, Laidlaw D, Malloy P, **Salloway S**. Superior longitudinal fasciculus and working memory in CADASIL. 37th Meeting of the International Neuropsychological Society. Atlanta, GA. February, 2009.
83. Sperling R, **Salloway S**, Fox N, Barakos J, Morris K, Francis G, Black R, Grundman M for the for the Bapineuzumab 201 clinical trial investigators. Risk Factors and Clinical Course Associated with Vasogenic Edema in a Phase II Trial of Bapineuzumab. 61st Annual Meeting of the American Academy of Neurology, April 2009, Seattle, WA. *Neurology* 2009;72:A270-1.
84. **Salloway S**, Sperling R, Gregg K, Black R, Grundman M. Cognitive and Functional Outcomes from a Phase 2 Trial of Bapineuzumab in Mild to Moderate Alzheimer's Disease. 61st Annual Meeting of the American Academy of Neurology, April 2009, Seattle, WA. *Neurology* 2009;72:A272.
85. Stopa E, Ott B, Johanson C, Klinge PM, **Salloway S**, Mernoff S, Stoukides J, delaMonte S, Silverberg G, Donahue J, Alvarez V, Geller M. Cognitive improvement after ventriculo-peritoneal (VP) shunt placement in Alzheimer's Disease (AD) and non-AD dementias. *Hydrocephalus* 2009, Baltimore Maryland, September, 2009.
86. Schlichting, E.G., Correia S., Malloy, P.F., **Salloway, S**. Performance on the MMSE, MoCA, and Expanded MoCA in Mild Cognitive Impairment and Dementia. (Poster abstract #725420) International Neuropsychological Society 38th Annual Meeting. February 3-6, 2010, Acapulco, Mexico.
87. Halilaj E., Correia S., Laidlaw DH, **Salloway S**. A quantitative tractography approach for exploring associations between white matter pathways and cognitive function. Annual ISMRM-ESMRMB Joint Meeting. May, 2010. Stockholm, Sweden.
88. Farlow M, **Salloway S**, Tariot P, Yardley J, Moline M, Wang Q, Zou, Brand-Schieber E, Satlin A, Hsu T. Donepezil high-dose extended-release tablets provide greater benefit to moderate-to-severe AD patients already treated with donepezil immediate release. 13th International Conference on Alzheimer's Disease and Related Disorders (ICAD), Honolulu, Hawaii, July, 2010. *Neurobiology of Aging* 2010.
89. Deoni S, Correia S, Malloy P, Su T, Mann J, **Salloway S**. Is myelin content altered in Alzheimer's disease? ISMRM Annual Meeting, Montréal, Québec, Canada, May, 2011.
90. **Salloway S**, Ramos H, Faison W, Zou H. Efficacy and safety of donepezil 23 mg/day vs. donepezil 10 mg/day in moderate-severe Alzheimer's disease: subgroup analysis of US participants in a global study. *Neurology* 2011. American Academy of Neurology 63rd Annual Meeting. Honolulu, Hawaii, April, 2011.
91. Farlow M, **Salloway S**, Tariot P, Yardley J, Moline M, Wang Q, Zou H, Bran-Schieber E, Satlin A, Tsu T. Efficacy and safety of higher dose (23mg) donepezil extended release formulation in moderate-severe Alzheimer's disease. *Neurology* 2011. American Academy of Neurology 63rd Annual Meeting. Honolulu, Hawaii, April, 2011.
92. Batish D, Towne C, Aster J, Blacklow S, Jones J, Wallace S, **Salloway S**. Spectrum of NOTCH3 cysteine change mutations in 884 confirmed cases of CADASIL from North America. *Neurology* 2011. American Academy of Neurology 63rd Annual Meeting. Honolulu, Hawaii, April, 2011.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

93. Bateman R, Aisen P, Fox N, Morris J, Ringman J, **Salloway S**, Santa Cruz A, Xiong C, Sperling R. Dominantly Inherited Alzheimer's Network: A model for prevention trials. *Neurology* 2011. American Academy of Neurology 63rd Annual Meeting. Honolulu, Hawaii, April, 2011.
94. Sperling RA, Bronen R, Greenberg SM, Sorensen G, **Salloway S**, Gass A, Meadowcroft M, Berman RM, Albright C, Coric V, Feldman HH. Three Cases of Apparent Vasogenic Edema (VE) from a Phase 2 Clinical Trial of the Gamma Secretase Inhibitor BMS-708163 in patients with Mild-to-Moderate AD. *Alzheimer's and Dementia* 2011. International Conference on Alzheimer's Disease 2011, Paris France.
95. **Salloway S**, Coric V, Brody M, Andreasen N, van Dyck C, Soininen H, Thein S, Shiovitz T, Kumar S, Pilcher G, Colby S, Rollin L, Feldman H, Berman R. Safety and tolerability of BMS-708163 in a phase 2 study in mild-to-moderate Alzheimer's disease. *Alzheimer's and Dementia* 2011. International Conference on Alzheimer's Disease 2011, Paris France.
96. Feldman H, Berman R, Coric V, Sperling R, **Salloway S**, Bronen R, Sorensen G, Kaplita S, Meadowcroft M, Albright C. Cerebral microbleeds in a phase 2 clinical trial of mild to moderate AD with the gamma secretase inhibitor BMS 708163. *Alzheimer's and Dementia* 2011. International Conference on Alzheimer's Disease 2011, Paris France.
97. **Salloway S**. Vasogenic edema in immunotherapy: sign of efficacy or danger? *Alzheimer's and Dementia* 2011. International Conference on Alzheimer's Disease 2011, Paris France.
98. **Salloway S**, Porsteinsson A, Sperling R, Keren R, van Dyck C, Tariot P, Gilman S, Crans G, Hernandez C, Quinn G, Bairu M, Cedarbaum J, Pastrak A, Abushakra S. Safety and efficacy results of a phase 2 dose-ranging study of ELND005 (scyllo-inositol) in mild to moderate Alzheimer's disease. *Alzheimer's and Dementia* 2011. International Conference on Alzheimer's Disease 2011, Paris France.
99. Porsteinsson A, Sperling R, **Salloway S**, Keren R, van Dyck C, Tariot P, Arnold D, Crans G, Hernandez C, Quinn G, Liang E, Bairu M, Cedarbaum J, Pastrak A, Abushakra S. Imaging and cerebrospinal fluid biomarker results of a phase 2 dose-ranging study of ELND005 (scyllo-inositol) in mild to moderate Alzheimer's disease. *Alzheimer's and Dementia* 2011. International Conference on Alzheimer's Disease 2011, Paris France.
100. **Salloway S**, Ramos H, Faison W, Zou H. Efficacy and safety of donepezil 23 mg/d versus donepezil 10 mg/d in moderate and severe Alzheimer's disease: Subgroup analysis of US participants in a global study. National Association Director of Nursing Administrators 2011 Conference. Kissimmee, FL July, 2011.
101. **Salloway S**, Porsteinsson A, Crans G, Hernandez S, Abushakra S. A 78 week phase 2 study of ELND005 (scyllo-inositol) in Alzheimer's disease: Clinical outcomes by various MMSE definitions of mild disease. *Clinical Trials in Alzheimer's Disease* 4th Annual Meeting, November, 2011, San Diego, CA. *J Nutrition, Health, and Aging* 2011;15 suppl 1:S8.
102. Porsteinsson A, Sperling R, **Salloway S**, Crans G, Hernandez C, Abushakra S. Responders to ELND005 (scyllo-inositol) in an Alzheimer's disease study of 78 weeks: analysis of their clinical, V-MRI, and CSF characteristics. *Clinical Trials in Alzheimer's Disease* 4th Annual Meeting, November, 2011, San Diego, CA. *J Nutrition, Health, and Aging* 2011;15 suppl 1:S8.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

103. Ahern D, Rabinowitz A, Jerskey B, Deoni S, **Salloway S**, Correia S. Lowering the floor on Trail Making Test Part B: A new scoring metric. International Neuropsychological Society 40th Annual Meeting, February 2012, Montreal, Canada.
104. Treem J, Rabinowitz A, Jerskey B, Deoni S, Ahern D, **Salloway S**, Correia S. Brain correlates of a new scoring metric for Trail-Making-Test-B. International Neuropsychological Society 40th Annual Meeting, February 2012, Montreal, Canada.
105. Rabinowitz A, Correia S, Ahern D, D'Angelo C, Salloway S, Malloy P, Deoni S. White matter correlates of a new scoring metric for Trail-Making-Test-B. Alzheimer's and Dementia 2012. Alzheimer's Association International Conference July, 2012, Vancouver, Canada.
106. **Salloway S**, Sperling R, Portsteinsson A, Crans G, Hernandez C, Abushakra S. Responder analyses from a phase 2 placebo-controlled trial of ELND005 (scyllo-inositol) in mild-moderate Alzheimer's disease. Neurology 2012. Presented at the American Academy of Neurology Annual Meeting, New Orleans, April, 2012.
107. Portsteinsson A, Sperling R, **Salloway S**, Crans G, Hernandez C, Abushakra S. Responders to ELND005 (scyllo-inositol) display clinical and biomarker characteristics consistent with mild Alzheimer's disease. Neurology 2012. Presented at the American Academy of Neurology Annual Meeting, New Orleans, April, 2012.
108. Barakos J, Sperling R, **Salloway S**, Jack C, Gass A, Fiebach J, Tampieri D, Melanson D, Miaux Y, Rippon G, Black R, Yu Y, Liu E, Brashear H, Arrighi H, Morris K, Grundman M. MR imaging features of ARIA (Amyloid-related imaging abnormalities) in subjects treated with bapineuzumab. 12th International Stockholm-Springfield Symposium on Advances in Alzheimer's Therapy, Stockholm, Sweden, May, 2012.
109. Chatwal, J, Schultz A, Johnson K, Benzinger T, Jack C, **Salloway S**, Ringman J, Koeppe R, Marcus D, Thompson P, Saykin A, Correia S, Schofield P, Rowe C, Fox N, Brickman A, Mayeux R, Mathis C, Weiner M, Fagan A, Goate A, Cairns N, Xiong C, Masters C, Ghetti B, Moulder K, Martins R, Bateman R, Buckles V, Morris J, Sperling R. Disrupted Functional Connectivity in Autosomal Dominant Alzheimer's Disease: Preliminary Findings From the DIAN Study. Alzheimer's and Dementia 2012. Alzheimer's Association International Conference July 2012, Vancouver, Canada.
110. Becker J, Koeppe R, Benzinger T, Jack C, Marcus D, Raichle M, Thompson P, Saykin A, Correia S, Schofield P, Rowe C, Fox N, Brickman A, Ghetti B, Masters C, Mathis C, Weiner M, Bateman R, Fagan A, Goate A, Xiong C, Buckles V, Moulder K, Mayeux R, Martins R, Cairns N, Ringman J, **Salloway S**, Morris J, Sperling R, Johnson K. FDG Metabolism in the DIAN Study of Autosomal Dominant Alzheimer's Disease. Alzheimer's and Dementia 2012. Alzheimer's Association International Conference July 2012, Vancouver, Canada.
111. Cash D, Ridgway G, Ryan N, Kinninen K, Yeatman T, Malone I, Benzinger T, Koeppe R, Jack C, Raichle M, Marcus D, Ringman J, Thompson P, Saykin A, **Salloway S**, Correia S, Johnson K, Sperling R, Schofield P, Masters C, Rowe C, Villemagne V, Martins R, Brickman A, Mayeux R, Weiner M, Bateman R, Goate A, Fagan A, Xiong C, Cairns N, Buckles V, Moulder K, Morris J, Rossor M, Ourselin S, Fox N. A Voxel- Based Morphometry Study of Volumetric MRI in Familial Alzheimer's Disease. Alzheimer's and Dementia 2012. Alzheimer's Association International Conference July 2012, Vancouver, Canada.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

112. Kinnunen K, Cash D, Liang Y, Leung K, Cardoso J, Modat M, Malone I, Yeatman T, Nicholas J, Benzinger T, Koeppe R, Jack C, Raichle M, Marcus D, Ringman J, Thompson P, Saykin A, Ghetti B, **Salloway S**, Correia S, Johnson K, Sperling R, Schofield P, Rowe C, Masters C, Villemagne V, Brickman A, Mayeux R, Martins R, Weiner M, Bateman R, Goate A, Buckles V, Moulder K, Morris J, Rossor M, Fox N. Cross Sectional Cerebral Volumetric Differences and Associations With Estimated Time To Age-At-Onset In Familial Alzheimer's Disease: Findings From the DIAN Study. Alzheimer's and Dementia 2012. Alzheimer's Association International Conference July 2012, Vancouver, Canada.
113. Bateman R, Benzinger T, Cairns N, Fagan A, Goate A, Marcus D, Storandt M, Xiong C, Buckles V, Holtzman D, Moulder K, Oliver A, Santacruz A, Fox N, Ghetti B, Klunk W, Martins R, Masters C, Mayeux R, Ringman J, Rossor M, Schofield P, Sperling R, **Salloway S**, Morris J. Presymptomatic Alzheimer's Disease in the Dominantly Inherited Alzheimer's Network (DIAN). Alzheimer's and Dementia 2012. Alzheimer's Association International Conference July 2012, Vancouver, Canada.
114. Benzinger T, Blazey T, Koeppe R, Jack C, Raichle M, Su Y, Snyder A, Marcus D, Ringman J, Thompson P, Ghetti B, Saykin A, **Salloway S**, Correia S, Johnson K, Sperling R, Schofield P, Masters C, Rowe C, Villemagne V, Fox N, Brickman A, Mayeux R, Martins R, Mathis C, Klunk W, Weiner M, Bateman R, Fagan A, Goate A, Cairns N, Buckles V, Moulder K, Morris J. Elevated PIB Precedes Dementia In Autosomal Dominant Alzheimer's Disease: PIB, FDG and Atrophy In The DIAN Cohort. Alzheimer's and Dementia 2012. Alzheimer's Association International Conference July 2012, Vancouver, Canada.
115. Benzinger T, Blazey T, Ances B, Raichle M, Snyder A, Su Y, Marcus D, Ringman J, Thompson P, Ghetti B, Saykin A, **Salloway S**, Correia S, Johnson K, Sperling R, Schofield P, Masters C, Rowe C, Villemagne V, Fox N, Brickman A, Mayeux R, Martins R, Mathis C, Weiner M, Bateman R, Fagan A, Goate A, Cairns N, Buckles V, Moulder K, Morris J. Progressive White Matter Abnormalities in Autosomal Dominant Alzheimer's Disease: Results of The DIAN Study. Alzheimer's and Dementia 2012. Alzheimer's Association International Conference July 2012, Vancouver, Canada.
116. Kinnunen K, Cash D, Leung K, Liang Y, Cardoso M, Modat M, Malone I, Benzinger T, Koeppe R, Jack C, Raichle M, Marcus D, Ringman J, Thompson P, Saykin A, Ghetti B, **Salloway S**, Correia S, Johnson K, Sperling R, Schofield P, Rowe C, Masters C, Villemagne V, Brickman A, Mayeux R, Martins R, Weiner M, Bateman A, Goate A, Moulder K, Morris J, Rossor M, Ourselin S, Fox N. Brain and Hippocampal Rates of Atrophy in Familial Alzheimer's Disease Mutation Carriers: Preliminary Findings From The DIAN Study. Alzheimer's and Dementia 2012. Alzheimer's Association International Conference July 2012, Vancouver, Canada.
117. Sperling R, **Salloway S**, Raskind M, Ferris S, Honig L, Porsteinsson A, Sabbagh M, Liu E, Miloslavsky M, Reichert M, Ketter N, Lu Y, Wang D, Nejadnik B, Grundman M, Black R, Brashear R. Bapineuzumab Phase 3 trials in mild to moderate Alzheimer's disease dementia in apolipoprotein E e4 carriers (Study 302) and non-carriers (Study 301). American Neurological Association Annual Meeting, Boston, MA, October, 2012.
118. Lehman K, O'Muircheartaigh J, Brescia M, Correia S, Malloy P, **Salloway S**, Deoni S. Myelin content changes in Alzheimer's disease. Society for Neuroscience Annual Meeting, New Orleans, LA, October, 2012.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

119. Scheltens P, Sperling R, **Salloway S**, Fox N. Bapineuzumab IV phase 3 results. *J Nutrition, Health and Aging* 2012; 16:797, presented at the 5th Clinical Trials in Alzheimer's Disease Annual Meeting, Monte Carlo, Monaco, October, 2012.
120. Barakos J, Sperling R, **Salloway S**, Jack C, Gass A, Fiebach J, Tampieri D, Melancon D, Miaux Y, Rippon G, Black R, Lu Y, Brashear H.R., Arrighi H.M., Morris K, Grundman M. MR Imaging Features of Aria (Amyloid-Related Imaging Abnormalities) in Patients Treated in Phase 2 Clinical Studies of Bapineuzumab. *J Nutrition, Health and Aging* 2012; 16:852, presented at the Clinical Trials in Alzheimer's Disease Annual Meeting, Monte Carlo, Monaco, October, 2012.
121. **Salloway S**, Sperling R, Honig L, Porsteinsson A, Sabbagh M, Liu E, Yuen E, Lull J, Miloslavsky M, Reichert M, Ketter N, Grundman M, Black R, Brashear R A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E ϵ 4 non-carriers. Presented at the 16th Congress of the European Federation of Neurological Societies, *European Journal of Neurology* 2012;19 (Suppl. 1).
122. Sperling R, **Salloway S**, Raskind M, Ferris S, Liu E, Yuen E, Lu Y, Wang D, Nejadnik B, Guenzler V, Grundman M, Black R, Brashear R. A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E ϵ 4 carriers. Presented at the 16th Congress of the European Federation of Neurological Societies, *European Journal of Neurology* 2012;19 (Suppl. 1).
123. Spader H, Piryatinsky I, **Salloway S**, Malloy P, Klinge P. Do we need comprehensive cognitive test batteries in post TAP and post-surgical evaluation of NPH patients? *International Society of Hydrocephalus and CSF Disorders Annual Meeting*, Kyoto, Japan, October, 2012.
124. **Salloway S**, Curtis C, Gamez J, Singh U, Sadowsky C, Sherwin P, Smith A, Grachev I, Buckley C, McLain R, Sabbagh M. Clinical diagnosis of Alzheimer's disease and Flutemetamol PET image interpretation compared with post-mortem diagnosis. 11th International Conference on Alzheimer's and Parkinson's Disease, AD/PD 2013, Florence, Italy, March, 2013.
125. **Salloway S**, Gamez J, Curtis C, Singh U, Sadowsky C, Sherwin P, Smith A, Grachev I, Buckley C, McLain R, Sabbagh M. Flutemetamol PET imaging: Predictive values, sensitivity, and specificity of blinded visual interpretation. 11th International Conference on Alzheimer's and Parkinson's Disease, AD/PD 2013, Florence, Italy, March, 2013.
126. **Salloway S**, Curtis C, Gamez J, Singh U, Sadowsky C, Sherwin P, Smith A, Grachev I, Buckley C, McLain R, Sabbagh M. Clinical diagnosis of Alzheimer's disease and flutemetamol PET image interpretation compared with neuritic plaque density using modified CERAD criteria. *American Academy of Neurology Annual Meeting*, San Diego, CA, March, 2013.
127. Sperling R, **Salloway S**, van Dyck C, Brashear H, Ketter N, Banerjee K, Arrighi H, Guenzler V, Morris K, Lobello K. Clinical correlates of amyloid-related imaging abnormalities in phase 3 studies of bapineuzumab in Alzheimer's disease. *American Academy of Neurology Annual Meeting*, San Diego, CA, March, 2013.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

128. Ringman J, Liang L, Flores M, Wharton D, Goate A, Cairns N, Marcus D, Benzinger T, Fagan A, Xiong C, Ghetti B, McDade E, Martins R, Masters C, Mayeux R, Rossor M, Schofield P, Sperling R, **Salloway S**, Bateman R, Morris J. Early behavioral changes in familial Alzheimer's disease: results from the Dominantly Inherited Alzheimer Network. American Academy of Neurology Annual Meeting, San Diego, CA, March, 2013.
129. Piryatinsky I, Malloy P, Klinge P, Blennow K, **Salloway S**. Response to shunt surgery in patients with normal pressure hydrocephalus (NPH) negative or positive for CSF amyloid. Alzheimer's Association International Conference 13, Boston, MA, July, 2013.
130. Kinnunen K, Ryan N, Cash D, Bastos Leite A, Finnegan S, Cardoso M, Leung K, Modat M, Benzinger T, Jack C, Marcus D, Raichle M, Thompson P, Ringman J, Ghetti B, **Salloway S**, Sperling R, Schofield P, Masters C, Mayeux R, Martins R, Weiner M, Bateman R, Goate A, Fagan A, Cairns N, Buckles V, Morris J, Rossor M, Ourselin S, Fox N. Are Early Atrophy Patterns in Autosomal Dominant Familial Alzheimer's Disease Gene-Dependent? Alzheimer's Association International Conference 13, Boston, MA, July, 2013.
131. Thomas J, Brier M, Bateman R, Snyder A, Benzinger T, Xiong C, Raichle M, Sperling R, Mayeux R, Ghetti B, Ringman J, **Salloway S**, McDade E, Rossor M, Schofield P, Masters C, Martins R, Jack C, Oliver A, Blazey T, Moulder K, Buckles V, Hornbeck R, Chhatwal J, Schultz A, Goate A, Fagan A, Cairns N, Marcus D, Morris J, Ances B. Resting State Functional Connectivity in Autosomal Dominant and Sporadic Alzheimer's Disease. Alzheimer's Association International Conference 13, Boston, MA, July, 2013.
132. Lee A, Rao J, Van Huiden S, Correia S, O'Muircheartaigh J, Deoni S, **Salloway S**, Malloy P. Myelin Integrity, Cognitive Function and Hypertension in MCI and Alzheimer's Disease. Alzheimer's Association International Conference 13, Boston, MA, July, 2013.
133. Coric V, **Salloway S**, van Dyck C, Kerselaers W, Kaplita S, Curtis C, Ross J, W. Richter R, Andreasen N, Brody M, K. Sharma S, Cedarbaum J, Berman R. A Phase II Study of the Gamma-Secretase Inhibitor Avagacestat (BMS-708163) in Predementia Alzheimer's Disease. Alzheimer's Association International Conference 13, Boston, MA, July, 2013.
134. Blazey T, Jack C, Kantarci K, Preboske G, Ringman J, Brickman A, Raichle M, Hornbeck R, Saykin A, **Salloway S**, McDade E, Rossor M, Fox N, Thompson P, Correia S, Rowe C, Weiner M, Mayeux R, Ghetti B, Sperling R, Schofield P, Bateman R, Cairns N, Goate A, Marcus D, Fagan A, Xiong C, Buckles V, Moulder K, Morris J, Benzinger T. Prevalence and Growth of Cerebral Microhemorrhages in Autosomal Dominant Alzheimer's Disease. Alzheimer's Association International Conference 13, Boston, MA, July, 2013.
135. Rolf Streffer J, Blennow K, **Salloway S**, Zetterberg H, Xu Y, Lu Y, Lull J, Collins P, Cristina Tudor I, Gregg K, Styren S, Yuen E, Grundman M, Brashear R, Liu E. Effect of Bapineuzumab on CSF p-Tau and t-Tau in Mild-to-Moderate Alzheimer's disease: Results From Two Phase III Trials in APOE-ε4 Carriers and Noncarriers. Alzheimer's Association International Conference 13, Boston, MA, July, 2013.
136. Cash D, Ridgway G, Modat C, Ryan N, Kinnunen K, Cardoso J, Benzinger T, Jack Jr. C, Raichle M, Marcus D, Ringman J, Thompson P, Ghetti B, **Salloway S**, Sperling R, Schofield P, Masters C, Martins R, Mayeux R, Weiner M, Bateman R, Fagan A, Goate A, Buckles V, Moulder K, Morris J, Rossor M, Ourselin S, Fox N. Dissociating Volume and Intensity Differences in Familial Alzheimer's Disease. Alzheimer's Association International Conference 13, Boston, MA, July, 2013.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

137. Chhatwal J, Schultz A, Johnson K, Benzinger T, Jack C, Ances B, Sullivan C, **Salloway S**, Ringman J, Koeppe R, Marcus D, Thompson P, Saykin A, Correia S, Schofield P, Rowe C, Fox N, Brickman A, Mayeux R, McDade E, Bateman R, Goate A, Xiong C, Buckles V, Morris J, Sperling R. Disrupted functional connectivity in autosomal dominant Alzheimer's disease demonstrates network specificity and precedes brain volume loss: Findings from The Dominantly Inherited Alzheimer Network. Alzheimer's Association International Conference 13, Boston, MA, July, 2013.
138. **Salloway S**, Sperling R, Gregg K, Yu P, Joshi A, Lu M, Mintun M, Pontecorvo M, Booth K, Wyman B, Sun J, Sundell K, Schmidt M, Margolin R, Skovronsky D, Liu E, Siemers E, Brashear R. Incidence and clinical progression of placebo-treated amyloid-negative subjects with mild-moderate Alzheimer's disease (AD): Results from the phase 3 PET sub-studies of bapineuzumab and solanezumab. Alzheimer's Association International Conference 13, Boston, MA, July, 2013.
139. Margolin R, Andrews R, Lukic A, Zhao X, Tudor I, **Salloway S**, Shaw L, Brashear R, Schmidt M, Liu E, Krams M, Matthews D. Biomarkers and cognition in amyloid-positive and amyloid-negative ADNI-2 MCI subjects: implications for AD therapeutic trials. 6th Annual Clinical Trials in Alzheimer's Disease, San Diego, CA, November, 2013. *J Nutrition Health and Aging* 2013;17:795-6.
140. Chhatwal J, Schultz A, Johnson K, Benzinger T, Jack C, Ances B, Sullivan C, **Salloway S**, Ringman J, Koeppe R, Marcus D, Thompson P, Saykin A, Morris J, Sperling R. Differential temporal patterns of amyloid B and functional imaging markers across mutation types in autosomal dominant Alzheimer's disease. 8th Human Amyloid Imaging, Miami, Florida, January, 2014.
141. Doraiswamy P, Siderowf A, Pontecorvo M, **Salloway S**, Fleisher A, Sadowsky C, Nair A, Lu M, Arora A, Skovronsky D, Mintun M, Grundman M. Amyloid imaging changes diagnosis and treatment in patients with progressive cognitive impairment: 3 month post-scan outcomes. 8th Human Amyloid Imaging, Miami, Florida, January, 2014.
142. Margolin R, Di J, Andrews R, **Salloway S**, Sperling R, Shaw L, Brashear R, Schmidt M, Mathews D. Relationship between amyloid burden and clinical course across AD pathophysiological stages. 8th Human Amyloid Imaging, Miami, Florida, January, 2014.
143. Hartman ERT, Nelson Schmitt SS, Correia S, Lee A, Rao J, Malloy P, **Salloway S**, Deoni S. Myelin integrity and Trails B performance in normal elderly, mild cognitive impairment, and Alzheimer's disease. 42nd Annual Meeting International Neuropsychological Society, February 12-15, 2014 Seattle, WA.
144. Seider TR, Cohen RA, Correia S, Gongvatana A, Cummings T, Tashima KT, de la Monte SM, & Navia B. Synergistic Effects of Age and HIV on White Matter Hyperintensities. Abstract, The American Academy of Clinical Neuropsychology, June 2014.
145. **Salloway S**, Cho W, Clayton D, Honigberg L, Rabe C, Friesenhahn M, Ward M, Brunstein F, Suliman S, Ho C, Paul R. Amyloid PET Imaging Results from a Study to Evaluate the Impact of Crenezumab on Fibrillar Amyloid in Patients with Mild-to-Moderate Alzheimer's Disease. 7th Conference Clinical Trials in Alzheimer's Disease. Philadelphia, PA, November, 2014. *J Prevention Alzheimer's Disease* 2014;1:221.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

146. Smith Watts, AK, Farrer TJ, Walker L, Hartman ERT, Nelson Schmitt S, Lee A, Correia S, **Salloway S**, Malloy P, & Deoni S. Pilot Test of the Utility of a Visual Rating System for Identifying Artifacts in Diffusion-Tensor Imaging (DTI) Data. 43rd Annual Meeting of the International Neuropsychological Society, Feb 2015, Denver.
147. Farrer TJ, Smith Watts, AK, Hartman ERT, Correia S, van Huiden S, **Salloway S**, Malloy P, & Deoni S. Association between White Matter Hyperintensities and Alternate Scoring for Trail Making Test Part B. 43rd Annual Meeting of the International Neuropsychological Society, Feb 2015, Denver.
148. Liu E, Wang D, Sperling R, **Salloway S**, Fox N, Blennow K, Scheltens P, Schmidt M, Streffer J, G Novak, Ketter N, Booth K, Brashear HR. Biomarker pattern in ARIA-E patients from the bapineuzumab 301/302 trials. 12th International Conference of Alzheimer's and Parkinson's Disease, AD/PD 2015. Nice, France, March, 2015.
149. Lyketsos C, Smith G, Fosdick L, Leoutsakos J, Munro C, Esther Oh E, Drake K, Rosenberg P, Anderson W, **Salloway S**, Pendergrass C, Burke A, Wolk D, Tang-Wai D, Ponce F, Asaad W, Sabbagh M, Okun M, Baltuch G, Foote K, Targum S, Lozano A. Deep brain stimulation targeting the fornix for mild Alzheimer's disease: Initial results of the Advance randomized controlled trial. Alzheimer's Association International Conference, Washington, DC, July, 2015.
150. Pontecorvo M, Siderowf A, Grundman M, Dubois B, Nobili F, Sadowsky C, Doraiswamy M, **Salloway S**, McGeehan A, Lowrey M, Dudek A, Flitter M, Dell Agnello G, Chevrette A, Deverdt W, Arora A, Devous M, Mintun M. A randomized, controlled, multicenter, international study of the impact of florbetapir (18F) PET amyloid imaging on patient management and outcome. Alzheimer's Association International Conference, Washington, DC, July, 2015.
151. Snyder P, Lim Y, Marcuff P, Schindler R, Ott B, **Salloway S**, Noto R, Yoo D. Disruption of cholinergic neurotransmission unmasks A β -related cognitive impairment in preclinical Alzheimer's disease. Alzheimer's Association International Conference, Washington, DC, July, 2015.
152. Viglietta V, O'Gorman J, Williams L, Doody R, **Salloway S**, Barkhof F, Vellas B, Sano M, Aisen P, Sevigny J. Randomized. Double-blind, placebo-controlled studies to evaluate treatment with aducanumab (BIIB037) in patients with early Alzheimer's disease: Phase 3 study design. 8th Clinical Trials on Alzheimer's Disease. Barcelona, Spain, November, 2015.
153. Lyketsos C, Smith G, Fosdick L, Leoutsakos J, Munro C, Esther Oh E, Drake K, Rosenberg P, Anderson W, **Salloway S**, Pendergrass C, Burke A, Wolk D, Tang-Wai D, Ponce F, Asaad W, Sabbagh M, Okun M, Baltuch G, Foote K, Targum S, Lozano A. Deep brain stimulation targeting the fornix for mild Alzheimer's disease: Results of the Advance randomized controlled trial. 8th Clinical Trials on Alzheimer's Disease. Barcelona, Spain, November, 2015.
154. Katipally R, Correia S, **Salloway S**. An amyloid PET connectome for Alzheimer's disease. Human Amyloid Imaging, Miami, FL, January, 2016.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

155. Hartman ERT, Correia S, Cabeen R, Laidlaw D, Malloy P, **Salloway S**, & Deoni S. Effects of Cerebrovascular Risk on White Matter Network Characteristics in Mild Cognitive Impairment and Alzheimer's Disease. 44th Meeting of the International Neuropsychological Society Annual Meeting, February 2016, Boston.
156. Seonjoo L, Zimmerman M, Viqar F, Narkhede A, Tosto G, Benzinger T, Marcus D, Goate A, Fox N, Cairns N, Holtzman D, Buckles V, Ghetti B, McDade E, Martins R, Saykin A, Masters C, Ringman J, Ryan N, Firster S, Laske C, Schofield P, Sperling R, **Salloway S**, Correia S, Weiner M, Bateman R, Morris J, Jack C, Mayeux R, Brickman A. Are white matter hyperintensities a core feature of Alzheimer's disease or just a reflection of amyloid angiopathy? Evidence from the Dominantly Inherited Alzheimer Network (DIAN). Alzheimer's Association International Conference, Toronto, Canada, July, 2016.
157. Wang G, McDade E, Bateman R, Hassenstab J, Farlow M, **Salloway S**, Kennedy R, Schneider L, Berry S, Xiong K. Planning dose escalation in phase iii clinical trials may prevent underpowered trials and mitigate the increase in sample size or duration of adaptive trials. Alzheimer's Association International Conference, Toronto, Canada, July, 2016.
158. Ikonovic M, **Salloway S**, Thal D, Sherwin P, Farrar G, Zanette M, Buckley C, Smith A. Performance of [18f]flutemetamol amyloid imaging against the current (2012) NIA-AA recommendations for the neuropathological diagnosis of Alzheimer's disease. Alzheimer's Association International Conference, Toronto, Canada, July, 2016.
159. Buckles V, Xiong C, Weng H, Bateman R, Chhatawal J, Ghetti B, Goate A, Graff-Radford N, Hassenstab J, Mayeux R, Masters C, McDadae E, Moulder K, Paumier K, Ringman J, **Salloway S**, Schofield P, Morris J. The DIAN-NIA UDS comparison study: rates of cognitive decline. Association International Conference, Toronto, Canada, July, 2016.
160. Lim Y, Hassenstab J, Cruchaga C, Goate A, Fagan A, Benzinger T, Maruff P, Snyder P, Masters C, Ricardo A, Chhatawal J, farlow M, Graff-Radford N, Laske C, Levin J, McDade E, Ringman J, Rossor M, **Salloway S**, Schofield P, Holtzman D, Morris J, Bateman R. BDNF val66met moderates cognitive impairment, neuronal dysfunction and tau in preclinical autosomal dominant Alzheimer's disease. Association International Conference, Toronto, Canada, July, 2016.
161. Bateman R, Benzinger T, Berry S, Clifford D, Fagan A, Duggan C, Fanning K, Goate A, Hassenstab J, McDade E, Mills S, Morris J, **Salloway S**, Farlow M, Santacruz A, Wang G, Xiong C. The Dominantly Inherited Alzheimer's Disease Trials Unit. Association International Conference, Toronto, Canada, July, 2016.
162. McDade E, Weng H, Wang G, Xiong C, Fagan A, Hassenstab J, Marcus D, Morris J, Benzinger T, Cairns N, Goate A, Buckles V, Holtzman D, Berman S, Getti B, Farlow M, Mayeux R, Ringman J, Chhatwal J, Graff-Radford N, **Salloway S**, Schofield P, Masters C, martins R, Rossor M, Fox N, Levin J, Danek A, Jucker M, Bateman R. Longitudinal clinical and biomarker changes in dominantly inherited Alzheimer's disease: The Dominantly Inherited Alzheimer's Network. Alzheimer's disease. Association International Conference, Toronto, Canada, July, 2016.
163. Edwards M., Hartman E, Cabeen R, Correia S, Laidlaw D, Malloy P, **Salloway S**, & Deoni S. Association between network connectivity of select brain regions and cognitive abilities based on deterministic single tensor and multi-fiber diffusion MRI tractography. International Neuropsychological Society, 50th Annual Meeting, New Orleans. February 1-5, 2017.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

164. McDade E, Wang G, Benzinger T, Buckles V, Fagan A, Gordon BA, Hassenstab J, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier KL, Xiong C, Ricardo A, Berman S, Mayeux R, Ringman JM, Ghetti BF, Farlow MR, Chhatwal JP, **Salloway S**, Graff-Radford NR, Schofield PR, Masters CL, Martins RN, Rossor MN, Fox NC, Levin J, Jucker M and Bateman, RJ. Longitudinal Biomarker Changes in Autosomal Dominant Alzheimer's Disease from the Dian Study. Alzheimer's Association International Conference (AICC), London, England, July 16-20, 2017.
165. Joseph-Mathurin N, Kantarci K, Jack CR Jr., Ringman JM, **Salloway S**, McDade E, Clifford D, Blazey T, Friedrichsen KA, Su Y, Gordon BA, Hornbeck RC, Mills S, Ances BM, Raichle ME, Marcus DS, Cairns NJ, Xiong C, Cruchaga C, Goate A, Buckles V, Paumier KL, Morris JC, Bateman RJ, Benzinger T and Dominantly Inherited Alzheimer Network (DIAN). Clinical Risk Related to Cerebral Microhemorrhages in Autosomal Dominant Alzheimer's Disease: Longitudinal Results from the DIAN Study. Alzheimer's Association International Conference (AICC), London, England, July 16-20, 2017.
166. Hanseeuw BJ, McDade E, Schultz AP, Martins RN, Schofield PR, Masters CL, Graff-Radford NR, **Salloway S**, Danek A, Levin J, Buckles V, Goate AM, Benzinger T, Morris JC, Bateman RJ, Johnson K, Sperling RA and Chhatwal JP. Genotypic Variance May Explain the Balance of Early Cortical Vs. Striatal Amyloid Deposition in Autosomal Dominant AD. Alzheimer's Association International Conference (AICC), London, England, July 16-20, 2017.
167. Brown BM, Sohrabi HR, Taddei K, Gardener SL, Rainey-Smith SR, Peiffer JJ, Xiong C, Fagan AM, Benzinger T, Buckles V, Erickson KI, Clarnette R, Shah TM, Masters CL, Weiner M, Cairns NJ, Rossor MN, Graff-Radford NR, **Salloway S**, Voglein J, Laske C, Noble J, Schofield PR, Bateman RJ, Morris JC, Martins RN and The Dominantly Inherited Alzheimer Network (DIAN). Habitual Exercise Levels Are Associated with Cerebral Amyloid Load in Pre-Symptomatic Autosomal Dominant Alzheimer's Disease. Alzheimer's Association International Conference (AICC), London, England, July 16-20, 2017.
168. Snyder PJ, Santos CY, Getter C, Schindler R, Ott BR, **Salloway S**, Yoo DC, Noto RB, Lim Y and Maruff P. Cholinergic Deficit as a Predictor of Disease Progression: Amyloid Accumulation and Episodic Memory Decline in a 27 Month Preclinical AD Study. Alzheimer's Association International Conference (AICC), London, England, July 16-20, 2017.
169. Lee A, Alber J, Monast D, Menard W, Tang T, Bodge C, Malloy P and **Salloway S**. The Butler Alzheimer's Prevention Registry: Recruitment and Interim Outcome. Alzheimer's Association International Conference (AICC), London, England, July 16-20, 2017.
170. Vöglein J, Paumier KL, Jucker M, Preische O, Laske C, Xiong C, Schofield PR, **Salloway S**, Mori H, Cairns NJ, Morris JC, Bateman RJ, Danek A and Levin J. Motor Symptoms in Familial Alzheimer's Disease: Frequency, Severity and Predictive Value. Alzheimer's Association International Conference (AICC), London, England, July 16-20, 2017.
171. Santos CY, Johnson LN, Lim Y, Fernandez BM, Ott BR, **Salloway S** and Snyder PJ. Retinal Nerve Fiber Layer and Ganglion Cell Layer Volume Changes in Preclinical Alzheimer's Disease over 27 Months. Alzheimer's Association International Conference (AICC), London, England, July 16-20, 2017.

Curriculum Vitae:**Stephen P. Salloway, MD, MS****Rev. May 2024**

172. Schultz A, Sperling R, Buckley R, Johnson K, Benzinger T, Ances B, Morris J, Buckles V, Xiong C, McDade E, Cairns N, Marcus D, Fulbright A, Jack C, Ringman J, Farlow M, Kinnunen K, Fox N, Masters C, Schofield P, **Salloway S**, Levin J, Bateman R and Chhatwal J. Longitudinal Change of Functional Connectivity in the DIAN Cohort: Functional Connectivity as a Longitudinal Biomarker in Autosomal Dominant AD. 12th Human Amyloid Imaging Conference (HAI), Miami, FL, January 17-19, 2018.
173. Nguyen DV, Lee A, Malloy P, Piryatinsky I, Klinge P, and **Salloway S**. Post-Shunting Cognitive Outcomes in Normal Pressure Hydrocephalus Patients. International Neuropsychological Society (INS), Washington DC, February 14, 2018.
174. Lindbergh CA, Correia S, Van Huiden S, Hartman E, **Salloway S**, Malloy P, and Deoni S. White Matter Hyperintensities Relate to Functional Ability in Individuals with Mild Cognitive Impairment and Dementia. International Neuropsychological Society (INS), Washington DC, February 14, 2018.
175. Shaw L, Arias J, Blennow K, Galasko D, Molinuevo J, **Salloway S**, Schindler S, Carillo M, Hendrix J, Ross A, Illes J, Ramus C, Fifer S. Appropriate Use Criteria for Lumbar Puncture and Cerebrospinal Fluid Testing in the Diagnosis of Alzheimer's Disease. Alzheimer's Association International Conference, Chicago IL, July 2018.
176. Thompson L, Lee A, Collier M, Goldfarb D, Dawson B, **Salloway S**, Alber J. Application of an APOE disclosure model at a clinical trial site and the impact of dual disclosure of amyloid PET results. Clinical Trials on Alzheimer's Disease, J Preven of Alz Dis 2018;4:S7-8, Barcelona, Spain, October 2018.
177. Apostolova L, Aisen P, Eloyan A, Fagan A, Foroud T, Gatsonis C, Jack C, Kramer J, Keoppe R, Saykin A, Toga A, Venuri P, Day G, Graff-Radford N, Honig L, Jones D, Johnson S, Masdeu J, Mendez M, Onyike C, Rogalski E, **Salloway S**, Wolk D, Wingo T, Carrillo M, Dickerson B, Rabinovici G. Advancing Clinical and Biomarker Research in AD: The LEAD Study. Clinical Trials on Alzheimer's Disease, J Preven of Alz Dis 2018;4:S110, Barcelona, Spain, October 2018.
178. Lee A, Menard W, Tonini G, Thompson L, Alber J, **Salloway S**. Reliability of a Rapid APOE Assay for Alzheimer's Risk Assessment and Clinical Trial Screening. Clinical Trials on Alzheimer's Disease J Preven of Alz Dis 2018;4:S181, Barcelona, Spain, October 2018.
179. Arora A, Pontecorvo M, Mintun M, Fleisher A, Devous M, Lu M, Galanta N, Stevenson P, Flitter M, Beach T, Montine T, Serrano G, Sue L, Intorcchia A, Curtis C, **Salloway S**, Thein S, Wellman C, Perrin A, Lowe V, Grossman M, Irwin D, Ikonomic M, Seeley W, Rabinovici G, Masdeu J. Evaluation of a Visual Read Method for Flortaucipir PET Scans. 13th Human Amyloid Imaging Conference, Miami, FL, January 2019.
180. Jacobs H, Buckley R, Mormino E, Schultz A, Raman R, Donohue M, Sun C, Marek K, Seibyl J, Mintun M, Shcherbinin S, Pontecorvo M, Rowe C, VanDyck C, **Salloway S**, Jack C, Yaari R, Holdridge K, Aisen P, Sperling R, Johnson K. Regional Sex-Differences in Tau Pathology in Asymptomatic Individuals with Elevated Amyloid. 13th Human Amyloid Imaging Conference, Miami, FL, January 2019.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

181. Mintun M, Devous M, Fleisher A, Lu M, Beach T, Montine T, Serrano G, Curtis C, Perrin A, **Salloway S**, Thein S, Wellman C, Kennedy I, Navistsky M, Southehal S, Arora A, Stevenson P, Flitter M, Pontecorvo M. Relationships between Flortaucipir PET Signal and Tau Neurofibrillary Tangle Pathology at Autopsy. 13th Human Amyloid Imaging Conference, Miami, FL, January 2019.
182. Getter C, Grammas P, Ott B, Renehan W, **Salloway S**, Santos C, Stoukides J. Clinical Trial Design for a Pilot Study Evaluating Thrombin Inhibition in Alz Disease (The BEACON Trial). The Alzheimer's Association International Conference® 2019, Los Angeles, CA, July 2019.
183. Alber J, Lee A, **Salloway S**, Thompson L, Williams R. Subjective Cognitive Decline before and after APOE and Amyloid PET Disclosure in Cognitively Normal Older Adults Screening for Alz Diseas Prevention Trials). The Alzheimer's Association International Conference® 2019, Los Angeles, CA, July 2019.
184. Adedokun A, Bateman R, Benzinger T, Brooks W, Chen G, Farlow M, Flores S, Gauthier S, Gordon B, Hornbeck R, Hsiung G, Jack C, Jimenez-Velazquez I, Marple L, McDade E, Noto R, Robertson E, **Salloway S**, Soucy J, Su Y, Surti G, Wang Q. Regional and Voxel-Wise Spatial Relationships among Fluorine-18 Amyloid PET Tracers and Pittsburgh Compound B). The Alzheimer's Association International Conference® 2019, Los Angeles, CA, July 2019.
185. Aisen P, Apostolova L, Borowski B, Carrilo M, Collins J, Day G, Dickerson B, Eloyan E, Fagan A, Foroud T, Gatsonis C, Graff-Radford N, Honig L, Iaccarino L, Jack C, Jones D, Koeppe R, Kramer J, Masdeu J, Mendez M, Onyike C, Rabinovici G, Rogalski E, **Salloway S**, Saykin A, Toga A, Vernuri P, Wingo T, Wolk D. Advancing Clinical and Biomarker Research in AD: The Lead Study). The Alzheimer's Association International Conference® 2019, Los Angeles, CA, July 2019.
186. Alber J, Thompson L, **Salloway S**, Tonini G, Lee, A. Recruitment Strategies for the Generation Program AD Prevention Clinical Trials: Lessons from the Butler Hospital Memory & Aging Program. Clinical Trials on Alzheimer's Disease, San Diego, CA, December 2019.
187. Franzmeier N, Koutsouleris N, Benzinger T, Goate A, Karch C, Fagan A, Duering M, Dichgans M, Levin J, Gordon B, Ying Lim Y, Masters C, Fox N, Chhatwal J, **Salloway S**, Mcdade E, Morris J, Bateman R, Ewers M. Predicting sporadic Alzheimer's progression via inherited Alzheimer's-informed machine learning. Clinical Trials on Alzheimer's Disease, San Diego, CA, December 2019.
188. Oh H, Correia C, **Salloway S**. Associations between Alzheimer's disease biomarkers and cognition in cognitively normal older adults. Human Amyloid Imaging, 2020, Miami, Florida.
189. Iaccarino, La Joie, Lesman-Segev, Soleimani-Meigooni, Provost, Collins, Aisen, Borowski, Eloyan, Fagan, Foroud, Gatsonis, Jack Jr., Kramer, Saykin, Toga, Vemuri, Day, Graff-Radford, Honig, Jones, Masdeu, Mendez, Onyike, Rogalski, **Salloway**, Wolk, Wingo, Koeppe, Dickerson, Apostolova, Carrillo, Rabinovici. In vivo amyloid-PET and tau-PET evidence in early-onset Alzheimer's disease: taking the LEADS. Human Amyloid Imaging, 2020, Miami, Florida.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

190. Flaherty R, Ezzo R, Collins JA, Krivensky S, Eckbo R, Vemuri P, Borowski B, Iaccarino L, La Joie R, Lesman-Segev O, Bourakova V, Eloyan A, Aisen P, Fagan A, Foroud TM, Gatsonis C, Jack Jr C., Kramer JH, Koeppe RA, Saykin AJ, Toga AW, Day GS, Graff-Radford NR, Honig LS, Jones DT, Masdeu JC, Mendez MF, Onyike C, Rogalski EJ, **Salloway S**, Wolk D, Wingo TS, Carrillo MC, Apostolova LG, Rabinovici G, and Dickerson B. White Matter MRI T1 Hypointensity Volume in Young onset Alzheimer's Disease Patients is Not Accounted for by Age or Cardiovascular Risk Factors. (Poster.) Alzheimer's Association International Conference, Webinar, July, 2020.
191. Collins JA, Ezzo R, Vemuri P, Borowski B, Iaccarino L, La Joie R, Lesman-Segev O, Bourakova V, Eloyan A, Aisen P, Fagan AM, Foroud TM, Gatsonis C, Jack Jr. C, Kramer JH, Koeppe R, Saykin A, Toga AW, Day GS, Graff-Radford N, Honig LS, Jones DT, Masdeu JC, Mendez MF, Onyike C, Rogalski EJ, **Salloway S**, Wolk DA, Wingo T, Carrillo MC, Apostolova LG, Rabinovici G, and Dickerson BC. Neurodegeneration in the Longitudinal Evaluation of Early-Onset Alzheimer's Disease (LEADS) Sample: Results from the MRI Core. (Poster.) Alzheimer's Association International Conference, Webinar, July, 2020.
192. Alber J, Arthur E, Thompson LI, Goldfarb D, Fernandez BM, **Salloway S**, Sinoff S and Snyder PJ. The Atlas of Retinal Imaging in Alzheimer's Study (ARIAS): Study Design and Objectives. (Poster.) Alzheimer's Association International Conference, Webinar, July, 2020.
193. Oh H, Correia S, and **Salloway S**. Differential Associations between PET and CSF Alzheimer's Disease Biomarkers and Cognition among Cognitively Normal Older Adults. (Poster.) Alzheimer's Association International Conference, Webinar, July, 2020.
194. **Salloway S**, Lyons M, Lane, C, Rossomanno S, Wojtowicz J, Plank R, Warren F, Smith J, Boada M, GRADUATE I and II: Safety Results from Two Phase III Trials of Subcutaneous Gantenerumab in Early Alzheimer's Disease. ADPD, Gothenberg, Sweden, March, 2023.
195. **Salloway S**, Lee E, Papka M, Pain A, Our E, Ferguson M, Wang H, Case M, Lu M, Collins E, Brook D, Sims J. TRAILBLAZER-ALZ 4: Topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer's disease. American Academy of Neurology, Boston, MA April, 2023. AAN Merit of Distinction 2023.
196. Matthew Howe, Karysa Britton, Melanie Faust, Brittany Dawson, Meghan Riddle, & **Stephen Salloway**. Initial experiences with amyloid-related imaging abnormalities in patients receiving aducanumab following accelerated approval. AAIC 2023, July 16-20, Amsterdam, Netherlands.
197. Matthew D. Howe, Sheina Emrani, Zachary J. Kunicki, Karysa Britton, **Stephen P. Salloway** & Hwamee Oh (on Behalf of the Alzheimer's Disease Neuroimaging Initiative). Utility of accessible neuroimaging markers of cerebrovascular disease in identifying cerebral amyloidosis across the Alzheimer's disease spectrum. AAIC 2023, July 16-20, Amsterdam, Netherlands.
198. Catherine Dion, Zachary Kunicki, Sheina Emrani, Jennifer Strenger, Alyssa De Vito, Karysa Britton, Karra Harrington, Nelson Roque, **Stephen Salloway**, Martin Sliwinski, Stephen Correia, Richard N. Jones, & Louisa Thompson. Remote and in-clinic digital cognitive screening outperforms the MoCA to distinguish cerebral amyloid status among cognitively healthy older adults. AAIC 2023, July 16-20, Amsterdam, Netherlands.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

199. Jennifer Strenger, Sheina Emrani, Zachary Kunicki, Karra Harrington, Nelson Roque, Martin Sliwinski, **Stephen Salloway**, Stephen Correia & Louisa Thompson. Time of day cognitive performance differences in remote, self-administered assessments and its association with cerebral amyloidosis. AAIC 2023, July 16-20, Amsterdam, Netherlands.
200. Alyssa De Vito, Zachary Kunicki, Sheina Emrani, Jennifer Strenger, Karra Harrington, Nelson Roque, Martin J. Sliwinski, **Stephen Salloway**, Stephen Correia, & Louisa Thompson. Fatigue Interacts with Amyloid Status to Predict Daily Working Memory Performance in Preclinical Alzheimer's Disease. AAIC 2023, July 16-20, Amsterdam, Netherlands.
201. **Salloway S**, Pain A, Ferguson M, Wang H, Lee E, Papka M, Hu H, Lu M, Oru E, Collins E, Brooks D, Sims J. TRAILBLAZER-ALZ4: Results of a Direct Comparison of Donanemab to Aducanumab on Amyloid-Lowering in Early Alzheimer's Disease at 18 months. ADPD, Lisbon, Portugal, March, 2024.
202. Megan R. Caruso, Matthew D. Howe, Masood Manoochehri, Zachary J. Kunicki, Sheina Emrani, Edward D. Huey, **Stephen P. Salloway** and Hwamee Oh (for the Alzheimer's Disease Neuroimaging Initiative), The Application of Cerebrovascular Radiographic Biomarkers in Predicting Cerebral Amyloidosis across the Alzheimer's Disease Spectrum. Brown Medical School Mind Brain Research Day, Department of Psychiatry and Human Behavior, 1st Prize Poster. March, 2024.

SCHOLARLY WORK PUBLISHED IN OTHER MEDIA:

Educational Videotapes and CD-ROMs

1. Between a Rock and a Hard Place-Ethical Decision-Making in the Hospital-a training film for medical students. Sachs J Director. Palo Alto, CA, Stanford Video Productions, 1985.
2. **Salloway S**. Intensive Review of Neurology. Irvine, CA, CME Inc. 1996.
3. **Salloway S**. Treatment of Fragile Elderly. Houston, TX, American Medical Communications. 1996.
4. **Salloway S**. Vascular Dementia CD ROM-A Unique Disease Entity or a Variation of Alzheimer's Disease. Innovia Education Institute Columbia, MD, 2003.
5. **Salloway S**. Advances in the Diagnosis and Treatment of Vascular Dementia in Highlights of the 2nd Annual Dementia Congress: An Interactive CME Activity on CD-ROM, Academy for Health Care Education, New York, New York, 2004.
6. **Salloway S**. Management of Early Dementia. CD-Pharma Productions, Montreal, CA November, 2005.
7. **Salloway S**. Advances in Mild Cognitive Impairment and Alzheimer Disease. CD ROM. Clinical Geriatrics/Center for Biomedical Communication Inc., December, 2005.
8. **Salloway S**. Diagnosis and Treatment of Mild Cognitive Impairment: Now and in the Future. CD ROM. Highlights of the Fifth Annual Dementia Congress. Academy for Health Care Education Inc., New York, NY, 2007.
9. **Salloway S**. Diagnosis Dementia: but what type? Medscape Neurology, Medscape Clinic, on-line October, 2012.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

10. Johnson K, **Salloway S**, Apostolova L. Amyloid imaging for Alzheimer's disease in practice. Medscape Neurology Spotlight. on-line April, 2013.
11. Johnson K, **Salloway S**. Amyloid imaging in clinical practice. Medscape Neurology Curbside Consult. on-line May, 2013.
12. Johnson K, **Salloway S**. Amyloid imaging: understanding the appropriate use criteria. Medscape Neurology, March, 2014.
13. **Salloway S**, Atri A, Herman L. Alzheimer's Disease in Primary Care: The Significance of Early Detection, Diagnosis and Intervention. The American Journal of Medicine, 2017, available on line.
14. **Salloway S**, Herman L. Practical Approaches to the Identification of Alzheimer's Disease in Primary Care. Medscape, February 2017, available on line.
15. Neurostories.com, live, or available as an Apple Podcast, "The Push: A Pregnancy Neurology Podcast". Neurological issues related to pregnancy in CADASIL. October 2017.
16. Know the Early Warning Signs of Alzheimer's Disease. Alzheimer's Association Video, July, 2018.

INVITED PRESENTATIONS:

1. Sleep and Depression, Clinical Research Unit of the Palo Alto Veterans Hospital, Department of Psychiatry Research Seminar, August 1983.
2. Sleep and Aging, Department of Pediatrics Research Conf., Santa Clara Valley Medical Center, January 1984.
3. Management of Chronic Pain (Platform), American Psychiatric Association Annual Meeting, Montreal, Canada, May 1988.
4. Neuropsychiatric Aspects of Parkinson's Disease and Update on Fetal Cell Transplantation, American Psychiatric Association/NIMH Annual Fall Research Symposium, September 1988.
5. Steroid Psychosis, Yale University, Department of Neurology Grand Rounds, September 1989.
6. Updates in Neuroradiology with Clinical Correlations, Gaylord Hospital Grand Rounds, Wallingford, CT, March 1990.
7. Advances in multiple sclerosis (Platform), Symposium Chair: Updates in Neurology, American Psychiatric Association Annual Meeting, New York, NY, May 1990.
8. Practical Neuroanatomy and Neuropharmacology, Gaylord Hospital Grand Rounds, Wallingford, CT, May 1990.
9. Movement Disorders, Gaylord Rehabilitation Hospital Grand Rounds, Wallingford, CT, June 1990.
10. Delayed-Onset Hypoxic Encephalopathy, Yale University Department of Neurology Grand Rounds, July 1990.
11. Yale University Comprehensive Review of Neurology and Psychiatry, Director of a two-day course on clinical neurology, New Haven, CT, September 1990.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

12. Yale University Comprehensive Review of Neurology and Psychiatry, Director of a two-day course on clinical neurology, New Haven, CT, January 1991.
13. Neuropsychiatric Aspects of Movement Disorders, Beth Israel Hospital Behavioral Neurology Grand Rounds, Boston, MA, February 1991.
14. Neuropsychiatric Aspects of Movement Disorders, Allegheny Neuropsychiatric Institute Grand Rounds, Pittsburgh, PA, February 1991.
15. Neuropsychiatric Aspects of Movement Disorders, Dartmouth University Department of Neurology Grand Rounds, Hanover, NH, February 1991.
16. Differentiating Seizures from Pseudoseizures, National Institute of Mental Health Brain Disorders Branch Grand Rounds, Washington, DC, February 1991.
17. Topic: Director of a one-day course on clinical neurology, Comprehensive Review of Neurology and Psychiatry, Los Angeles, CA, February 1991.
18. Neurotransmitter Systems Relevant to Psychiatry, Clinical Neurology for Psychiatrists, Albert Einstein, New York, NY, March 1991.
19. Course Director: Clinical Neurology for Psychiatrists, American Psychiatric Association Annual Meeting, New Orleans, LA, May 1991.
20. Yale University Comprehensive Review of Neurology and Psychiatry, New Haven, CT, September 1991.
21. Intensive Review of Neurology and Psychiatry, Director of a one-day course on clinical neurology, Irvine, CA, October 1991.
22. Yale University Comprehensive Review of Neurology and Psychiatry, director of a two-day course on clinical neurology, New Haven, CT, January 1992.
23. Intensive Review of Neurology and Psychiatry, Director of a one-day course on clinical neurology, Irvine, CA, February 1992.
24. Clinical neurochemistry for psychiatrists, Clinical Neurology for Psychiatrists. Albert Einstein, New York, NY, March 1992.
25. Symposium Chairman: The Medial Temporal Lobe and Neuropsychiatric Illness American Psychiatric Association Annual Meeting, Washington, DC, May 1992.
26. Course Director: Clinical Neurology for Psychiatrists, American Psychiatric Association Annual Meeting, Washington, DC, May 1992.
27. Disturbance of memory, space, color and time in a middle-aged artist (Platform), British Neuropsychiatry Association Annual Meeting, Oxford, England, July 1992.
28. Advances in Brain Imaging, Department of Psychiatry Grand Rounds, Manchester Memorial Hospital, Manchester, CT, September 1992.
29. Yale University Comprehensive Review of Neurology and Psychiatry, director of a two-day course on clinical neurology, New Haven, CT, September 1992.
30. Symposium Chairman, The Frontal Lobes and Neuropsychiatric Illness, The Fifth Annual Michael Webb Memorial Symposium, Butler Hospital, Providence, RI, October 1992.
31. Intensive Review of Neurology and Psychiatry, Director of a one-day course on clinical neurology, Irvine, CA, October 1992.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

32. Practical Neuroimaging for Psychiatrists, US Psychiatric Congress, Chicago, IL, November 1992.
33. Movement Disorders: A Video Clinic, US Psychiatric Congress, Chicago, IL, November 1992.
34. Sleep Physiology and Neuropsychiatric Aspects of Insomnia, Sleep Disorders: Causes, Assessment and Treatment, VA Hospital, Providence, RI, November 1992.
35. Neurobiology of Violent Behavior, National CME conference on Violence and Aggression: A Clinical Update, New Orleans, LA, December 1992.
36. Yale-Ochsner Review Course, Clinical Neurology for Psychiatrists, New Orleans, LA, January 1993.
37. Intensive Review of Neurology and Psychiatry, Director of a one-day course on clinical neurology, Irvine, CA, February 1993.
38. Subcortical MRI changes in late-life onset depression (Platform), American Neuropsychiatric Association Fifth Annual Meeting, San Antonio, TX, March 1993.
39. Apathy and memory loss following bilateral anteromedial thalamic infarction (Platform), American Neuropsychiatric Association Fifth Annual Meeting, San Antonio, TX, March 1993.
40. Clinical Neurochemistry, Clinical Neurology for Psychiatrists, Albert Einstein, New York, NY, March 1993.
41. Symposium Chairman: The Frontal Lobes and Neuropsychiatric Illness, American Psychiatric Association Annual Meeting, San Francisco, CA, May 1993.
42. Course Director: Clinical Neurology for Psychiatrists, American Psychiatric Association Annual Meeting, San Francisco, CA, May 1993.
43. Course Co-director: Clinical Neuroimaging for Psychiatrists, American Psychiatric Association Annual Meeting, San Francisco, CA, May 1993.
44. Meeting Chairman: Brain Imaging in Neuropsychiatry, Michael Webb Symposium Brown University, Providence, RI, October 1993.
45. Lesion localization and clinical correlation in behavioral neurology, Michael Webb Symposium Brown University, Providence, RI, October 1993.
46. Co-chair: Session on Neuropsychiatric Aspects of Neurologic Disease, American Academy of Neurology Annual Meeting, Washington, DC, May 1994.
47. Clinical significance of subcortical encephalomalacia in early and late onset depression (Platform), American Academy of Neurology Annual Meeting, Washington, DC, May 1994.
48. Symposium Chairman: Brain Imaging in Neuropsychiatry, American Psychiatric Association Annual Meeting, Philadelphia, PA, May 1994.
49. Course Director: Clinical Neurology for Psychiatrists, American Psychiatric Association Annual Meeting, Philadelphia, PA, May 1994.
50. Course Co-director: Neuroimaging for Psychiatrists, American Psychiatric Association Annual Meeting, Philadelphia, PA, May 1994.
51. Meeting Chairman, Symposium Chair - Subcortical Disease in Neuropsychiatry, American Neuropsychiatric Association Annual Meeting, Newport, RI, July 1994.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

52. Utilization behavior and disinhibition in an 82 year old woman, American Neuropsychiatric Association Annual Meeting, Newport, RI, July 1994.
53. REM Sleep Behavior Disorder associated with a cingulate lesion, American Neuropsychiatric Association Annual Meeting, Newport, RI, July 1994.
54. Laryngeal botulinum toxin injection for refractory vocal tics, American Neuropsychiatric Association Annual Meeting, Newport, RI, July 1994.
55. Reduplicative paramnesia following lacunar infarction of the right genu of the internal capsule, American Neuropsychiatric Association Annual Meeting, Newport, RI, July 1994.
56. Clinical significance of subcortical encephalomalacia in early and late onset depression, American Neuropsychiatric Association Annual Meeting, Newport, RI, July 1994.
57. Subcortical Vascular Disease in Aging, Rhode Island Hospital, Department of Medicine, Grand Rounds, March 1995.
58. Resolution of long-standing obsessive compulsive disorder following left anteromedial thalamic infarction (poster), American Academy of Neurology Annual Meeting, Seattle, WA, May 1995.
59. Neuroimaging Tutorial: An introductory software program to teach neuroimaging (poster), American Academy of Neurology Annual Meeting, Seattle, WA, May 1995.
60. Course Director-Clinical Neurology for Psychiatrists, American Psychiatric Association Annual Meeting, Miami, FL, May 1995.
61. Course Co-Director-Introduction to Brain Imaging, American Psychiatric Association Annual Meeting, Miami, FL, May 1995.
62. Movement Disorders in the Elderly (platform), American Psychiatric Association Annual Meeting, Miami, FL, May 1995.
63. Epilepsy (platform), American Psychiatric Association Annual Meeting, Miami, FL, May 1995.
64. MRI in Clinical Practice (platform), American Psychiatric Association Annual Meeting, Miami, FL, May 1995.
65. CME Intensive Review of Neurology, Washington, D.C., September 1995.
66. Frontal and Temporal Lobe Disorders, National CME Conference on Behavioral Disorders in the Elderly, San Francisco, CA, September 1995.
67. Subcortical Vascular Disease in Aging, National CME Conference on Behavioral Disorders in the Elderly, San Francisco, CA, September 1995.
68. Epilepsy and Movement Disorders, Yale-Ochsner Review Course, New Orleans, LA, September 1995.
69. Scientific Program Chairman, American Neuropsychiatric Association 7th Annual Meeting, Pittsburgh, PA, October 1995.
70. Aphasia and delusions as primary symptoms in a case of multiple sclerosis (platform), American Neuropsychiatric Association 7th Annual Meeting, Pittsburgh, PA, October 1995.
71. Sexual delusions: A case series, American Neuropsychiatric Association 7th Annual Meeting, Pittsburgh, PA, October 1995.

Curriculum Vitae:**Stephen P. Salloway, MD, MS****Rev. May 2024**

72. Clinical profile of patients referred for evaluation of adult attention deficit hyperactivity disorder, American Neuropsychiatric Association 7th Annual Meeting, Pittsburgh, PA, October 1995.
73. Advances in Clinical Neuropharmacology, Albert Einstein College of Medicine, New York, NY, October 1995.
74. Frontal-Subcortical Disorders, Toronto General Hospital Department of Psychiatry Grand Rounds. November 1995.
75. The New Anticonvulsants, Butler Hospital Medical Staff Association Featured Speaker, December 1995.
76. Disorders of Attention, Butler Hospital Professional Lecture Series, February 1996.
77. Traumatic Brain Injury, Butler Hospital Professional Lecture Series, March 1996.
78. Symposium Co-Chairman: Neurology of Mood Disorders, American Academy of Neurology, March 1996.
79. Biopsy proven CADASIL; pathological and radiological findings (platform), American Academy of Neurology, March 1996.
80. Frontal subcortical contributions to memory (poster) (Presentation chosen for the Highlights in Behavioral Neurology Session), American Academy of Neurology March 1996.
81. Advances in Vascular Dementia, Rhode Island Alzheimer's Association Caregiver Conference, May 1996.
82. Brain Changes in Late-Life Depression, Department of Psychiatry Grand Rounds, Rhode Island Hospital, May 1996.
83. Course Director: Clinical Neurology for Psychiatrists, American Psychiatric Association Annual Meeting, New York, NY, May 1996.
84. Course Co-Director: Introduction to Brain Imaging, American Psychiatric Association Annual Meeting, New York, NY, May 1996.
85. Symposium Chairman: Neuropsychiatry of Limbic and Subcortical Disorders, American Psychiatric Association Annual Meeting, New York, NY, May 1996.
86. Paroxysmal Temporal Lobe Disorders Seen in Clinical Practice (platform), American Psychiatric Association Annual Meeting, New York, NY, May 1996.
87. Movement Disorders in the Elderly (platform), American Psychiatric Association Annual Meeting, New York, NY, May 1996.
88. Epilepsy: The New Anticonvulsant (platform), American Psychiatric Association Annual Meeting, New York, NY, May 1996.
89. MRI in Clinical Practice (platform), American Psychiatric Association Annual Meeting, New York, NY, May 1996.
90. Discussant: Neurology of Catatonia, American Psychiatric Association Annual Meeting, New York, NY, May 1996.
91. Pathways to Recovery from Brain Injury, Butler Hospital Public Lecture Series, July 1996.
92. The Aging Brain, Advances in Geriatric Medicine, Hilton Head, SC, August 1996.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

93. Movement Disorders in the Elderly, Advances in Geriatric Medicine, Hilton Head, SC, August 1996.
94. Comprehensive Review of Neurology, Washington, DC, August 1996.
95. Epilepsy and Primary Care: The New Anticonvulsants, Brown University Department of Family Medicine Grand Rounds, Memorial Hospital, Pawtucket, RI, August 1996.
96. Neurological Aspects of Aging, Yale/Ochsner Neurology Review Course, New Orleans, LA, October 1996.
97. Clinical Neurochemistry, Clinical Neurology for Psychiatrists, Albert Einstein College of Medicine, NY, October 1996.
98. The Aging Brain, University of Connecticut Department of Psychiatry Grand Rounds, Farmington, CT, November 1996.
99. Paroxysmal Disorders of the Limbic System, Wilford Hall Medical Center Department of Psychiatry Grand Rounds, San Antonio, TX, November 1996.
100. The Aging Brain: Normal and Pathological Aging, University of Texas, San Antonio Department of Psychiatry Grand Rounds, San Antonio, TX, November 1996.
101. The CADASIL Syndrome: A Genetic Form of Subcortical Dementia, American Neuropsychiatric Association 8th Annual Meeting, Orlando, FL, February 1997.
102. The Executive Director's Address, American Neuropsychiatric Association 8th Annual Meeting, Orlando, FL, February 1997.
103. The Aging Brain: What lesions tell us about the functional organization of the human brain, National CME Presentation, New Orleans, LA, April 1997.
104. Panel member on Emerging Treatments of Dementia, Rhode Island Alzheimer's Association Annual Caregiver's Conference, April 1997.
105. Comprehensive Review of Neurology CME Inc., Washington, D.C., August 1997.
106. Intensive Review of Neurology, Yale/Ochsner Board Review Course, New Orleans, LA, September 1997.
107. Clinical Neurochemistry, Clinical Neurology for Psychiatrists, Albert Einstein College of Medicine, New York, NY, October 1997.
108. The Aging Brain, Opening Lecture - 10th U.S. Psychiatric Congress, Orlando, FL, November 1997.
109. Welcoming Address, American Neuropsychiatric Association, Annual Meeting, Honolulu, HI, February 1998.
110. The role of microvascular disease in Alzheimer's disease & vascular dementia, American Assoc. of Geriatric Psychiatry, Annual Meeting, San Diego, CA, March 1998.
111. Clinical Neuroscience Update: Neuroimaging, American Assoc. of Geriatric Psychiatry, Annual Meeting, San Diego, CA, March 1998.
112. Use of Imaging in Clinical Practice, American Assoc. of Geriatric Psychiatry, Annual Meeting, San Diego, CA, March 1998.

Curriculum Vitae:**Stephen P. Salloway, MD, MS****Rev. May 2024**

113. CADASIL and Binswanger's: Neurobehavioral disorders caused by subcortical microvascular disease, Longwood Neuroscience Grand Rounds, Brigham and Women's Hospital, Boston, MA, March 1998.
114. Pharmacological Management of Cognitive and Behavioral Problems Following Stroke in the Course Pharmacology of Cognition, American Academy of Neurology 50th Annual Meeting, Minneapolis, MN, April 1998.
115. Clinical Research Panel Participant, Rhode Island Alzheimer's Association, Annual Caregiver Conference, Cranston, RI, April 1998.
116. Advances in the Diagnosis and Treatment of Dementia, St. Luke's Hospital Department of Psychiatry Grand Rounds, New Bedford, MA, May 1998.
117. Advances in the Treatment of Dementia, Rhode Island Hospital Department of Medicine Grand Rounds, Providence, RI, May 1998.
118. Advances in Understanding and Treating Vascular Dementia, Alzheimer's Association Annual Meeting, Indianapolis, IN, July 1998.
119. Comprehensive Review of Neurology, CME Inc., Irvine, CA, September 1998.
120. Clinical Neurochemistry, Clinical Neurology for Psychiatrists, Albert Einstein College of Medicine, New York, NY, October 1998.
121. SPECT Scanning in Neurology and Psychiatry, St. Elizabeth's Hospital Department of Psychiatry Grand Rounds, Boston, MA, October 1998.
122. The Aging Brain, US Psychiatric Congress, San Francisco, CA, November 1998.
123. Movement Disorders Recognition and Management, US Psychiatric Congress, San Francisco, CA, November 1998.
124. Diagnosis and Treatment of Depression in the Elderly, Brown University Department of Family Medicine Grand Rounds, Memorial Hospital, Pawtucket, RI, November 1998.
125. Advances in the Treatment of Dementia, Landmark Hospital Department of Family Medicine Grand Rounds, N Providence, RI, December 1998.
126. Advances in the Diagnosis and Treatment of Dementia, Bedford VA Hospital Department of Psychiatry Grand Rounds, Bedford, MA, March 1999.
127. The CADASIL Syndrome and Binswanger's Disease, Neurology Grand Rounds, Cornell University Medical Ctr., New York, NY, June 1999.
128. Brain Imaging and MRI in the Diagnosis of Late-life Mental Disorders, US Geriatric Congress, Orlando, FL, June 1999.
129. Comprehensive Review of Neurology, CME INC., Washington, D.C., September 1999.
130. Clinical Neurochemistry, Albert Einstein College of Medicine, New York, NY, October 1999.
131. Diagnosis and Treatment of Movement Disorders, US Psychiatric Congress, Atlanta, GA, November 1999.
132. The Aging Brain, US Psychiatric Congress, Atlanta, GA, November 1999.
133. Advances in the Management of Vascular Dementia, US Psychiatric Congress, Atlanta, GA, November 1999.

Curriculum Vitae:**Stephen P. Salloway, MD, MS****Rev. May 2024**

134. Symposium Chair: Implications of Microvascular Disease in Managing Alzheimer's Disease, Clinical Update 2000, San Juan, Puerto Rico, February 2000.
135. The Role of Microvascular Disease in Alzheimer's Disease, Clinical Update 2000, San Juan, Puerto Rico, February 2000.
136. Vascular Dementia and Late-life Depression, Clinical Update 2000, San Juan, Puerto Rico, February 2000.
137. The Diagnosis and Treatment of Early and Atypical Dementia, American Association of Geriatric Psychiatry Annual Meeting, Miami, FL, March 2000.
138. Review of Neuropharmacology, Rhode Island State Nurses Association Advanced Psychopharmacology, Providence, RI, March 2000.
139. Dementia Update, Rhode Island Academy of Family Physicians Annual Conference, Newport, RI, April 2000.
140. Neuropsychiatry of Limbic and Subcortical Disorders, Third International Neuropsychiatry Congress, Kyoto Japan, April 2000.
141. Advances in the Management of Dementia and Brain Imaging in Late-life Psychiatric Disorders, US Geriatric Conference, Las Vegas, NV, June 2000.
142. New and Emerging Treatments for Dementia, New England Medical Center Neurology Department Grand Rounds, Boston, MA, October 2000.
143. Clinical Neurochemistry, Albert Einstein College of Medicine, New York, NY, October 2000.
144. Mechanisms of Neurodegenerative Diseases, US Psychiatric Congress, San Diego, CA, November 2000.
145. Diagnosis of Early and Atypical Dementia, American Association of Geriatric Psychiatry 14th Annual Meeting, San Francisco, CA, February 2001.
146. Differential Diagnosis of Delirium, Dementia and Depression, American Association of Geriatric Psychiatry 14th Annual Meeting, San Francisco, CA, February 2001.
147. Brain Imaging in Late-Life Mental Disorders, US Geriatric Congress, New Orleans, LA, July 2001.
148. New and Emerging Treatments for Dementia, US Geriatric Congress, New Orleans, LA, July 2001.
149. Intensive Review of Neurology, Washington, D.C., September 2001.
150. Mad Cow Disease and Other Atypical Causes of Dementia, Conference on Improving Quality of Life in the Elderly, Las Vegas, NV, October 2001.
151. New Treatments for Dementia: Improving Quality of Life for Caregivers, Conference on Improving Quality of Life in the Elderly, Las Vegas, NV, October 2001.
152. New and Emerging Treatments for Dementia, Brown Department of Family Medicine Grand Rounds, November 2001.
153. The Aging Brain: Diagnosis and Treatment of Memory Disorders in the New Millennium, US Psychiatric Congress, Boston, MA, November 2001.
154. Movement Disorders: Improved Recognition and Treatment, US Psychiatric Congress, Boston, MA, November 2001.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

155. Management of Behavioral Symptoms in Dementia, US Psychiatric Congress, Boston, MA, November 2001.
156. Effect of APOE4 genotype on capillary basement membrane area in Alzheimer's disease, 2nd International Congress on Vascular Dementia, Salzburg, Austria, January 2002.
157. MRI Subcortical hyperintensities in outpatients with geriatric depression: Results from two placebo-controlled trials, 2nd International Congress on Vascular Dementia, Salzburg, Austria, January 2002.
158. MRI subcortical hyperintensities in outpatient geriatric major depression, AAGP 15th Annual Meeting, Orlando, FL, February 2002.
159. Basal ganglia-subcortical dementia syndromes, AAGP 15th Annual Meeting, Orlando, FL, February 2002.
160. New treatments for Alzheimer's disease, Maine Medical Center Neurology Grand Rounds, Portland, ME, March 2002.
161. New approaches for research in vascular dementia, International Stroke Society, Geneva, Switzerland, May 2002.
162. New treatments for Alzheimer's disease and vascular dementia, International Dementia Update for Primary Care Physicians, New York, NY, June 2002.
163. Small Artery Disease in the Aging Brain, Case Western Reserve University, Cleveland, OH, July 2002.
164. Vascular Dementia Overview, International Vascular Dementia Summit Consensus Conference, New York, NY, September 2002.
165. Vascular dementia, Maui Clinical Update: 2002, Maui, Hawaii, September 2002.
166. New treatments for vascular dementia and stroke, Battling the Big Three: Heart Disease, Cancer and Stroke, Maui, Hawaii, September 2002.
167. Clinical neurochemistry, Albert Einstein College of Medicine, New York, NY, October 2002.
168. The Aging Brain: New and Emerging Treatments for Memory Disorders, US Psychiatric Congress, Las Vegas, October 2002.
169. Movement Disorders: Better Identification and Treatment, US Psychiatric Congress, Las Vegas, October 2002.
170. Aricept Global Investigators Meeting, Meeting Co-Chair and presentations on VaD study 307: A placebo-controlled trial of donepezil in VaD and Donepezil Mild Cognitive Impairment Study, Key Biscayne, Florida, February 2003.
171. Small Artery Disease in the Aging Brain, University of Iowa Department of Psychiatry Visiting Professor, Iowa City, Iowa, April 2003.
172. Differentiating Vascular Dementia from Alzheimer's Disease, Multinational Vascular Dementia Advisory Meeting, Nice, France April 2003.
173. Subcortical Vascular Dementia: Binswanger's Disease and CADASIL, in Vascular Dementia and Vascular Cognitive Impairment, American Academy of Neurology 55th Annual Meeting, Honolulu, Hawaii April 2003.
174. Benefits of Donepezil Treatment in Patients with Mild Cognitive Impairment. American Academy of Neurology 55th Annual Meeting, Honolulu, Hawaii, April 2003.

Curriculum Vitae:**Stephen P. Salloway, MD, MS****Rev. May 2024**

175. The Variable Presentation of Normal Pressure Hydrocephalus, St. Luke's Hospital Medical Grand Rounds, New Bedford, MA, May, 2003.
176. Cholinesterase Inhibitors in Vascular Dementia: A New Treatment Model? In the Symposium Challenges in Dementia, American Psychiatric Association 156th Annual Meeting, San Francisco, May, 2003.
177. Advances in the Diagnosis and Treatment of Vascular Dementia. National Stroke Association Webcast, May, 2003.
178. Co-Chair Session on Vascular Depression. First Congress of the International Society for Vascular Cognitive and Behavioral Disorders, Gothenberg Sweden, August, 2003.
179. Advances in the Diagnosis and Treatment of Vascular Dementia. 2nd Annual Dementia Congress, Washington, D.C., September, 2003.
180. Small Artery Disease in the Aging Brain. Columbia University Department of Psychiatry Grand Rounds. New York, NY, October 2003.
181. Assessing the Impact of Dementia: Evidence-Based Strategies and Therapeutic Options Pri-Med East, Boston. November, 2003.
182. New and Emerging Treatments for Memory Disorders. US Psychiatric Congress, Orlando, FL, November, 2003.
183. Updates in Vascular Dementia and Stroke. US Psychiatric Congress, Orlando, FL, November, 2003.
184. Advances in Small Artery Disease and Vascular Dementia. Dartmouth Medical School Department of Neurology Grand Rounds, Hanover NH, November, 2003.
185. CADASIL: A New Genetic Form of Vascular Dementia. International Neuropsychological Society 32nd Annual Meeting, Baltimore, MD, February, 2004.
186. New and Emerging Treatments for Memory loss. RI Psychiatric Society. February, 2004.
187. Dealing with Dementia. University of Wisconsin Psychiatric Update. March, 2004.
188. Treatment of Memory Loss from MCI through more Advanced Dementia. Beaumont Hospital Neurology Rounds. Birmingham, MI, March, 2004.
189. Treatment of Vascular Dementia. American Academy of Neurology 56th Annual Meeting, San Francisco, April, 2004.
190. Exploring Differences between Vascular Dementia and Alzheimer's Disease. American Psychiatric Association 157th Annual Meeting, New York City, May, 2004.
191. Small Artery Dementia. Boston University Alzheimer's Center Grand Rounds, Boston, May, 2004.
192. Treatment of Dementia. Brown Department of Family Medicine Grand Rounds, Memorial Hospital, Pawtucket, RI, May, 2004.
193. Imaging and Cognitive Findings in CADASIL. United Leukodystrophy Foundation Annual Meeting, DeKalb, Illinois, July 14, 2004.
194. New Opportunities for Optimal Treatment, from AD to VaD in 9th International Conference on Alzheimer's Disease satellite symposium, The Pivotal Role of Cholinesterase Inhibitors. Philadelphia, PA, July 19, 2004.

Curriculum Vitae:**Stephen P. Salloway, MD, MS****Rev. May 2024**

195. Advances in Early Intervention in The Memory Fitness Institute Symposium, “Treating the Spectrum of Brain Impairment”, New York, NY, July 25, 2004.
196. Director of the Neurology Track and lecturer on Updates in Amnestic Mild Cognitive Impairment and Vascular Cognitive Impairment in the 3rd Annual Dementia Congress, Los Angeles, September, 2004.
197. Treatment of Amnestic MCI: Lessons Learned from the 24 Week Donepezil MCI Trial, Alzheimer’s Association research roundtable Mild Cognitive Impairment Meeting, Washington, DC September, 2004.
198. Clinical Perspective on Mild Cognitive Impairment, Multi-Modal Imaging Trial Meeting, New York City, September, 2004.
199. Differential Diagnosis of Dementia in Updates in Alzheimer’s Disease, Maine Medical Center, Portland, ME, October 9, 2004.
200. Dementia Update, Rhode Island American College of Physicians Internal Medicine Update, Newport, Rhode Island, October, 2004.
201. Dealing with Dementia: Now and In the Future, American Society of Clinical Psychopharmacology New York City CME Program, New York, NY, November, 2004.
202. Non-Alzheimer’s Dementia, Neurology Update 2004, New York City, December. 2004.
203. Cholinesterase Inhibitors, Short-Term Symptomatic Studies. International Psychogeriatric Special Expert Conference, MCI in the Elderly and Populations at Risk, Bethesda, MD, January, 2005.
204. How Rare is Pure VaD? Educational Forum for the Diagnosis and Treatment of Alzheimer’s Disease with Cerebrovascular Disease. Berlin, Germany, February, 2005.
205. Assessing Cognitive Decline in Relation to Alzheimer’s Disease. Lahey Clinic Internal Medicine Grand Rounds, Burlington, MA, March, 2005.
206. Diagnostic Criteria for Mild Cognitive Impairment and Efficacy of Donepezil as Treatment for Mild Cognitive Impairment, Thailand Neurological Society Annual Meeting, Bangkok, Thailand, March 2005.
207. Key Lessons Learned from the Donepezil 24 week Mild Cognitive Impairment Trial, 3rd Annual Wein Center, University of Miami MCI Symposium, Miami, Florida, March, 2005.
208. Vascular Dementia: Clinical Aspects, Treatment and Prevention, American Academy of Neurology 57th Annual Meeting. Miami, FL, April, 2005.
209. Early Diagnosis and Treatment of Alzheimer’s disease. 46th Annual Meeting of the Societas Neurologica Japonica, Kagoshima, Japan, May, 2005.
210. Treatment of Mild Cognitive Impairment. Eisai Tsukuba Laboratory, Tsuchiura, Japan, May, 2005.
211. Vascular Dementia and Alzheimer’s Disease: Clinical-Pathological Correlations. 2nd Congress of the International Society for Vascular Behavioral and Cognitive Disorders. Florence, Italy, June, 2005.
212. Symposium Chairman: Cholinergic Treatment Across the Spectrum of Dementia and Lecturer: Management of MCI and Early Dementia. International Psychogeriatric Association 12th Congress, Stockholm, Sweden, September, 2005.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

213. Neurology Track Chair, 4th Annual Dementia Congress and Lecturer: Early Diagnosis and Treatment of Alzheimer's Disease. Atlanta, GA, October, 2005.
214. Management of Early Dementia. Jewish General Hospital Geriatric Medicine Grand Rounds, Montreal, CA, November, 2005.
215. Early Diagnosis and Treatment of Alzheimer's Disease. Alzheimer's Services of Cape Cod 8th Annual Alzheimer's Awareness Conference, Mashpee, MA, November 2005.
216. Management of MCI and Early Alzheimer's Disease. 57th Annual Meeting of the Spanish Neurological Society, Barcelona, Spain, November, 2005.
217. CADASIL: A Genetic Cause of Stroke and Vascular Cognitive Impairment. Neurology Grand Rounds, Cooper University Hospital, Camden, New Jersey, January, 2006.
218. Vascular Dementia and Vascular Cognitive Impairment: Treatment Approaches. Rotman Research Institute 16th Annual Conference Stroke and Cognition. Toronto, Canada, March, 2006.
219. Current Concepts in Mild Cognitive Impairment. American Association of Geriatric Psychiatry 19th Annual Meeting, San Juan Puerto Rico, March, 2006.
220. Treatment of Early Dementia. Department of Neurological Sciences. Centre Hospitalier, University Laval. Quebec, Canada, May, 2006.
221. CADASIL: A Genetic Model of Stroke and Small Artery Dementia. Vancouver General Hospital/University of British Columbia Neuroscience Rounds. Vancouver, CA, May, 2006.
222. Diagnosis and Management of Early Alzheimer's Disease. Glenrose Rehabilitation Hospital Geriatric Grand Rounds, Edmonton, Alberta, CA, May, 2006.
223. Diagnosis and Treatment of Mild Cognitive Impairment: Now and In the Future. The 22nd Annual Alzheimer's Disease Symposium. Alzheimer's Association East Tennessee Chapter, Gatlinburg, Tennessee, June, 2006.
224. Diagnosis and Management of MCI and Early AD: Now and in the Future. Worcester Medical Center Neurology Grand Rounds. Worcester, MA, June, 2006.
225. CADASIL: Pathobiology and Clinical Phenotype. West Virginia University School of Medicine Department of Neurology Grand Rounds. Morgantown, West Virginia, July, 2006.
226. CADASIL: A Genetic Cause of Stroke and Vascular Dementia. Beth Israel Phillips Medical Center Neurology Grand Rounds. New York, NY, September, 2006.
227. Understanding the Clinical and Genetic Phenotype of CADASIL. Long Island Jewish Medical Center Department of Neurology Grand Rounds, Great Neck, NY, October, 2006.
228. Genetics of Dementia. Cooper University Hospital Neurology Grand Rounds, Camden, New Jersey, November, 2006.
229. Neurology Track Chair, Fifth Annual Dementia Congress, Orlando, FL, a) Diagnosing and Treating MCI: Now and in the Future, b) Practical Tips for Diagnosing and Treating Vascular Cognitive Impairment, c) Case Study Challenge, November, 2006.
230. CADASIL and Inherited Dementias. Neurogenetics for the Practitioner. New York University, New York, November, 2006.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

231. US Psychiatric Congress. New Orleans, LA, a) Alzheimer's Disease Centennial Lecture, b) Differential Diagnosis of Dementia, c) Diagnosis and Treatment of Movement Disorders, November, 2006.
232. CADASIL and Inherited Dementia. Army Medical Department Neurology 26th Annual Meeting. San Antonio, TX, November, 2006.
233. CADASIL: Stroke, Genetics, and Dementia. University of Utah Neurology Grand Rounds, Salt Lake City, Utah, January, 2007.
234. Current Controversies in Vascular Cognitive Impairment session co-chair, American Heart Association International Stroke Conference, San Francisco, CA, February, 2007.
235. Taking The Next Steps in Alzheimer's Disease. Symposium Chair and lecturer, Disease-Modifying Agents for AD. American Association of Geriatric Psychiatry 2007 Annual Meeting. New Orleans, LA, March, 2007.
236. 5th Annual Mild Cognitive Impairment Symposium: Toward an Earlier Diagnosis of Alzheimer's Disease. Discussant-"Next Steps". Mount Sinai Medical Center. Miami, Florida, April, 2007.
237. CADASIL: Arteriolar Degeneration, White Matter Injury and Dementia. Neurology Grand Rounds Tufts New England Medical Center, Boston, MA, June, 2007.
238. Clinical-Pathological Case Presentations: Exploring the interface between degenerative and vascular dementia and Chair: Defining Small Vessel Disease Dementia. 3rd International Vas-Cog Congress. San Antonio, July 2007.
239. CADASIL: Arteriolar Degeneration, Stroke, and Dementia. Albany Medical Center Neurology Grand Rounds, Albany, NY, October, 2007.
240. Diagnosing Alzheimer's Disease Before Dementia. Plenary lecture at the 4th Canadian Colloquium on Dementia. Vancouver, Canada, October, 2007.
241. Neurology Track Chair and Lecturer 1) Diagnosing Alzheimer's Before Dementia 2) The Interface Between Vascular and Degenerative Dementia 3) Clinical Pathological Correlations 6th US Dementia Congress Chicago, IL November, 2007.
242. CADASIL: Arteriolar Degeneration, Stroke and Dementia. Hartford Hospital Neurology Grand Rounds Hartford, CT, January, 2008.
243. CADASIL and Vascular Contributions to Dementia. St. Vincent's Hospital Neurology Grand Rounds Worcester, MA, January, 2008.
244. MCI: Results of Studies with Cholinesterase Inhibitors in Clinical Relevance and Treatment Update in MCI 10th International Hong Kong/Springfield Pan-Asian Symposium on Advances in Alzheimer Therapy. Hong Kong, China February, 2008.
245. Evidence-based Strategies for Managing Alzheimer's Disease. Washington Academy of Family Physicians 59th Annual Scientific Assembly. Cle Elum, WA, May, 2008.
246. Early Diagnosis and Treatment of Alzheimer's Disease. Yale University Department of Neurology Grand Rounds. New Haven, CT, June, 2008.
247. CADASIL and Vascular Contributions to Dementia. Bridgeport Hospital Department of Medicine Grand Rounds. Bridgeport, CT, June, 2008.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

248. Early Recognition and Treatment of Alzheimer's Disease, Symposium Chair and lecturer- Optimizing Treatment Outcomes in the Era of Disease Modification. International Congress of Alzheimer's Disease 2008, Chicago, IL, July, 2008.
249. The CADASIL Syndrome. Mid Atlantic Headache Institute. Baltimore, MD, September, 2008.
250. Early Diagnosis of Alzheimer's Disease and Treatment of MCI and Alzheimer's Disease. 24th Annual Alzheimer's Disease Symposium, Alzheimer's Association East Tennessee Chapter, Knoxville, Tennessee, October, 2008.
251. Early Diagnosis and Treatment of Alzheimer's Disease and Neurology Track Chair. 7th US Dementia Congress. Washington, DC, November 2008.
252. Diagnosing and Treating Alzheimer's Disease Before Dementia. Keynote Address, 13th Annual Conference on Alzheimer's Disease. Southern Illinois University, Springfield, IL, November, 2008.
253. CADASIL and Vascular Contributions to Dementia. New York Methodist Hospital Department of Neurology Grand Rounds. Brooklyn, NY, November, 2008.
254. Early Diagnosis and Treatment of Alzheimer's Disease. North Shore Long Island Jewish Department of Neurology Grand Rounds, Manhasset, NY, November, 2008.
255. CADASIL as a Genetic Model of Vascular Cognitive Impairment. 7th Annual Mount Sinai Medical Center Mild Cognitive Impairment Symposium. Miami, Florida, March, 2009.
256. Cognitive and Functional Outcomes from a Phase 2 Trial of Bapineuzumab for Mild-Moderate Alzheimer's Disease. American Academy of Neurology 61st Annual Meeting, Seattle Washington, April 2009.
257. Inhibitors of the Receptor for Advanced Glycation Endproduct and Phosphodiesterase 9A: New Targets for Treatments of Alzheimer's Disease. International Psychogeriatric Association Annual Meeting, Montreal, Canada, September, 2009.
258. Prodromal Alzheimer's Disease. Prodromal Alzheimer's Disease Gamma Secretase Investigator Meeting. Paris, France, September, 2009.
259. Differential Diagnosis of Normal Pressure Hydrocephalus. Plenary Keynote Address, International Hydrocephalus Society Annual Meeting. Baltimore, MD, September, 2009.
260. Immunotherapy for Alzheimer's Disease. Hartford Hospital Neurology Grand Rounds. Hartford, CT. January, 2010.
261. CADASIL: A Genetic Model of Cerebral Vasculopathy. Neurology Grand Rounds Cooper Union Medical Center. Camden, NJ, February, 2010.
262. Diagnostic Challenges in Clinical Practice. American Association of Geriatric Psychiatry Annual Meeting. Savannah, Georgia, March, 2010.
263. Promising Criteria for Capturing Pre-Dementia Stages of Alzheimer's Disease. International Congress of Alzheimer's Disease. Honolulu, Hawaii. July, 2010.
264. Best Clinical Practices in Dementia Care: Now and in the Future. 10th Annual T. Evans Wyckoff Memorial Lectureship Virginia Mason Neuroscience, Seattle Washington, October, 2010.

Curriculum Vitae:**Stephen P. Salloway, MD, MS****Rev. May 2024**

265. CADASIL. Thomas Jefferson University Department of Neurology Grand Rounds. Philadelphia, PA October, 2010.
266. Diagnosing and Treating Alzheimer's Disease: Now and in the Future. Western Rhode Island Alzheimer's Association. Westerly Hospital, Westerly, RI, November, 2010.
267. CADASIL: Arteriolar Degeneration, Migraine, and Cognitive Decline. Neurology Grand Rounds. Dartmouth Hitchcock Medical Center. Hanover, NH, November, 2010.
268. Applying the New Diagnostic Criteria for Alzheimer's Disease. 9th Annual Mount Sinai Medical Center Mild Cognitive Impairment Symposium. Miami, FL, April, 2011.
269. Vasogenic Edema in Immunotherapy: Sign of Efficacy or Danger? Alzheimer's and Dementia 2011, in press. International Conference on Alzheimer's Disease 2011, Paris France.
270. Can We Stem the Rising Tide of Alzheimer's Disease? Colorado Society of Clinical Neurologists, September, 2011, Denver, Colorado.
271. Are the New Diagnostic AD Criteria Helpful in Clinical Trials: Imaging? Clinical Trials in Alzheimer's Disease 4th Annual Meeting, San Diego, CA, November, 2011.
272. Imaging and Pathophysiology of Amyloid-Related Imaging Abnormalities with Amyloid-Modifying Therapy. Clinical Trials in Alzheimer's Disease 4th Annual Meeting, San Diego, CA, November, 2011.
273. Applying the New Diagnostic Criteria for AD. Alzheimer's International Symposium. Busan, South Korea, November, 2011.
274. Stage-Adjusted Treatment for Alzheimer's Disease. Alzheimer's International Symposium. Busan, South Korea, November, 2011.
275. Dementia: Clinical and Pathological Syndromes. Brown University Aging Brain Symposium. Providence, Rhode Island, November, 2011.
276. A Case of Stroke and Limbic Predominant Alzheimer's Disease. Mount Sinai Medical Center Early Alzheimer's Diagnostic Workshop. Miami, FL, January, 2012.
277. Diagnosing and Treating Alzheimer's Disease Before Dementia. Juntero University Department of Neurology, Tokyo, Japan, March, 2012.
278. Keynote lecture: Hot Topics in Alzheimer's Disease: The Role of Biomarkers in Preclinical Alzheimer's Disease. First Annual Alzheimer Symposium. Tokyo, Japan, March, 2012.
279. Preclinical Alzheimer's Disease: A New Target for Treatment. American Society of Neuroradiology 50th Annual Meeting, New York, New York, April, 2012.
280. Understanding and Interpreting Amyloid-Related Imaging Abnormalities. American Society of Neuroradiology 50th Annual Meeting, New York, New York, April, 2012.
281. Panelist, Clinical Development in Frontotemporal Disorders, National Institute of Neurological Disorders and Stroke/The Association for Frontotemporal Degeneration, Washington, D.C, June, 2012.
282. Translational Imaging in Alzheimer's Disease Clinical Trials. World Pharma Congress: Targeting Alzheimer's Disease, Philadelphia, PA, June, 2012.
283. Treating Preclinical and Symptomatic Alzheimer's Disease. Norman Prince Neurosciences Institute Inaugural Symposium. Providence, RI, June, 2012.

Curriculum Vitae:**Stephen P. Salloway, MD, MS****Rev. May 2024**

284. Treating Alzheimer's Disease Before Dementia. Keynote address in Progress in Alzheimer's Disease: New Hope, New Challenges. Connecticut Alzheimer's Association/Yale University, New Haven, CT, June, 2012.
285. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intravenous Bapineuzumab in Patients with Alzheimer's Disease Who Are Apolipoprotein E4 Non-Carriers. European Federation of Neurological Societies Annual Meeting, Stockholm, Sweden, September, 2012.
286. Challenges in Selecting Biomarker Outcomes for Alzheimer's Disease Clinical Trials. 8th Berg Symposium, Washington University, September, 2012.
287. Results of Immune-Based Trials in Neurological Disorders Panel Discussant, American Neurological Association Annual Meeting, Boston, October, 2012.
288. Imaging in the Evaluation of Dementia. The Aging Brain. 3rd Annual Antonio Capone, MD, Memorial Lecture. Butler Hospital, Providence, RI, October, 2012.
289. Bapineuzumab Phase 3 Clinical Outcomes. Clinical Trial in Alzheimer's Disease Annual Meeting, Monte Carlo, Monaco, October, 2012.
290. Advances in Alzheimer's Disease Imaging. 2nd Annual Imaging Conference for the Clinician. Babson College, Wellesley, MA, November, 2012.
291. Treating Alzheimer's Disease Before Dementia. Ottawa Hospital Department of Neurology Grand Rounds, Ottawa, Canada, November, 2012.
292. Highlights of Clinical and Biomarker Outcomes from Recent AD Clinical Trials. 11th MCI Annual Meeting. Mount Sinai Medical Center, Miami, FL, January, 2013.
293. Recommending Adoption of the Appropriate Use Criteria for Amyloid Imaging. MEDCAC Meeting on Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease. Center for Medicare Services. Baltimore, MD, January, 2013.
294. Amyloid Imaging in Clinical Practice. International Neuropsychological Society Annual Meeting. Kona, Hawaii, February, 2013.
295. Diagnosing Challenging Cases Using Biomarkers and the New AD Diagnostic Criteria. Symposium Chair and Presenter. International Neuropsychological Society Annual Meeting. Kona, Hawaii, February, 2013.
296. Clinical Diagnosis of Alzheimer's Disease and Flutemetamol PET Image Interpretation Compared with Post-mortem Diagnosis. AD/PD 2013, Florence, Italy, March, 2013.
297. Value of Imaging in AD/PD Clinical Practice: Lessons Learned (panel discussant). 11th International Conference on Alzheimer's and Parkinson's Disease, AD/PD 2013, Florence, Italy, March, 2013.
298. Clinical Diagnosis of Alzheimer's Disease and Flutemetamol PET Image Interpretation Compared with Neuritic Plaque Density Using Modified CERAD Criteria. American Academy of Neurology Annual Meeting, San Diego, CA, March, 2013.
299. Appropriate Use of Amyloid Imaging in Clinical Practice. Center for Medicare and Medicaid Services. Washington, DC, April, 2013.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

300. Participant in Roadmap to Combination Therapies for Alzheimer's Disease Expert Retreat. Sponsored by ACT-AD, Critical Path Institute, Alzheimer's Association, Washington, DC, May, 2013.
301. Managing the Different Stages of CADASIL. 2013 CADASIL family Conference, Boston, MA, June, 2013.
302. Panel Discussant Forum for Responding to Draft Coverage Recommendations of the Center for Medicare Services for Amyloid PET Imaging. Alzheimer's Association International Conference 13, Boston, MA, July, 2013.
303. Treatment for Alzheimer's Disease: Where Do We Stand? Harvard Neuroradiology Postgraduate Course. Cambridge, MA, September, 2013.
304. Diagnosing and Treating Alzheimer's Disease before Dementia. Touro University Geriatric Medicine Symposium. Henderson, Nevada, November, 2013.
305. Participant, NY Academy of Sciences Alzheimer's Disease Summit: The Path to 2025. New York, NY, November, 2013.
306. Moderator, Neuroimaging PET for Clinical Trials, 6th Annual Clinical Trials in Alzheimer's Disease, San Diego, CA, November, 2013.
307. Keynote, Challenges in the Diagnosis of Early Alzheimer's Disease, 3rd Early Alzheimer's Diagnostic and Treatment Workshop, Mt. Sinai Hospital, Miami, Florida, January, 2014.
308. Moderator and Presenter, The Role of Amyloid Imaging in the Diagnosis of Mild Cognitive Impairment, 2nd Alzheimer's Public Educational Forum, Mt. Sinai Hospital, Miami, Florida, January, 2014.
309. Diagnosing and Treating Alzheimer's Disease before Dementia. Albert Einstein College of Medicine 18th Annual Symposium: Comprehensive Approach to Dementia. New York, NY, March, 2014.
310. AD Drug Development: Where Have We Been and Where Are We Headed? Byrd Alzheimer Institute, University of South Florida. Tampa, Florida, March, 2014.
311. AD Trials with Biomarkers. Alzheimer's Association Research Roundtable. Washington, DC, May, 2014.
312. Amyloid Imaging in Clinical Practice. Society for Nuclear Medicine and Molecular Imaging, Regional Annual meeting, Stamford, CT, November, 2014.
313. Participant in EU/US Task Force on Alzheimer's Trials: Outcome Measures, Philadelphia, PA, November, 2014.
314. Amyloid PET Imaging Results from a Study to Evaluate the Impact of Crenezumab on Fibrillar Amyloid in Patients with Mild-to-Moderate Alzheimer's Disease. 7th Conference Clinical Trials in Alzheimer's Disease. Philadelphia, PA, November, 2014.
315. Alzheimer's Disease Prevention Trials. 4th Annual Nantz Alzheimer's Center Symposium. Methodist Hospital, Houston, Texas, February, 2015.
316. Prevention of Alzheimer's Disease. Houston Alzheimer's Association, Houston, Texas, February, 2015.
317. Prevention of Alzheimer's Disease. University of Rhode Island Neuroscience Colloquium, Kingston, RI, March, 2015.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

318. Update on Alzheimer's Disease Clinical Trials: Prevention and Treatment. Rhode Island Alzheimer's Disease Research Conference, Warwick, RI, March, 2015.
319. Challenges in Studying Immunotherapy Treatment in Early AD. 12th International Conference of Alzheimer's and Parkinson's Disease, AD/PD 2015. Nice, France, March, 2015.
320. Treating Alzheimer's Disease 10 Years or More Before Dementia. Brown University Department of Psychiatry Grand Rounds. April, 2015.
321. Detecting and Preventing Alzheimer's Disease. RI Bar Association Annual Meeting. Providence, RI, June, 2015.
322. Disease Modification: Challenging Expectations. Alzheimer's Disease International Conference. Washington, DC, July, 2015.
323. Immunotherapy Treatment for Early AD. Alzheimer's Disease International Conference. Washington, DC, July, 2015.
324. Charting a Path to 2025. South Ferry Church Summer Speakers Series. Narragansett, RI, August, 2015.
325. Charting a Path Toward a Treatment Breakthrough for Alzheimer's Disease by 2025. Keynote, 8th Canadian Conference on Dementia, Ottawa, Ontario, October, 2015.
326. Debate: Amyloid PET and CSF Biomarkers Should be Used to Clarify Diagnosis in Clinical Practice. 8th Canadian Conference on Dementia, Ottawa, Ontario, October, 2015.
327. Experience in Prevention Trials. EU/US CTAD Task Force on Alzheimer's Trials. Barcelona, Spain, November, 2015.
328. Understanding the Stages of Alzheimer's Disease and Moving Toward Prevention. Estate Planning Council of Rhode Island, Providence, RI, November, 2015.
329. Charting a Path to 2025. New England Ophthalmological Society 759th Meeting, Boston, MA, April, 2016.
330. Aging, Alzheimer's and Hydrocephalus. 1st Annual CSF Symposium. Providence, RI, June, 2016.
331. Challenges in Developing Breakthrough Treatments for Alzheimer's Disease. Visiting Scholar University of Pennsylvania Institute on Aging. Philadelphia, PA, November, 2016.
332. Developing Breakthrough Treatments for Alzheimer's Disease. Rhode Island Neurological Society. Providence, RI, November, 2016.
333. What We Have Learned from AD Prevention Trials from the Site Perspective. EU/US-CTAD Task Force. 9th Conference on Clinical Trials in Alzheimer's Disease. San Diego, CA, December, 2016.
334. The Importance of Early Intervention. 13th International Conference of Alzheimer's and Parkinson's Diseases, March, 2017, Vienna, Austria.
335. Prevention of Alzheimer's Disease. Rhode Island Assisted Living Association Annual Meeting, Warwick, RI, April, 2017.
336. Treating Dementia and Advances Toward Prevention of Alzheimer's Disease. Annual Meeting of the Rhode Island Chapter of the American College of Physicians, Providence, RI, May, 2017.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

337. Expedition III: Academic Perspective. EU-US Task Force, Clinical Trials in Alzheimer's Disease 10th Annual Meeting. Boston, MA, November, 2017.
338. Global Alzheimer's Platform Network Summit Keynote-Scaling Up to Develop Breakthrough Treatments by 2025. Las Vegas, NV, February, 2018.
339. Symposium Chair: Controversies in Preclinical Alzheimer's Disease: Risk Factors, Biomarkers and Reimbursement. Alzheimer's Disease International Conference, Chicago, July, 2018.
340. Session Co-Chair, Combination Therapy Trials in the EU/US CTAD Task Force on Anti-Tau Trials and Combination Therapy. October, 24, 2018, Barcelona, Spain.
341. Multimodal Imaging in the Diagnosis of Early Neurodegenerative Disease. 17th Annual Mild Cognitive Impairment Symposium. Miami, FL, January, 2019.
342. Lessons for Building a Successful Career and Vibrant Research Community. Keynote Alzheimer's Disease Clinical Trial Consortium Inaugural Mentoring Breakfast. Scottsdale, February, 2019.
343. How Risky Is It to Find Out about Alzheimer's Risk? Brown Department of Psychiatry Master Clinicians' Series, May, 2019.
344. Active Immunotherapy. Discussant Alzheimer's Association Research Roundtable. Washington, DC, May, 2019.
345. Session Chair: Unraveling the Central Role of Amyloid in Alzheimer's Disease. Alzheimer's Association International Conference, Los Angeles, CA, July, 2019.
346. LATE Biomarkers and Impact on Alzheimer's Disease Clinical Trials. Limbic-Predominant Age-related TDP Encephalopathy. Alzheimer's Association International Conference, Los Angeles, CA, July, 2019.
347. Incorporating the Experimental Medicine Approach in Primary Prevention Trials. National Academy of Medicine. Washington, DC, October, 2019.
348. Clinical Meaningfulness: A Clinician's Perspective. Alzheimer's Association Research Roundtable, Washington, DC, November 2019.
349. How to Interpret the Results of Recent Trials in AD Drug Development. Opening Keynote. Clinical Trials in Alzheimer's Disease 2019, San Diego, Ca. December, 2019.
350. AD Clinical Trials: An Investigator's Perspective. EU-US Task Force, San Diego, CA, December, 2019.
351. Phase 3 Results of Aducanumab, Clinical Trials in Alzheimer's Disease 2019, San Diego, CA, December, 2019.
352. Investigational Therapies across the Spectrum of Alzheimer's Disease. Medscape CME Alzheimer's Disease Year in Review. May, 2020.
353. DIAN-TU-001 Gantenerumab Results in Focused Topic Session: Results of the DIAN-TU Prevention Trial in Autosomal Dominant Alzheimer's Disease. Salloway S, Bateman R et al. Alzheimer's Association International Conference Webinar, July, 2020.
354. Solanezumab In-Depth Outcomes. Farlow M, Bateman R, Salloway S, et al. Alzheimer's Association International Conference Webinar, July, 2020.

Curriculum Vitae:**Stephen P. Salloway, MD, MS****Rev. May 2024**

355. Amyloid and tau PET in sporadic early-onset Alzheimer's Disease: Preliminary Results from LEADS. Rabinovici G, Salloway S, et al. Alzheimer's Association International Conference Webinar, July, 2020.
356. The Impact of COVID-19 on Alzheimer's Research in the United States in a Special Topic Session on COVID-19 and Alzheimer's Research around the World. Alzheimer's Association International Conference Webinar, July, 2020.
357. DIAN-TU Trial Collaborative Effort, Panel Discussion. Bateman R, Ryan LM, Carrillo M, Kerchner G, Farlow M, Salloway S, Yaari R. Alzheimer's Association International Conference Webinar, July, 2020.
358. The Evolution of Alzheimer's Disease Dementia trials and faculty mentor in The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD), September, 2020.
359. Advancing toward Breakthroughs for Alzheimer's Disease. Brown University Stem Cells and Aging COBRE, October, 2020.
360. Amyloid-related Imaging Abnormalities: Radiologic Findings in Patients Treated with Anti-amyloid Therapies. Radiological Society of North America Society 2020 Annual Meeting, October, 2020.
361. Tauriel Topline Results and Panel Discussion. Clinical Trials in Alzheimer's Disease, November, 2020.
362. Aducanumab for the Treatment of Alzheimer's Disease. FDA Peripheral and Central Nervous System Drugs Advisory Committee, November, 2020.
363. Biomarkers for Decision-Making in Alzheimer's Disease Clinical Trials: Are We There Yet? Alzheimer's Association Research Roundtable, December, 2020.
364. Opening the Modern Era for the Treatment of Alzheimer's Disease. Keynote-The 3rd Annual Student Neurosurgery and Neurology Research Conference. January, 2021.
365. Advancing Toward Breakthroughs for Alzheimer's Disease. VA Colloquium, January, 2021.
366. Advancing Toward Breakthroughs for Alzheimer's Disease. Obstetrics and Gynecology Grand Rounds Women and Infants Hospital, Providence, RI, January, 2021.
367. Creating Pathways for Breakthroughs in Alzheimer's Disease. AD/PD International Conference. March, 2021.
368. Moderator, Symposium on AD Treatment Strategies, AD/PD International Conference, March, 2021.
369. Amyloid-related Imaging Abnormalities: Radiologic Findings in Patients Treated with Anti-amyloid Therapies. Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting, March, 2021.
370. Perspectives on Aducanumab. Alzheimer's Association, June 21, 2021.
371. Alz Talks: New Advancements in Alzheimer's Treatments. Alzheimer's Association webinar June 24, 2021.
372. Translating Advances into Practice. Expert panelist. Alzheimer's Association International Conference, Denver, CO, July, 2021.

Curriculum Vitae:**Stephen P. Salloway, MD, MS****Rev. May 2024**

373. Detection and Management of ARIA. Expert panelist. Alzheimer's Association webinar, August, 2021.
374. Use of Aducanumab in Clinical Practice. Dementia Update. VU Medical Center Amsterdam, September, 2021.
375. New and Emerging Treatments for Alzheimer's Disease. Brown University Neurology Grand Rounds, Providence, RI, October, 2021.
376. New and Emerging Treatments for Alzheimer's Disease. Landmark Medical Center Internal Medicine Grand Rounds, Woonsocket, RI, October, 2021.
377. The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies, Therapeutic Targets: Amyloid vs. Non-Amyloid and Tackling Diversity in Clinical Trials, Discussant, EU/US-CTAD Task Force, Boston November, 2021.
378. New Hope in Translational Research for Alzheimer's Drug Development, Discussant, CTAD 2021, Boston, November, 2021.
379. Phase 2 Trial of Semorinamab in Mild-Moderate Alzheimer's Disease (Lauriet): Topline Results, Discussant, CTAD 2021, November, 2021.
380. Dose and Time Dependent Changes in Plasma ptau181 in Patients Treated with Aducanumab in the ENGAGE and EMERGE Trials, Moderator, CTAD 2021, Boston, November, 2021.
381. New and Emerging Treatments for Alzheimer's Disease. Tufts Neuroscience Grand Rounds, Boston, November 2021.
382. New and Emerging Treatments for Alzheimer's Disease. University of California San Francisco Memory and Aging Center Grand Rounds, December, 2021.
383. New and Emerging Treatments for Alzheimer's Disease. Brian R. Ott, MD Annual Research Symposium, Rhode Island Alzheimer's Association December, 2021.
384. New Treatments for Alzheimer's Disease. Neurology Update. Geneva University Hospital. Geneva, Switzerland, January, 2022.
385. New and Emerging Treatments for Alzheimer's Disease. Rhode Island Department of Health Grand Rounds, February, 2022.
386. Disease-Modifying Treatments for Alzheimer's Disease. American Association of Geriatric Psychiatry Plenary Session. March 20, 2022.
387. Treatment Advances for Alzheimer's Disease. AD/PD International Conference, Barcelona, Spain, March 19, 2022.
388. Aducanumab Appropriate Use Recommendations Update, Alzheimer's Association International Conference, July, 2022, San Diego, CA.
389. Updates in Alzheimer's Disease. NeurologyWeek 2022, September, 2022.
390. Dementia Clinical Trials. IMPACT-AD NIA-ACTC-Alzheimer's Association, San Diego, September, 2022.
391. The Emerging Landscape for the Diagnosis and Treatment for Alzheimer's Disease. Linday Farrell Lecture, University of Alabama Neurology Grand Rounds, Birmingham, AL, October, 2022.
392. Perspective: New Era of Alzheimer's Treatment. Alzheimer's Association Webinar. October, 2022.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

393. Presentation, Mexican Academy of Neurology, Oct 30-Nov 5, 2022.
394. Discussant, FDA Workshop on Quantitative Brain Amyloid PET, November 17, 2022.
395. LB3-Trailblazer-ALZ 4: Topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer's disease. Clinical Trials in Alzheimer's Disease. San Francisco, November 30, 2022.
396. Discussant, Two Phase 3 Trials of Gantenerumab (Graduate) for Early AD. Clinical Trials in Alzheimer's Disease. San Francisco, November 30, 2022.
397. Discussant, Are Plasma Biomarkers Ready for Stand-Alone Use in Screening for AD Clinical Trials? EU-US Task Force, Clinical Trials in Alzheimer's Disease. San Francisco, November 29, 2022.
398. Alzheimer's Disease: What We Know Now. One Day University, December 13, 2022.
399. Emerging Treatments for Alzheimer's Disease. International Psychiatric Association Webinar, January 19, 2023.
400. Future of Blood Biomarkers in AD Clinical Trials. Leon Thal Symposium, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, January, 2023.
401. GRADUATE I and II: Safety Results From Two Phase III Trials of Subcutaneous Gantenerumab in Early Alzheimer's Disease. ADPD, Gothenberg, Sweden, March, 2023.
402. Co-Moderator, Monoclonal Antibodies Targeting Amyloid, Evidence of Biomarker Effects in MCI Symposium, Miami, FL, March, 2023.
403. TRAILBLAZER-ALZ 4: Topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer's disease. American Academy of Neurology, Boston, MA April, 2023.
404. Evolution of AD Treatment Trials. IMPACT-AD, San Diego, August, 2023.
405. Keynote Presentation: A New Paradigm for Diagnosing and Treating Alzheimer's Disease. Ministerial Conference on Defeating Dementia, The Hague, Netherlands, October, 2023.
406. ARIA Risk Factors and Safety Management. NINDS Conference on Anti-Beta-Amyloid Passive Immunotherapy for Alzheimer's Dementia and Amyloid Related Imaging Abnormalities (ARIA): what's next? Bethesda, MD, September, 2023.
407. Chair, Symposium Implementation of Blood Biomarkers in Clinical Practice and Trials. Clinical Trials in Alzheimer's Disease Annual Meeting, Boston, October, 2023.
408. Characteristics of Participants in INTERCEPT-AD Who Developed ARIA with ACU193. Clinical Trials in Alzheimer's Disease Annual Meeting, Boston, October, 2023.
409. Discussant, Clinical Meaningfulness and Optimizing Therapies. International CTAD Task Force. Boston, October, 2023.
410. RI in the Forefront in the War on Alzheimer's: Earlier Diagnosis and Better Treatment. Brian H. Ott Lecture, Rhode Island Alzheimer's Association, Warwick, RI, November, 2023.
411. Opening the Modern Era for the Diagnosis and Treatment of AD. University of Connecticut Department of Psychiatry Grand Rounds, December, 2023.
412. Advances in Alzheimer's Research. Hear Me Now Podcast. A discussion on emerging treatments with me, Rudy Tanzi and David Shenk. December 28, 2023.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

413. Improving Treatment for Early Alzheimer’s Disease. Payer Summit, Arlington, VA, January, 2024.
414. Meet the Expert. Amyloid-Related Imaging Abnormalities. International Stroke Conference-24, Phoenix, AZ February, 2024.
415. Lunch with the Professor. ADPD, Lisbon, Portugal, March, 2024.
416. Forum Discussant: Immunotherapies in Alzheimer’s Disease. ADPD, Lisbon, Portugal, March, 2024.
417. ARIA Detection and Safety Management. ADPD, Lisbon, Portugal, March, 2024.
418. TRAILBLAZER-ALZ4 Directly Comparing Donanemab to Aducanumab on Amyloid-Lowering at 18 Months. ADPD, Lisbon, Portugal, March, 2024.
419. 22nd Annual MCI Symposium, Wien Center for Alzheimer’s Disease and Memory Disorders, Online, “Role of Plasma Biomarkers of AD Pathology in Diagnosis of Patients with Cognitive Complaints”, and “Implementation of a Treatment Program using Anti-Amyloid Monoclonal Antibodies”, April, 2024.
420. Opening the Molecular Era for the Diagnosis and Treatment of Alzheimer’s Disease. Plenary Lecture Taiwan Neurological Society Annual Meeting, Tainan City, Taiwan, April, 2024.
421. ARIA Detection and Safety Management. Hong Kong Geriatric Medicine Association, Hong Kong, April, 2024.
422. ARIA Detection and Safety Management. Mt. Sinai Hospital Annual MCI Meeting, Miami, FL, April, 2024.

MEDIA REPORTS:

Beneficial Effects of Glycine on Memory, WebMD, 1/5/00AR
Alcohol Consumption as a Risk Factor for Alzheimer’s Disease, Channel 7 News, 6/14/00
New Treatments for Alzheimer’s Disease, Providence Journal, 8/2/00
Highlights of the World Alzheimer Congress, Providence Business News, 8/6/00
Caregiver Burden, CBS Healthwatch, 10/6/00
Depression as a Prodrome of Dementia, Channel 10 Health Check 3/02
Estrogen for Prevention of Alzheimer’s Disease Channel 10 Health Check 6/02
MRI Subcortical Hyperintensities and Response to Sertraline and Citalopram in Geriatric Depressed Outpatients, AAGP, 2002 Meeting Symposia Highlights, 19-20
Vascular Dementia Satellite TV Media Broadcast, Chicago, IL, Medical update on vascular dementia broadcast to over 20 regional TV news programs, October 1, 2002
New Treatments for Memory Loss Due to Stroke, Channel 10 Health Check, Dec. 11, 2002
New Treatments for Vascular Dementia, Channel 12 News Health Report, Jan. 7, 2003
New Treatments for Memory Loss, NESN TV Health Report, February, 2003
First Cholinesterase Inhibitor for Mild Cognitive Impairment, Medscape.com, April, 2003
Advances in Vascular Dementia, Public Broadcasting American Medical Review, May, 2003
Cholesterol and Alzheimer’s Disease, Channel 10 Health Check, June, 2003

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

New Treatments for Mild Cognitive Impairment, Channel 10 Health Check, June, 2003

New Treatments for Memory Loss, ABC World News Tonight, August 21, 2003

New Treatments for Memory Loss, A Touch of Gray, September 8, 2003

Research Advances and President Reagan's Alzheimer's Disease, Newsweek June 20, 2004

Treatment of Mild Cognitive Impairment, ABC World News Tonight, July 18, 2004

New Trials for Mild Cognitive Impairment, Channel 10 Health Check, September 13, 2004

New Targets for the Treatment of Alzheimer's Disease, Channel 10 Health Check, November 12, 2004

Cardiac Complications in Trials of Non-Steroidal Anti-Inflammatory Agents for Alzheimer's Disease, Channel 10 Health Check, December, 2004.

Assessment of the Persistent Vegetative State: The Case of Terri Schiavo, Boston Globe 3/23/05.

Vascular Dementia: Clinical Aspects, Treatment and Prevention. MD Net Guide.Com, April 9, 2005.

Three Year Comparison of Donepezil, Vitamin E, and Placebo for Mild Cognitive Impairment. ABC World News Tonight and Bloomberg Wire Services, April 13, 2005

Donepezil, Vitamin E, and Placebo for Mild Cognitive Impairment. Good Morning America, 4/14/05.

Treatment of AD with an Amyloid Vaccine, Channel 10 Health Check, July, 2005.

CADASIL: A Genetic Form of Stroke Causing Migraine and Memory Loss Channel 10 Health Check, September 12, 2005.

New Leuprolide Implant Trial to Slow Progression of Alzheimer's Disease, Channel 10 Health Check, and NBC and MSNBC national news, December 15, 2005.

Development of an Active Amyloid Vaccine to slow progression of Alzheimer's Disease, Channel 10 Health Check, April 3, 2006.

CADASIL: A New Disease-Causing Migraine, Memory Loss, and Stroke. Fox9 News Minneapolis, MN, January 22, 2008.

Good News for the Forgetful: Aging Needn't Wipe Memory. Chicago Tribune February 19, 2008.

Update on Vaccine Treatment for Alzheimer's Disease. NBC Channel 10 Health Check. May 30, 2008.

Familial Alzheimer's Disease. NBC Channel 10 Health Check. July 3, 2008.

Results of the Flurizan and Amyloid Vaccine Trials NBC Channel 10 Health Check. July 9, 2008.

Amyloid-based Immunotherapy for Alzheimer's Disease. NBC Nightly News, July 29, 2008.

Three new treatments for Alzheimer's disease. NBC Channel 10 Health Check, March 9, 2009.

Anti-amyloid monoclonal antibodies for Alzheimer's disease. NBC Nightly News, March 24, 2009.

Bapineuzumab for Alzheimer's disease. WHJJ Radio, Providence, RI, March 29, 2009.

Phase 2 multi-ascending dose trial of bapineuzumab for mild-moderate Alzheimer's disease. Neurology podcast, December, 2009.

Phase 2 trial of bapineuzumab for mild-moderate Alzheimer's disease. Reuters Health, December, 2009.

Phase 2 trial of bapineuzumab for mild-moderate Alzheimer's disease. NBC Channel 10 Health Check, December 11, 2009.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

C11 PIB-PET change of fibrillar amyloid following treatment with bapineuzumab. NBC Channel 10 Health Check, March 5, 2010.

New hope in the fight against Alzheimer's disease. Providence Journal op-ed article. February 1, 2011.

Amyloid imaging a milestone achievement. Providence Journal feature story, January 30, 2011.

Long-term follow-up of patients treated with bapineuzumab in phase 2. AAIC-11 Paris France, July 20, 2011. Covered in the Wall Street Journal, Bloomberg, Reuters, Neurology Today.

Alzheimer's Disease. Visual MD, New York, NY, 6/1/11. <http://www.thevisualmd.com/>

Memory gets jolt in brain research. Wall Street Journal, February 9, 2012.

Four-Arm Alzheimer Therapy Trial Documents Long-Term Donepezil Benefits in Moderate to Severe Disease. Comment in Neurology Today on NEJM report, March, 2012

Importance of minority recruitment in ADNI. NBC Channel 10 Health Check, March 16, 2012.

Cost of treating Alzheimer's disease and plans for prevention. NBC Channel 10 Health Check, March 16, 2012.

Phase 3 results of intravenous bapineuzumab for mild-moderate Alzheimer's disease, Bloomberg, Associated Press, Wall Street Journal, Reuters and other media outlets, September 11, 2012.

New Treatments for Alzheimer's Disease. Bloomberg On-Line, October 26, 2012.

Debate over brain scans and Alzheimer's. New York Times, February 12, 2013.

Combination treatment for Alzheimer's disease. AlzForum, February 13, 2013.

Memory Medication: Today and tomorrow. Psychology Today June, 2013.

Deep brain stimulation for Alzheimer's disease. Providence Journal, June 17, 2013.

Biomarker picks up Alzheimers early on. MedPage Today August 14, 2013.

The Aging Mind. RI Monthly, September, 2013, p. 106

FDA approves a second amyloid imaging agent, AlzForum, November 18, 2013.

Ten-year effects of advanced cognitive training in the elderly, MedPage Today, January 13, 2014.

Results of the phase 3 trials of bapineuzumab and solanezumab in the NEJM, covered by the LA Times, Alzforum, Medscape, MD-FM Paris, Healthforum and others, January 23, 2014.

Butler Hospital launches new Alzheimer's prevention trial. Channel 10 Health Check, Associated Press, Providence Journal, AARP, June 9, 2014.

Amyloid PET Imaging Results from a Study to Evaluate the Impact of Crenezumab on Fibrillar Amyloid in Patients with Mild-to-Moderate Alzheimer's Disease in Clinical Neurology News, November 21, 2014.

Can Alzheimer's Be Stopped? Nova Special on Public Broadcasting. April 13, 2016.

Comment on CSF Tau Rivals A β for Predicting Cognitive Decline. Alzforum April 15, 2016.

The antibody aducanumab reduces amyloid plaques in Alzheimer's disease. Covered by media outlets worldwide including Time, Science, Nature September 1, 2016.

Attacking Alzheimer's feature story in the Providence Journal 8/28/16.

Launch of new Alzheimer's prevention study for individuals at high genetic risk. Channel 10 Health Check, April 18, 2017.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

Can Eye Exams Detect Alzheimer's Disease? Launch of retinal imaging study to monitor disease progression in the A4 prevention trial. Channel 6 ABC, June 20, 2017.

Army for the Ages: Genetic Swab for Alzheimer's Disease. Providence Journal feature story January 7, 2018.

New England Journal of Medicine Group Open Forum Expert Commentary on a Phase 3 Trial of Solanezumab for Mild Alzheimer's Disease. On-line discussion 1/24/18-2/3/18.

Please Be the Drug. Feature article in Time Magazine, February 26, 2018.

BAN-241 lowers amyloid plaque and slows cognitive decline-comment in USA Today, Associated Press, Reuters, Vox, and Alzforum 7/25/18

Appropriate Use Criteria for CSF Testing in the Diagnosis of Alzheimer's Disease. Podcast 10/10/18.

R.I. researcher helps pioneer Alzheimer's diagnostic published in the Providence Journal 10/13/2018.

Pushing Past the Stigma of Spinal Taps to Diagnose Alzheimer's Earlier. Stephen Salloway and Jose Luis Molinuevo. Diagnostics World News. November, 2018.

New Way to Diagnose Alzheimer's Disease. NBC Channel 10 Health Check, November 30, 2018.

Transmission of Amyloid Plaques from Cadaveric Tissue Samples (Nature). In Scientific American, December 14, 2018.

Biogen/Eisai Halt Phase 3 Aducanumab Trials. Comment in Alz Forum March 22, 2019.

Alzheimer's Research Dealt a Blow. Providence Journal, March 22, 2019.

What the End of A Promising Drug Trial Means for One Patient in the Study. Time Magazine, March 25, 2019.

Research Finds that Brain Imaging Can Improve the Diagnosis of Alzheimer's Disease. Providence Journal, April 2, 2019.

Longitudinal Tau PET as an Important New Biomarker in Alzheimer's Diagnosis, Prognosis and Research. Alzforum coverage of the article in Brain, May 9, 2019.

Biogen announces aducanumab to be submitted for FDA approval. Associated Press and AlzForum, October 22, 2019, WPRI and Providence Journal October 23, 2019, Time October 25, 2019. Providence Business News, November 4, 2019.

Resistance to Autosomal Dominant Alzheimer's Disease on an APOE3 Christchurch homozygote. Chemical and Engineering News, November 5, 2019.

China Approves a New Drug for Alzheimer's Disease. Alzforum November 6, 2019.

Aducanumab Phase 3 Results, Associated Press, Reuters, Time Magazine, NBC News, Alzforum, December 5, 2019.

Testing Emtricitabine for Early Alzheimer's Disease. Providence Journal, NBC News HealthCheck, US News and World Report, December 10, 2019.

New Test for Alzheimer's to Begin Trial (retinal imaging). Providence Journal, NBC HealthCheck, Boston Globe, USA Today, January 6, 2020.

CTAD Lessons for 2020: More Phase 2 Trials, More Diversity. Alzforum January 9, 2020.

Possible Missing Link in Alzheimer's Pathology Identified, Scientific American, January 16, 2020.

Topline Result for First DIAN-TU Clinical Trial: Negative on Primary, Alzforum, February 10, 2020.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

Coronavirus Takes Its Toll on Alzheimer's Clinical Studies. Alzforum, March 27, 2020.

Impact of Coronavirus on Alzheimer's Research. NBC HealthCheck, April 28, 2020.

Even during Coronavirus, the Global Fight against Alzheimer's Disease Continues. Providence Journal, May 13, 2020.

Drug Studied at Butler and Rhode Island Hospitals becomes First Approved by FDA for the Early Diagnosis of Alzheimer's Disease. NBC Healthcheck, June 2, 2020.

Can a Healthy Lifestyle Protect Memory in Older Adults? NBC HealthCheck, June 30, 2020.

Aducanumab Submitted to the FDA for Fast-Track Approval. ABC News and NBC News Health Check, July 13, 2020.

Butler Hospital among First in U.S. to Launch New Clinical Study of Treatment to Prevent Alzheimer's Symptoms. Providence Journal and NBC News HealthCheck, July 15, 2020.

DIAN-TU-001 Gantenerumab Results. Alzheimer's Association International Conference, July, 2020.

Attleboro Man Begins Test of Drug that Could Slow or Block Alzheimer's, Providence Journal September 24, 2020 and NBC News Healthcheck, September 23, 2020.

Aducanumab for the Treatment of Alzheimer's Disease. Time Magazine, November 6, 2020.

Advancing toward Breakthroughs in Alzheimer's Disease. VJ Neurology, March 11, 2021.

Positive Results of Donanemab for Early Alzheimer's Disease, Boston Globe, Providence Journal, GoLocalProv, NBC News Healthcheck, March, 2021.

COVID-19 and Alzheimer's Disease. Providence Journal, April 8, 2021.

Announcing the Brown Center for Alzheimer's Disease Research, Boston Globe, Providence Journal, NBC News Healthcheck, April 28, 2021.

Alzheimer's Drug Sparks Emotional Battle as FDA Nears Decision on Whether to Approve. Washington Post May 31, 2021 and Boston Globe June 2, 2021.

Medicine for Alzheimer's Poses a Dilemma for US Regulators, New York Times, June 6, 2021.

FDA Approved New Medication for Alzheimer's. New York Times, Providence Journal and Channel 12 Providence, June 7, 2021.

The First Treatment for Alzheimer's Disease is Here, Time Magazine, June 8, 2021.

First Treatment for Aducanumab Given at Butler Hospital. Boston Globe, June 16, 2021.

Experts Recommend Severely Restricting Use of New Alzheimer's Drug. New York Times, June 22, 2021.

Biogen's Alzheimer's New Drug Out of Reach for Many. Wall Street Journal, August 27, 2021.

Roll Out of Aducanumab. Wall Street Journal, September 30, 2021.

Not Finding the Camel is Not a Reliable Test for Alzheimer's Disease. USA Today, September, 29, 2021.

Aduhelm Administration Remains a Trickle, ARIA a Concern. Alzforum, October 20, 2021.

Sales of Biogen's Controversial Alzheimer's Drug Disappoint. Boston Globe, October 20, 2021.

Adulhelm Lowers Tau, Registry to Track Real-World Performance. Alzforum, November 20, 2021.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

Aduhelm Phase 3 Data Shows ARIA is Common, Sometimes Serious. Alzforum, December 14, 2021.

CMS Plans to Limit Aduhelm Coverage to Clinical Trials. Alzforum, January 20, 2022.

Emerging Treatments for Alzheimer's Disease. Public Health Post, February 4, 2022.

Faith-based Approach for Recruitment for Alzheimer's Disease Clinical Trials with Pastor Jenkins. Doctor Radio, Sirius FM, February 7, 2022.

Medicare Limits New Alzheimer's Drug. USA Today, February 18, 2022.

Aducanumab Safety Update: ARIA Clinical Data and Guidance. VuMedi, February 17, 2022.

On Aduhelm, Medicare Agency Gets Pressure From All Sides. Alzforum, February 18, 2022.

Can Brain-Training Stave Off Dementia? Boston Globe, July 11, 2022.

Appropriate Use Recommendations for Blood Tests for Alzheimer's Disease. NBC News Health Check, August 3, 2022.

Bringing Aduhelm—and Antibodies to Come—Into Practice, Alzforum, August 30, 2022.

CLARITY Shows Positive Results in Phase 3 Trial for Early AD. Reuters, Boston Globe, Alzforum, WPRI, Providence Journal, WJAR, Yahoo Finance. September 29, 2022.

Two Phase 3 Trials of Gantenerumab for Early AD. AlzForum, November 14, 2022.

Trailblazer 4: Results of Donanemab vs. Aducanumab on Amyloid Lowering at 6 months. Fierce Biotech, December 1, 2022.

Lecanemab for Early AD. Bloomberg, Reuters, November 30, 2022.

Lecanemab Slows Decline in Early Alzheimer's and MCI; "The First True Disease-Modifying Therapy in AD" Neurology Today, December, 2022.

Gantenerumab Mystery: How Did It Lose Potency in Phase 3? Alzforum, December, 2022.

New Alzheimer's Drug Faces Hurdle. Wall Street Journal 1/9/2023.

Alzheimer's Drug Wins Approval from FDA, Boston Globe 1/6/2023.

New Alzheimer's Drug Approved but may not be Available, Healthcheck WJAR 1/11/2023.

Lecanemab and Early Alzheimer's Disease, Doctor Radio, SiriusXM, 1/10/2023.

Community Involvement in US POINTER, WBRU 1/10/2023.

Legacy of A4 Secondary Prevention Study Goes Beyond Negative Result, Alzforum, March 17, 2023.

And Then There Were Three: Donanemab Phase 3 Trial Positive. Alzforum, May 4, 2023.

How Donanemab Compares with Aducanumab in Amyloid Clearance. Neurology Today, May 11, 2023.

Latest Experimental Alzheimer's Drug May Soon Be Ready for Prime Time. Healthcheck WJAR, May 20, 2023.

After a Decade, Amyloid PET Scans Receive Broad Insurance Coverage, AlzForum, October 19, 2023.

Treat Before 'A β Bothers Tau,' Scientists Say at CTAD, Alzforum, November 8, 2023.

AI to Detect ARIA. Neurology Today, March 5, 2024.

The Evolving Alzheimer's Treatment Landscape. NeuroCentury Podcast, Brussels, Belgium, April

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

2, 2024.

New and Emerging Treatments for Alzheimer's Disease. Speaking of Alzheimer's Podcast, April 4, 2024.

RESEARCH INTERESTS

1. Treatment and prevention of Alzheimer's disease
2. Imaging, molecular, and genetic biomarkers of dementia
3. Pathophysiology and genetic features of subcortical microvascular disease in aging, including vascular changes in Alzheimer's disease and the CADASIL syndrome

GRANTS

1. Sleep patterns in people over age 75
National Institute on Aging
\$15,000.
1982 – 1983
Role: Principal investigator.
2. A trial of gamma knife anterior capsulotomy to treat refractory obsessive compulsive disorder. A collaborative trial by Brown University, Massachusetts General Hospital and the Karolinska Institute. Jenike M, Rasmussen S. Principal Investigators
1992-present
Role: Investigator assisting with neurological assessment and quantitative imaging analysis.
3. Imitrex post-marketing surveillance study: a multi-center study
Glaxo Pharmaceuticals S2B-350
1994-5
Role: Investigator
4. A multi-center, randomized double-blind, comparative study of gabapentin administered as an initial dosage of 900 mg/day versus a dosage titrated to 900 mg/day over three days.
Parke-Davis Pharmaceuticals 945-090
\$3,610.
1994-5
Role: Investigator
5. Subcortical vascular disease in aging
Neurology Foundation Faculty Development Fund
\$18,000.
1994-5
Role: Principal Investigator

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

6. Quantitative MRI analysis of subcortical white matter changes in late-life onset depression
Brown University Department of Psychiatry and Human Behavior Pilot Project Grant.
1992-3-\$30,000.
1994-5-\$16,000.
Role: Principal Investigator
7. Longitudinal course of subcortical cerebrovascular disease in late-life depression: an MRI follow-up study. Jenkins M-PI
Butler Hospital Faculty Research Fund
\$25,000.
1995-6
Role: Co-investigator
8. Subcortical vascular disease in geriatric hypertension
Surdna Foundation Fellowship for Research in Gerontology
\$15,000.
1995-6
Role: Principal Investigator
9. Cognex: neuropsychiatric testing and assessment of caregiver time
Parke-Davis Pharmaceuticals 970-87
\$2,000
1996-7
Role: Investigator
10. Vascular predictors of depression and cognitive impairment in the elderly.
Brown University, Dept. of Psychiatry and Human Behavior Pilot Project Grant
\$20,000
1996-7
Principal Investigator
11. Effect of pemoline on measures of attentional performance in adult ADHD
Abbott Laboratories
\$4,000
1996-7
Principal Investigator
12. An open-label trial of donepezil for the treatment of Alzheimer's disease
Pfizer/Esai Pharmaceuticals E2020-A001-313
\$22,500
1996-7
Co-Principal Investigator
13. Neuropathological, neuroimaging and neuropsychological features of CADASIL.
American Heart Association Grant-in-Aid 9706211S
\$20,000
1997-9
Principal Investigator

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

14. An eight-week, parallel group, double-blind, placebo-controlled study of sertraline in elderly outpatients with DSM-IV major depression. Martin Keller-PI
Pfizer Pharmaceuticals R-0552
\$71,000
1997-8
Brown site administrator, Co-investigator
15. Relationship of MRI hyperintensities to treatment response in geriatric depression.
Pfizer Pharmaceuticals R-0552 MRI study
\$150,000
1997-2000
Principal Investigator with Ranga Krishnan, M.D. of Duke for this multi-center study
16. Metrifonate Nationwide Investigational Trial
Bayer Pharmaceuticals D-97-019
\$10,000
1997-8
Principal Investigator
17. A 24 week, multi-center, randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil hydrochloride (E2020) in patients with dementia associated with cerebrovascular disease. Eisai Inc. E2020-A001-307
\$ 130,000
1998-2001
Principal Investigator, Brown site
18. A multi-center, double-blind comparison of efficacy and safety of Seroquel, haloperidol, and placebo in the treatment of elderly subjects residing in nursing homes or assisted care facilities and Presenting with Alzheimer's dementia and psychoses or other selected psychoses.
Zeneca Pharmaceuticals 5077IL/0039
\$120,000
1998-9
Investigator and administrator of the Brown site
19. A randomized, double-blind, placebo-controlled trial of citalopram in depressed patients at least 75 years of age.
Forest Laboratories CIT-MD3-97-03-000
\$130,000
1998-2000
Investigator, Brown site administrator
20. Subcortical microvascular disease in geriatric depression
National Institute of Mental Health 1 K08 MH01487
\$752,994
1999-2004
Principal Investigator

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

21. A 24-week, multicenter, randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil hydrochloride in subjects with mild cognitive impairment.
Eisai E2020-A001-401
\$110,000
1999-2000
Co-Principal Investigator with Paul Malloy, Ph.D.
22. A multi-center, randomized, double-blind, placebo-controlled trial of estrogen to prevent Alzheimer's disease in women at risk.
National Institute on Aging RO 1AG15922/Columbia University
\$146,000
1999-2003
Principal investigator, Brown site
23. Combined behavioral and pharmacological intervention to improve memory in Alzheimer's disease
Alzheimer's Association Investigator Award (Deborah Cahn-Weiner PI)
\$80,000
1999-2001
Consultant
24. Improving sleep and cognitive functioning in Alzheimer's disease
Eisai/Pfizer Investigator Award (Mark Aloia PI)
\$100,000
1999-2001
Investigator
25. Genetic Models of Human Dementia
P20 RR15578-01 (a project of the Brown Center for Genetics and Genomics COBRE total grant \$11,219,863)
\$1,013,374
2000-2005
Co-Principal Investigator (Justin Fallon, subproject PI)
26. Heart Disease, CNS Dysfunction and Outcome in the Elderly
NIH 1050258905
\$1,753,134 (Ronald Cohen, PI)
2000-2005
Investigator
27. A randomized double blind placebo-controlled trial to evaluate the efficacy and safety of galantamine in subjects with mild cognitive impairment clinically at risk for development of clinically probable Alzheimer's disease.
Janssen GAL-INT-11
\$300,000
2001-4
Principal Investigator

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

28. A randomized, 30-week, double-blind, placebo-controlled trial to evaluate the safety and efficacy of galantamine in the treatment of dementia secondary to cerebrovascular disease
Janssen Research Foundation GAL-INT-26
\$125,000
2001-3
Principal Investigator
29. Functional impairment in Alzheimer's disease and normal aging
National Institute on Aging
AG05898-01 (Patricia Boyle, PI)
\$60,000
2000-2
Consultant/Investigator
30. Treatment of apathy in Alzheimer's disease
Alzheimer's Association, (Patricia Boyle, PI)
\$100,000
2001-3
Consultant/Investigator
31. Electrical stimulation of the internal capsule for intractable OCD and depression (Ben Greenberg, P.I.)
Medtronics
2001-present
Investigator assisting with neurological assessment and quantitative imaging analysis
32. A double-blind, randomized pilot study to evaluate the effects of galantamine and donepezil on sleep and attention and GI tolerance in patients with mild-moderate Alzheimer's disease
Janssen Pharmaceutica
\$100,000
2002-2003
Principal Investigator
33. A telephone intervention for dementia caregivers
NIMH R21 MH62561, (Geoffrey Tremont, PI)
\$576,042
2002-5
Consultant/Investigator
34. An 80-week, randomized, multi-center, parallel-group, double-blind study of the efficacy and safety of atorvastatin 80 mg plus an acetylcholinesterase inhibitor versus an acetylcholinesterase inhibitor alone in the treatment of mild to moderate Alzheimer's disease (Protocol # A2581078)
Pfizer, Inc.
2003-5
\$274,240
Principal Investigator

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

35. NIA ZAG1 FAS-5 J1 Institutional National Research Service Award
Dementia Research Fellowship T-32 (Paul Malloy, PI)
\$1,492,665
2003-2008
Description: Dementia research fellowship for 2, 2-year post-docs in 2003 increasing to 4 2-year positions.
co-PI with Richard Besdine
36. A 24-week, multi-center, randomized, double-blind, placebo-controlled evaluation of the efficacy, safety and tolerability of donepezil hydrochloride (E2020) in patients with dementia associated with cerebrovascular disease (Protocol # E2020-A001-319)
Eisai Medical Research, Inc.
2003
\$81,336
Principal Investigator
37. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of Titration and Treatment with C105 in Subjects with Mild Cognitive Impairment (MCI) (Protocol # 22020)
Sention Inc.
2003
\$157,400
Co-Principal Investigator
38. Efficacy and Safety of LY451395 in Patients with Probable Alzheimer's Disease (Protocol #H6N-MC-LEAM)
Lilly Pharmaceuticals
2003
\$101,856
Principal Investigator
39. Working memory and frontal white matter integrity in mild cognitive impairment
Alzheimer's Association (Stephen Correia, Ph.D., PI)
NIRG-03-6195
2003-5
\$100,000
Mentor and investigator
40. An open-label, multi-center, one-year extension of the evaluation of donepezil hydrochloride (E2020, Aricept®) in patients with dementia associated with cerebrovascular disease (Protocol # E2020-A001-320)
Eisai Medical Research, Inc.
2003-2005
\$62,964
Principal Investigator

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

41. A 51 week, , multicenter, randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil hydrochloride (E2020) in subjects with mild cognitive impairment (Protocol # E2020-A001-412)
Eisai Medical Research, Inc.
2004-2006
\$128,832
Principal Investigator
42. Galantamine ER open label rapid dose escalation trial in Alzheimer's disease (Protocol # GAL-ALZ-303)
Janssen Pharmaceutica Products, L.P.
2004-2005
\$32,000
Principal Investigator
43. A double-blind, phase II, safety and efficacy evaluation of ONO-2506PO in patients with mild to moderate Alzheimer's disease (Protocol ONO-2506POU010)
Ono Pharmaceutical Co., Ltd.
2004-2005
\$214,890
Principal Investigator
44. A phase III study of the efficacy and safety of Alzhemed™ in patients in mild to moderate Alzheimer's disease (Protocol CL-758007)
Neurochem, Inc.
2004-2006
\$462,000
Principal Investigator
45. An open-label, 8-week clinical trial of the safety and efficacy of Escitalopram for the treatment of depression and anxiety in dementia caregivers
Forest Laboratories
2005-2007
\$106,111
Principal Investigator
46. Aging Brain: DTI, Subcortical Ischemia and Behavior
1 R03 AG023916-01A1
2005-2007
\$120,000
Principal Investigator
47. Metrics for Quantifying White Matter Variation: Image Analysis, Testing and Application
Brown Vice-President Seed Grant
2005-6
\$100,000
David Laidlaw, PI (Co-Investigator)

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

48. Treatment of apathy in Alzheimer's disease with modafinil
1 F32 MH075583-01
2005-2007
Laura Frakey, Ph.D., PI, (co-mentor with Dr. Malloy)
49. Phase 3 Multi Center, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognitive and Global Function in Subjects with Mild to Moderate Dementia of the Alzheimer's Type (MPC-7869-04-005.03)
Myriad Pharmaceuticals, Inc.
2005-2007
\$161,772
Principal Investigator
50. A Phase IIa Multicenter, Randomized, Double-Blind, Placebo Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 (ELN116727) in Patients with Mild to Moderate Alzheimer's Disease (AAB-001-210)
Elan Pharmaceuticals, Inc
2005-2009
\$196,482
Principal Investigator
51. A Phase I, Multicenter, Randomized, Blinded, Single Ascending Dose, Safety, and Tolerability Trial of ACC-001 (QS-21) in Patients with Mild to Moderate Alzheimer's Disease (ACC-001-10)
Elan Pharmaceuticals, Inc
2005-2008
\$181,454
Principal Investigator
52. A Double-Blind Placebo-Controlled Study of VP4896 For The Treatment Of Mild-To-Moderate Alzheimer's Disease (VP-AD-301)
Voyager Pharmaceutical Corporation
2005-2008
\$276,000
Principal Investigator
53. Alzheimer's Disease Neuroimaging Initiative ADNI-024
NIA U01 AG10483
2006-
\$130,825
Principal Investigator

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

54. An 18 Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment.
Eisai
2005-6
\$160,000
Principal Investigator, Steering Committee Member, assisted with study design
55. A 54' week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to donepezil on cognition and overall clinical response in APO €4-stratified subjects with mild to moderate Alzheimer's disease
Glaxo Smith Kline
2006-2010
\$250,000
Principal Investigator
56. Inter-rater reliability between expert and non-expert-physicians in the diagnosis of amnesic MCI in the community setting A2501051/E0000-A001-001
Pfizer, Eisai
2006
\$23,000
Principal Investigator, Consensus Committee Member
57. Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release to 10 mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer's Disease
Eisai
2007-2010
\$140,000
Principal Investigator
58. A phase IIa, multicenter, randomized multiple ascending dose, safety, tolerability and immunogenicity trial of ACC-001 with QS-21 adjuvant (amyloid vaccine trial) in patients with mild to moderate Alzheimer's Disease
Wyeth ACC-001 3134K1-2201
2007-present
\$190,649
Principal Investigator
59. A randomized, double-blinded, placebo-controlled, dose-ranging, safety, and efficacy study of oral ELND005 (AZD-103) in Alzheimer's disease
Elan Pharmaceuticals
2008-2011
\$244,048
Principal Investigator

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

60. A phase III, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in patients with mild-moderate Alzheimer's disease who are apolipoprotein E ϵ 4 carriers and non-carriers
Elan Pharmaceuticals, Janssen Alzheimer's Immunotherapy
2008-2012
\$519,998
Principal Investigator
61. A multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose safety, tolerability, reactogenicity, pharmacokinetic study of bapineuzumab (AAB-001) administered subcutaneously in patients with mild-moderate Alzheimer's disease.
Wyeth
\$200,999
2008-present
Principal Investigator
62. A Phase II, multicenter, randomized, double-blind, placebo-controlled study of the safety, tolerability, pharmacodynamic and pharmacokinetic effects of BMS-708163 in the treatment of patients with mild to moderate Alzheimer's disease.
Bristol Myers Squibb CN156-013
\$290,000
2009-2011
Principal Investigator
63. A Phase II, multicenter, randomized, double-blind, placebo-controlled study of the safety, tolerability, pharmacodynamic and pharmacokinetic effects of BMS-708163 in the treatment of patients with prodromal Alzheimer's disease.
Bristol Myers Squibb CN156-018
\$290,000
2009-2013
Principal Investigator
64. A Phase II, multicenter, randomized, double-blind, placebo-controlled study of the safety, tolerability, pharmacodynamic and pharmacokinetic effects of multiple intravenous doses of PF-04360365 in patients with mild to moderate Alzheimer's disease.
Pfizer A9951002
\$170,000
2008-2011
Principal Investigator
65. CONCERT: A phase 3 multicenter, randomized, placebo-controlled, double blind twelve month safety and efficacy study evaluating dimebon in patients with mild-moderate Alzheimer's disease on donepezil.
Medivation DIM14
\$177,800
2009-2012
Program Director (non-investigator)

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

66. An open-label, non-randomized, multi-center study to optimize image assessment and evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) for detection/exclusion of cerebral beta-amyloid in patients with probable Alzheimer's disease compared to healthy volunteers.
Bayer 311741
\$100,000
2009-2011
Principal Investigator
67. Dominantly Inherited Alzheimer's Network
5U19AG032438-01 John Morris, PI
NIA/Washington University
\$324,000
2009-2024
Site PI
68. Investigation of myelin loss associated with Alzheimer's dementia.
Alzheimer's Association
\$90,000
2009-2012
Co-Investigator (S. Deoni, PI)
69. Normal pressure hydrocephalus: Advancing diagnosis and treatment
2010-present
Co-Investigator, (Irene Piryatinsky, PI)
70. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in subjects with mild to moderate Alzheimer disease who are Apolipoprotein E ϵ 4 carriers and non-carriers.
Pfizer 3133K1-3001 and 3133K1-3000-US
2010-2013
Site-PI
\$440,000
71. A phase 2, multicenter, 24-month, randomized, third-party unblinded, placebo-controlled, parallel-group amyloid imaging positron emission tomography (PET) and safety trial of ACC-001 and QS-21 adjuvant in subjects with early Alzheimer's disease.
Pfizer B2571010
2011-present
Site PI
\$280,000
72. A principal open-labeled study to compare the brain uptake of ^{18}F]flutemetamol with brain fibrillar A β levels determined post-mortem.
GE 067-007
2011-2015
Site PI
\$140,000

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

73. Alzheimer's Disease Neuroimaging Initiative – Grand Opportunity Study (ADNI-GO)
NIA 1 RC2 AG036535
2010-2011
Site PI
\$84,000
74. Alzheimer's Disease Neuroimaging Initiative-ADNI-2
NIA U01AG024904
2011-2018
Site PI
\$420,000
75. A randomized, double-blind, placebo-controlled, phase II study to evaluate the impact of MABT5102A on brain amyloid load and related biomarkers in mild-moderate Alzheimer's disease
Genentech ABE4955g
2012-2017
Site PI
\$480,000
76. A phase 3 randomized, double-blind, placebo-controlled study of the safety and effectiveness of Immune Globulin Intravenous, 10% solution, for the treatment of mild-moderate Alzheimer's disease
Baxter
2012-2013
Site PI
\$600,000
77. Dominantly Inherited Alzheimer's Network: Opportunity to Prevent Dementia.
Alzheimer's Association, NIA U01AG042791
2012-present
Project Leader, Gantenerumab
\$42,885
78. Impact of Florbetapir F18 PET on the clinical diagnosis and management of patients with progressive cognitive decline
Avid Radiopharmaceuticals F-AV-45-A17
2012-2016
Site PI
\$216,000
79. Clinical trial to characterize the performance of MK-3328 (amyloid PET) in subjects with Alzheimer's disease and healthy elderly subjects
Merck
2011-2013
Site PI
\$68,000

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

80. A randomized, double-blinded, placebo-controlled multiple dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of BIIB037 in subjects with prodromal or mild Alzheimer's disease
Biogen
2012-2020
Site PI
\$300,000
81. A 12-month, masked, randomized, controlled, feasibility study to evaluate the efficacy, safety, and tolerability of deep brain stimulation of the fornix in patients with mild probable Alzheimer's disease
Functional Neuromodulation
2012-2018
Site PI
\$300,000
82. Multicenter, randomized, double-blind, placebo-controlled, parallel-group two year study to evaluate the effect of subcutaneous RO4909832 on cognition and function in prodromal Alzheimer's disease
Roche
2012-2015
\$240,000
83. A randomized, placebo controlled, parallel-group, double blind efficacy and safety trial of MK-8931, beta secretase inhibitor, in subjects with mild to moderate Alzheimer's disease.
Merck
2012-2018
Site PI
\$390,000
84. A randomized, multicenter, multicountry study, to evaluate the effectiveness of florbetapir (18F) PET imaging in changing patient management and to evaluate the relationship between florbetapir (18F) PET scan status and cognitive decline
Avid radiopharmaceuticals
2012-2017
Site PI
\$240,000
85. Amyloid pathology and shunt response in normal pressure hydrocephalus F-AV-45-A14
Avid Radiopharmaceuticals-investigator-initiated
2012-2018
PI
\$125,000

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

86. An open label, multicenter study, evaluating the safety and imaging characteristics of 18F-AV-1451 in cognitively healthy volunteers, subjects with Mild Cognitive Impairment, and subjects with Alzheimer's disease
Avid Radiopharmaceuticals
2014-2019
Investigator
\$380,000
87. Anti-amyloid in asymptomatic Alzheimer's disease
National Institute on Aging/Lilly
2014-present
PI
\$480,000
88. MK-7622-012, A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of MK-7622 as an Adjunctive Therapy to Donepezil for Symptomatic Treatment in Subjects with Alzheimer's Disease
Merck
2014-2016
\$185,000
89. A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD).
Merck
2014-2019
\$225,000
90. H8A-MC-LZAX; Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Lilly
2013-2018
Site PI
\$325,000
91. Global Alzheimer's Network Award
GAP-NET
2015-present
Site PI
\$100,000
92. A phase 3, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the safety and efficacy of aducanumab (BIIB037) in subjects with early Alzheimer's disease
Biogen
2015-2020
Site PI
\$990,000

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

93. A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology, protocol 18F-AV-1451-A16
Avid Radiopharmaceuticals
2015-2019
Site PI
\$180,000
94. Longitudinal Evaluation of Amyloid Risk and Neurodegeneration: THE LEARN STUDY ADC-051
NIA-Alzheimer's Treatment Research Institute
2015-present
Site PI
\$120,000
95. Christianson syndrome and NHE6-associated neurological disease network
Alpert Medical School of Brown University Dean's Award
2015-2016
Eric Morrow, PI, Stephen Salloway Co-PI
\$100,000
96. A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Lilly
2016-2019
Phase 3 trial of a beta secretase inhibitor for patients with mild Alzheimer's dementia
Site PI
97. Alzheimer's Disease Neuroimaging Initiative ADNI-3
NIA UO1AG024904
7/1/2011-6/30/2021
Site PI
\$130,000
98. Imaging Dementia – Evidence for Amyloid Scanning Study (IDEAS)
Center for Medicare Services
2/1/16-2/1/19
Site PI
\$70,000
99. A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's disease
Novartis/Banner/NIA
6/11/16-6/11/2022
\$740,000

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

100. A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)
Novartis/Banner
7/1/17-7/1/23
Site PI
\$960,000
101. A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymptomatic at Risk for Developing Alzheimer's Dementia
Janssen
4/1/17-4/1/19
Site PI
\$600,000
102. NIA U01AG042791
Dominantly Inherited Alzheimer's Network: Opportunity to Prevent Dementia
National Institute on Aging
3/1/2012-12/31/2021
Clinical trial to delay progression of preclinical Alzheimer's disease in individuals at high risk
Project arm leader
\$325,000
103. Longitudinal evaluation of [18F]MNI-798 as a PET radioligand for imaging tau in the brain of patients with prodromal, mild and moderate Alzheimer's disease compared to healthy volunteers
Genentech
8/1/16-2/1/18
Site PI
\$48,000
104. A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group, efficacy, and safety study of MTAU9937A in patients with prodromal to mild Alzheimer's disease.
Genentech
12/6/17-12/6/21
Site PI
\$440,00
105. A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer's Disease.
Eisai
10/28/17-10/28/21
Site PI
\$310,000
106. Alzheimer's Clinical Trials Consortium (ACTC)
U24AG057437 Paul Aisen, Reisa Sperling, Ronald Petersen, PIs

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

03/2018 – 02/2023
National Institute of Aging
Site PI
\$825,000

107. Longitudinal Early-onset Alzheimer’s Disease Study (LEADS)

1R56AG057195 Liana Apostolova, PI
10/2018 – 09/2023
National Institute of Aging/Alzheimer’s Association/University of Indiana
Site PI

108. Protect Brain Health Through Lifestyle Intervention to Reduce Risk (US POINTER)

Alzheimer’s Association/National Institute on Aging
2/20-2/26
Multi-domain lifestyle intervention to lower risk for Alzheimer’s disease
PI-RI New England site
\$9,000,000

109. Atlas of Retinal Imaging in Alzheimer’s Study (ARIAS)

St. Anthony’s Hospital Foundation
8/30/2019-8/30/2024
Longitudinal study of retinal imaging changes in preclinical AD
PI-Brown/Butler site
\$4,000,000

110. Reversing Nucleoside Reverse Transcriptase Inhibitors

Alzheimer’s Association Part The Cloud
4/1/2020-4/1/2024
A phase 1 placebo-controlled trial of emtricitabine for early Alzheimer’s disease
Co-PI with John Sedivy
\$750,000

111. A phase II, multicenter, placebo-controlled, efficacy, and safety study of MTAU9937A in mild to moderate Alzheimer’s disease.

Genentech
2/1/2019-2/1/2023
Site PI
\$400,000

112. A phase 3 trial of BAN2401-G000-301 for early Alzheimer’s disease

Eisai
8/2019-8/2023
Site PI
\$700,000

113. I8G-MC-LMDC

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

- Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Alzheimer's Disease
Lilly
2/2019-4/2023
Site PI
\$765,000
114. 251AD201
Phase 2 Trial BIIB092 in Subjects with Early Alzheimer's Disease
Biogen
10/2018-10/2023
Site PI
\$880,000
115. I5T-MC-AACG(a)
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Alzheimer's Disease
Lilly
2/2018-2/2021
Site PI
\$180,000
116. Trial-Ready Cohort (TRC) for preclinical/prodromal AD (PAD) trials (TRC-PAD)
NIA ATRI
9/2019-4/2023
Site co-PI with Athene Lee, PhD
\$88,000
117. 221AD304 (EMBARK)
Phase 3b Open-Label, Multicenter, Safety Study of BIIB03 in Alzheimer's disease
Biogen
5/2020-5/2023
Site PI
\$1,200,000
118. BAN2401-G000-303 AHEAD 3-45 Study
Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Preclinical
Alzheimer's Disease and Early Preclinical Alzheimer's Disease and Intermediate Amyloid
NIA/ACTC
6/2020-6/2026
Site PI
\$880,000
119. DigiCog AD Study
Implementing Digital Cognitive Tests for the Detection of Preclinical Alzheimer's Disease
Alzheimer's Association Clinician Scientist Fellowship
5/2020-11/2022

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

- Louisa Thompson PhD, PI, My role-project mentor
\$225,000
120. Evaluation of Retinal Autofluorescence Imaging to predict Amyloid Status in early AD
Neurovision
7/2020-12/2021
Jessica Alber, PhD, PI, My role-project mentor
\$120,000
121. Building an Infrastructure and Dynamic Dataset for AD Risk Assessment
Rhode Island Center for Clinical and Translational Science
NIA Alzheimer's supplement
5/2019-12/2020
Leslie Brick, PhD, PI, My role-project co-mentor
\$250,000
122. Using an Alzheimer's disease blood test to predict amyloid PET in APOE ε4 non-carriers
Rhode Island Center for Clinical and Translational Science Pilot Project
1/2019-12/2020
Athene Lee, PhD and Jessica Alber, PhD, co-PI's, My role-project co-mentor
\$90,000
123. U.S. Study to Protect Brain Health through Lifestyle Intervention to Reduce Risk, U.S.
POINTER.
Alzheimer's Association and the National Institute on Aging
9/2019-9/2025
Site PI, New England/Rhode Island
\$8,000,000
124. Biofinder: Brown
Validation of plasma biomarkers for detection and prognosis of preclinical Alzheimer's
Disease.
Center for Alzheimer's Disease Research, Brown University
11/2022-7/2027
Site PI, in collaboration with the Biofinder study group led by Oskar Hansson in Lund, Sweden
\$5,500,000 (includes support for brain imaging and immunoassays from Lilly, GE and Roche)

HOSPITAL AND UNIVERSITY TEACHING ROLES

- 1980-1981 **University of California Berkeley**
Teaching Assistant for the course: Human Growth and Development for medical
and graduate students.
- 1983-1985 **Stanford Medical School**
Coordinator of the psychiatry and behavioral science curriculum in the Primary
Care Program
Instructor for the course: Introduction to Clinical Medicine

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

- 1989-1991 **Yale University**
Director of the course: Behavioral Neurology - for medical students Seminar
Director: Neuroradiology/Clinical Correlations for the psychiatry housestaff and attending staff at Yale-New Haven Hospital
Co-director of the bi-weekly Movement Disorder seminar at Yale University
Instructor for the neurology section in The Introduction to Clinical Medicine Course for Medical Students
- 1990-1995 **Yale University**
Co-director of the course: Comprehensive Review of Neurology
Offered 2 times per year
- 1991-present **Brown University**

Undergraduate Education

Director of an Independent Study Course in neurobehavioral research for undergraduates majoring in neuroscience and biology (B195/196) (1-3 students per semester, includes honors thesis for eligible seniors).

Lisa Israeli, Neuroscience, fall and spring semesters 1994-5 and 1995-6.

Project: Development of a brain imaging rating scale. Co-author of one peer reviewed paper and one abstract.

Kathy Chang, Neuroscience, spring 1994-95, fall 1995-96.

Project: Clinical profiles of adults presenting with attentional disturbance. Honorable mention for the ANPA Young Investigator Award for abstract #12 at the American Neuropsychiatric Association Annual Meeting 1995.

Mary Lynn Mercado, Biology, spring 1994-95, fall and spring semesters 1995-96. Senior honors thesis: Subcortical vascular disease and late-life depression

Joseph Hong, Neuroscience, spring semester 1995-96, University Teaching and Research Assistant (UTRA) summer 1996, fall, spring 1996-97 Projects: I. Effect of pemoline on cognitive performance, II. Honors thesis. MRI and small artery changes in CADASIL and Binswanger's disease. Author of two peer-reviewed papers and Presentation at two national meetings

Jorge Intal, Neuroscience, summer 1996, fall, spring 1996-97

Project: Cerebral microvascular disease in aging: I. A comparison of FLAIR and PD MRI sequences and II. MRI-autopsy correlation of signal hyperintensities. Presented at the Society for Neuroscience 27th Annual Meeting, New Orleans (abstract #21).

Maureen Cruz, Biology, fall 1997

Project: Cerebral perfusion abnormalities in normal pressure hydrocephalus.

Mary Pan, Neuroscience, fall and spring 1998-9

Project: Neuropsychiatric symptoms in vascular dementia

Susan Rymer, Anthropology, fall and spring 1999-2000

Project: Awareness of cognitive deficit in Alzheimer's disease and caregiver burden

Tamar Gur, Biology Honors Thesis second reader, 1999-2000

Project: ApoE4 and agrin staining of microvascular integrity in Alzheimer's disease (co-mentor with Dr. Stopa)

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

Ellen Kotwas, spring 1999-2000, summer and fall 2000-2001

UTRA Fellow, Psychology Honors Thesis

Project: Affective and semantic priming in Alzheimer's disease

Awarded the Muriel Fain Sher Premium in Psychology by the Department of Psychology for her honors research (co-mentor with Dr. Heindel)

Audrey Kwak, 2001-2, Psychology Honors Thesis

Project: Predictors of functional impairment in Alzheimer's disease

Leah Belsky, 2001-2 Biology

Project: When familial FTD is suspected: Ethical and clinical issues in genetic research

Sophie Desbiens, Summer 2002 Brain Science UTRA Fellow

Project: Development of an assay for notch-3 mutations

Suzanne Drodge, Summer 2002 MRI Research Facility UTRA Fellow

Project: Diffusion tensor imaging in CADASIL

Stan Pelosi, Summer 2002 PLME summer research assistantship

Project: Working memory in Alzheimer's disease (co-mentor with Dr. Malloy)

Jonathan Greer, 2003 PLME summer research assistantship

Project: A PCR-SSCP reliant assay for notch-3 mutations in CADASIL patients

Irmak Turan, Barrington High School Senior Project (awarded honors)

Project: Is Down's syndrome a good genetic model for studying Alzheimer's disease?

Ryan Li, 2003-4 Neuroscience honors thesis

Project: MRI correlates of ambulation and motor functioning in Alzheimer's disease

Thea Brennan-Krohn, 2004 Summer Training in Aging Research Topics Mental Health- NIMH

Award- Diffusion tensor imaging and working memory in SIVD. 2005 Summer Training in Aging Research Topics Mental Health NIMH Award- Molecular analysis of notch and notch ligand expression in vascular dementias

Christopher Song, 2004 Summer Training in Aging Research topics Mental Health- NIMH Award

Project: Development of an assay for notch3 mutations

Sharon Song, 2007 Biology concentrator honors thesis (co-mentor with Stephen Correia, Ph.D.)

Project: MOCA is more sensitive than MMSE in MCI because of executive dysfunction

Brown Medical Student Education

Director of the second semester, first year course. The Human Brain and Behavior (Biomed 370)

Co-Leader of the Brain and Behavior section in BIOL3652 IMS-II: Brain Sciences, an integrated brain science course for first year medical students.

Co-leader of a small group and lecturer in the Neurologic Pathophysiology Course for second year students (Neurosciences 262)

Director, Neuropsychiatry and Behavioral Neurology Elective (Biomed 515)

Extended Medical Student Clinical and Research Electives

Ximena Morales, 1994-95, Medical School Columbia, South America, six-month neurobehavioral research elective in geriatric depression

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

Shirine Nassery, PLME summer research assistantship 2001

Relationship of subcortical microvascular changes in Alzheimer's disease to ApoE genotype and systolic hypertension

Risha Kopel, summer research project 2001

Use of diffusion tensor MRI to differentiate normal pressure hydrocephalus from Alzheimer's disease

Tyler Berzin, 2001-2, Brown Faculty Scholars Award recipient

Microvascular changes in Alzheimer's disease (co-mentor with Dr. Stopa)

Ari Blitz, 2000-1, Brown faculty Scholars recipient

Alterations in frontal-subcortical circuits in OCD

Ainsley MacLean, 2002 PLME summer research assistantship

Phenotypic variation in a large family with CADASIL, Recipient of an Alzheimer's Association Travel Award to present her work at the 8th World Alzheimer's Disease Congress in Stockholm, 7/2002

Colleen Craig 2005 3rd year medical student 6-month longitudinal neurology elective

Michael Joseph, Summer 2005, Clinical Neuroscience Mental Health Research Training-R25 MH

60477-05 Relationship of hippocampal and whole brain volume to cognitive impairment in CADASIL

James Enos, 2008 Summer Training in Aging Research Topics Mental Health NIMH Award,

Normal pressure hydrocephalus: clinical-pathological correlations. primary mentor with Dr. delaMonte.

Jon Treem 2012-3-4th year medical school 6-month longitudinal elective and concentration supervisor in geriatrics

Patrick Kelley, 2016, American Federation for Aging Research Fellow, Project: amyloid PET as a predictor of shunt response in normal pressure hydrocephalus

Rohan Katipally, 2016, project: an amyloid PET connectome for Alzheimer's disease.

Joanna Georgakas-2020-2021, 6-month longitudinal elective

Brown Post-graduate Medical Education

Director of the American Board of Psychiatry and Neurology/ACGME-Approved 855-43-44-005

Brown University Combined Residency Training Program in Neurology and Psychiatry, 1996-2012

NIA ZAG1 FAS-5 J1 Institutional National Research Service Award

Dementia Research Fellowship T-32 (Paul Malloy, PI) 2003-2008, co-PI with Richard Besdine

Supervisor. Memory Clinic Rotation, Brown Geriatric Psychiatry Fellowship, 2012-present

Director of the Neuropsychiatry/Behavioral Neurology Fellowship

Director of the Neuropsychiatry Track in the Psychiatry Residency

Neurology Ward and Consultation Service Attending - Rhode Island Hospital, 1991-present

Neurology Consultation Service Attending - Butler Hospital

Behavioral Neurology Outpatient Elective Rotation Attending

Mentor, Brown Psychiatry Residency Research Track

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

Lecturer in the Brown University Neuropsychology Training Seminar

Lecturer in the weekly neurology resident seminar series

Lecturer in the Geriatric Psychiatry and Geriatric Medicine fellowship programs

Lecturer on Geriatric research in the Brown University NIH T-32 Young Investigator Training Seminar

Brown Medical School Extended Resident Electives

Cleve Shirey, M.D. Senior Psychiatry Resident, 1993-4, Year-long one-half day weekly neuropsychiatry outpatient continuity clinic

Suda Bakshi, M.D. Triple Board Resident in Pediatrics, Child Psychiatry and Adult Psychiatry, 1994-5, Nine month one-half day weekly neuropsychiatry outpatient clinic

Jeffrey Daly, M.D. Senior Psychiatry Resident, 1994-5, 12-month, part-time elective in neuropsychiatric research. Published two peer-reviewed articles and one book chapter and was selected for the American Psychiatric Association Burroughs-Wellcome Award.

Neeta Jaine, M.D. Senior Psychiatry Resident, 1995-6, 4-month weekly neuropsychiatry outpatient continuity clinic

Ron Neeper, M.D., Ph.D., Triple Board Resident in Pediatrics, Child Psychiatry and Adult Psychiatry and Pediatric Neurology Resident 1994-6, 2-year neuropsychiatry continuity clinic two half-days/week

Gary Epstein-Lubow, M.D., Senior Psychiatry Resident, 4-month weekly neuropsychiatry outpatient elective 2001, Project-Neuropsychiatric aspects of NPH

Combined Residents in Neurology and Psychiatry

Curt LaFrance, M.D., 1995-2001

Current position: Director of Neuropsychiatry Research, Rhode Island Hospital. Recipient of a NINDS Career Development Award 2003-8.

Rochelle Woods, M.D., 1999-2005

Research project: Validating a scale for measuring outcome from intracerebral hemorrhage.
Current position: Assistant professor of neurology and psychiatry UCLA

Michael Gregory, M.D., 2005-2011

Current position: Clinical Fellow with the Section on Integrative Neuroimaging, Clinical Brain Disorders Branch, NIMH

Danielle Cabral, M.D., 2012-present

Research project: Prevention strategies for preclinical Alzheimer's disease

Neuropsychiatry Fellows

John Campbell, M.D., 1992-1993

Published two peer-reviewed papers and made two Presentations at national meetings during the fellowship. Current Position-Director of Neuropsychiatry, Maine Medical Center, Portland, ME

Colin Harrington, M.D., 1996-97

Current position-Director of Consultation-Liaison Psychiatry, Rhode Island Hospital. Dr.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

Harrington received the 2003 Senior Citation Award for best faculty mentorship from the 2003 Brown Medical School graduating seniors.

R25 Research Residents

Mathew Howe, MD, PhD, 2020-present, plasma biomarkers in Alzheimer's disease

Research Fellows in Neurodegenerative Disorders

Danielle Goldfarb, M.D., 2017-2018

Kevin Manning, PhD, 2019-2024, University of Connecticut Health Center, mentor for 1 K23 MH118420-01A1, Cognitive Remediation of Cognitive Control in Late-life Depression

Post-doctoral Fellows in Alzheimer's Research

Rebecca Gavett, Ph.D., 2014-2015

Research supervisor: Anti-amyloid in asymptomatic Alzheimer's disease secondary prevention trial.

Jessica Alber, Ph.D., 2015-2017

Research supervisor: Secondary prevention strategies for preclinical Alzheimer's disease

Louisa Thompson, PhD, 2017-2019

Research supervisor: ApoE genotype and retinal imaging biomarkers as predictors of cerebral amyloidosis in cognitively normal elderly

Dominique Popesque, PhD, 2019-2021

Research supervisor with Dr. Correia. Lifestyle modification to promote brain health in individuals at risk for Alzheimer's disease.

T-32 Post-Doctoral Research Fellows

Stephen Correia, Ph.D., 2003-2005

Working memory and frontal white matter integrity in mild cognitive impairment (mentor)

Gary Lubow, M.D., 2003-2005

Treatment of depression in dementia caregivers (co-mentor with Van Miller, Ph.D.)

Thesis Committee

Jang-Hoan Lee, 2018-present OTCA for detection of vascular changes in transgenic AD

Visiting Scholars

Paul O'Hara, M.D., 1998-2000, University of Western Australia

Research supervisor, Controlled treatment trials for vascular dementia

Thom Voorn 2006-7, neuroscience graduate student vrije Universiteit Amsterdam

Project: diffusion tensor imaging morphometry, co-mentor with Dr. Correia

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Rev. May 2024

Tanja Su, 2009-2010, neuroscience graduate student vrije Universiteit Amsterdam
Project: Imaging myelin water fraction in Alzheimer's disease, co-mentor with Dr. Correia

Steven VanHuiden, 2012-2013 neuroscience graduate student vrije Universiteit Amsterdam
Project: Myelin Integrity, Cognitive Function and Hypertension in MCI and Alzheimer's Disease, co-mentor with Dr. Correia

Neuropsychology Post-Doctoral Fellows

Deborah Cahn-Weiner, Ph.D., 1996-98

Research Supervisor, Cognitive performance and functional status in normal aging and dementia (co-mentor with Dr. Malloy)

Current position-Psychologist, UCSF School of Medicine

Lauren Norton, Ph.D., 1998-2000

Research Supervisor, Behavioral symptoms and activities of daily living in dementia (co-mentor with Dr. Malloy)

Current position Psychologist Massachusetts General Hospital

Patricia Boyle, Ph.D., 2000-2002

Research supervisor, NIA F-32 Executive function and activities of daily living in Alzheimer's disease (co-mentor with Dr. Malloy)

Current position: Associate Professor, Rush Medical School

Stephen Correia, Ph.D., 2002-2005

Research supervisor, NIA T-32 Dementia Research Fellow

Diffusion tensor imaging of frontal systems in mild cognitive impairment. (co-mentor with Dr. Malloy)

Current position: Assistant Professor, Psychiatry, Brown Medical School

Ryan Garrity, Ph.D., 2000-2002

Research supervisor, A trial of estrogens for prevention of Alzheimer's disease (co-mentor with Dr. Malloy) Current position-staff psychologist

Heather Belanger, Ph.D., 2002-2003

Research supervisor, Diffusion tensor imaging and executive function in Alzheimer's disease (co-mentor with Dr. Malloy)

Current position: Psychologist, University of South Florida Medical School

Kelly Wilder-Willis, Ph.D., 2002-2004

Research supervisor, Working memory in Alzheimer's disease (co-mentor with Dr. Malloy)

Laura Frakey, Ph.D., 2005-2007

Research supervisor, Treatment of apathy in Alzheimer's disease with modafinil (co-mentor with Dr. Malloy)

Current position: Psychologist, Memorial Hospital of Rhode Island

Irene Piryatinsky, Ph.D., 2008-2010

Research supervisor: Amyloid biomarkers predict response to shunt placement in normal pressure hydrocephalus.

Current position: Psychologist, Brigham and Women's Hospital

Curriculum Vitae:
Stephen P. Salloway, MD, MS

Rev. May 2024

LANGUAGES German, Hebrew